var title_f3_60_4032="Fibrous pleural tumor II CT";
var content_f3_60_4032=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F65286&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F65286&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Fibrous tumor of the pleura",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 324px; height: 323px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    CT scan shows a large left posterior chest mass.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Paul Stark, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_60_4032=[""].join("\n");
var outline_f3_60_4032=null;
var title_f3_60_4033="Leptomeningeal lymphoma";
var content_f3_60_4033=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F66435&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F66435&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Leptomeningeal involvement by non-Hodgkin's lymphoma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 390px; height: 503px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This axial T1 gadolinium-enhanced&nbsp;magnetic resonance imaging&nbsp;shows multifocal leptomeningeal enhancement (red arrows), consistent with lymphomatous involvement.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_60_4033=[""].join("\n");
var outline_f3_60_4033=null;
var title_f3_60_4034="Cauliflower ear in RPC";
var content_f3_60_4034=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F82354&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F82354&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Cauliflower ear in relapsing polychondritis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 229px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Auricular distortion in relapsing polychondritis induced by destructive changes in supporting structures of connective tissue.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Jerome H Herman, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_60_4034=[""].join("\n");
var outline_f3_60_4034=null;
var title_f3_60_4035="Genital warts in women";
var content_f3_60_4035=[" <h1 id=\"patTopicTitle\">",
"  Patient information: Genital warts in women (Beyond the Basics)",
" </h1>",
" <div id=\"patTopicContributors\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <table>",
"    <tr>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?3/60/4035/contributors\">",
"       Author",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/60/4035/contributors\" id=\"au6852\">",
"       Daniela A Carusi, MD, MSc",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?3/60/4035/contributors\">",
"       Section Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/60/4035/contributors\" id=\"se4464\">",
"       Robert L Barbieri, MD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?3/60/4035/contributors\">",
"       Deputy Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/60/4035/contributors\" id=\"de4555\">",
"       Vanessa A Barss, MD",
"      </a>",
"     </td>",
"    </tr>",
"   </table>",
"  </div>",
"  <div class=\"rcBottom\">",
"   <div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"patTopicTool\" id=\"patTopicToolTop\">",
"  <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"   Find",
"  </a>",
"  <a class=\"toolbutton printicon\" href=\"UTD.htm?3/60/4035?view=print\" title=\"Print This Topic\">",
"   Print",
"  </a>",
"  <script src=\"file://w.sharethis.com/button/sharethis.js#publisher=357881b8-c7e3-4c31-b7d2-242aeb1528e1&amp;type=website&amp;post_services=care2%2Cfacebook%2Ctwitter%2Cmyspace%2Cdigg%2Cdelicious%2Cfaves%2Creddit%2Cxanga%2Cstumbleupon%2Cblinklist%2Csimpy%2Cyigg%2Ctechnorati%2Cmeneame%2Corkut%2Cmixx%2Cfunp%2Cfresqui%2Cmister_wong%2Cfriendster%2Cfriendfeed%2Clinkedin%2Coknotizie%2Cgoogle_bmarks%2Cyahoo_bmarks%2Cfark%2Cnewsvine%2Clivejournal%2Ctypepad%2Cbus_exchange%2Cpropeller%2Cwordpress%2Cblogger%2Cblogmarks%2Cwindows_live%2Cfurl%2Cybuzz%2Cdiigo\" type=\"text/javascript\">",
"  </script>",
" </div>",
" <div id=\"patTopicMiddle\">",
"  <div id=\"topicContent\">",
"   <div id=\"topicText\">",
"    <p class=\"headingAnchor\" id=\"H1\">",
"     <span class=\"h1\">",
"      GENITAL WARTS OVERVIEW",
"     </span>",
"    </p>",
"    <p>",
"     Condyloma acuminata (genital warts) are a sexually transmitted infection that causes small, skin-colored or pink growths on the labia, at the opening of the vagina, or around or inside the anus. Genital warts are the most common sexually transmitted infection in the United States. Although warts affect both genders, more women have warts than men.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H2\">",
"     <span class=\"h1\">",
"      CAUSES OF GENITAL WARTS",
"     </span>",
"    </p>",
"    <p>",
"     Genital warts are caused by the human papillomavirus (HPV). HPV is the same virus that causes most cases of cervical cancer. However, there are over 100 different types of HPV. HPV types 6 and 11 are a major cause of warts, and types 16 and 18 are the major causes of cervical cancer. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?7/53/8019?source=see_link\">",
"      \"Patient information: Cervical cancer screening (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p>",
"     HPV is spread by direct skin-to-skin contact, including sexual intercourse, oral sex, anal sex, or any other contact involving the genital area (eg, hand-to-genital contact). It is not possible to become infected with HPV by touching a toilet seat. Most people with the virus do not have visible warts, but can still transmit the virus. Treating the warts may not decrease the chance of spreading the virus. Therefore, all people who are sexually active should be regarded as potential sources of HPV, not just those with visible warts.",
"    </p>",
"    <p>",
"     Warts may appear weeks to a year or more after being exposed to the virus; it is not usually possible to know when or how you became infected.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H3\">",
"     <span class=\"h1\">",
"      GENITAL WARTS SYMPTOMS",
"     </span>",
"    </p>",
"    <p>",
"     Warts are skin-colored or pink, and may be smooth and flat or raised with a rough texture. They are usually located on the labia or at the opening of the vagina, but can also be around or inside the anus.",
"    </p>",
"    <p>",
"     Most women with warts do not have any symptoms at all. Less commonly, there may be itching, burning, or tenderness in the genital area.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H4\">",
"     <span class=\"h1\">",
"      GENITAL WARTS DIAGNOSIS",
"     </span>",
"    </p>",
"    <p>",
"     Genital warts can be diagnosed based on an exam. If your doctor or nurse is not certain that the area is a wart, he or she may perform a biopsy (remove a small piece of tissue). (See",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/38/23144?source=see_link\">",
"      \"Condylomata acuminata (anogenital warts)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H5\">",
"     <span class=\"h1\">",
"      GENITAL WARTS TREATMENT",
"     </span>",
"    </p>",
"    <p>",
"     There are many ways to treat genital warts: some involve using a medicine and some involve a procedure. Even with treatment, it is possible that the warts will come back within a few weeks or months. This is because treating the warts does not necessarily get rid of all of the virus (HPV) causing the warts. Some cells in the normal-appearing genital skin and vagina may remain infected with HPV. There is currently no treatment that will permanently get rid of HPV in all infected cells, but most people will clear the virus and the warts with their own immune systems within two years. (See",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/34/27178?source=see_link\">",
"      \"Treatment of vulvar and vaginal warts\"",
"     </a>",
"     .)",
"    </p>",
"    <p>",
"     The \"best\" treatment for warts depends on how many warts you have, where they are located, and you and your doctor or nurse's preferences.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H6\">",
"     <span class=\"h2\">",
"      Medical treatments",
"     </span>",
"     &nbsp;&mdash;&nbsp;Medical treatments include creams or liquids that you or your doctor or nurse must apply to the wart. All of these treatments must be used one or more times per week for several weeks, until the wart(s) goes away.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H7\">",
"     <span class=\"h3\">",
"      Podophyllin",
"     </span>",
"     &nbsp;&mdash;&nbsp;Podophyllin is a treatment that destroys the wart tissue. A doctor or nurse applies the solution directly to the wart(s) with a cotton swab, and you should wash the area one to four hours later. The treatment is repeated weekly for four to six weeks, or until the lesions have cleared. Side effects range from mild skin irritation to pain and skin ulcers. Podophyllin is not used in pregnant women.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H8\">",
"     <span class=\"h3\">",
"      Podofilox",
"     </span>",
"     &nbsp;&mdash;&nbsp;Podofilox is similar to podophyllin, but you can apply podofilox (Condylox&reg;) at home. Using a cotton swab, you apply a gel or liquid solution to the wart(s) twice daily for three days in a row. Then you use no treatment for the next four days. You can repeat this cycle up to four times until the warts have gone away. Podofilox is not used in pregnant women. Side effects of podofilox are similar to those of podophyllin.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H9\">",
"     <span class=\"h3\">",
"      Bichloroacetic acid and trichloroacetic acid",
"     </span>",
"     &nbsp;&mdash;&nbsp;Both bichloroacetic acid (BCA) and trichloroacetic acid (TCA) are acids that destroy the wart tissue. TCA is used most commonly, and must be applied by a doctor or nurse. The provider applies the acid to the wart once per week for four to six weeks, or until the warts go away. Side effects of TCA include pain and burning. TCA is safe for use during pregnancy.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H10\">",
"     <span class=\"h3\">",
"      Imiquimod",
"     </span>",
"     &nbsp;&mdash;&nbsp;Imiquimod (Aldara&reg;) is a cream that triggers the immune system to get rid of the wart. You can apply the cream directly to the wart (generally at bedtime), and then wash the area with water six to 10 hours later. You use the cream three days per week for up to 16 weeks. Mild irritation and redness are normal while using imiquimod, and mean that the treatment is working. Imiquimod is not recommended during pregnancy.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H11\">",
"     <span class=\"h3\">",
"      Interferon",
"     </span>",
"     &nbsp;&mdash;&nbsp;Interferon is a medication that causes an immune response. It is available in several treatment forms (injection, topical gel), but studies have shown that it most effective when given as an injection into the wart.",
"    </p>",
"    <p>",
"     Side effects of interferon include flu-like symptoms, fatigue, lack of appetite, and pain. Interferon is not usually recommended as a first-line treatment. It may be used in combination with surgical",
"     <span class=\"nowrap\">",
"      and/or",
"     </span>",
"     other medical treatments, especially with warts that do not improve with other treatments. Interferon is not safe during pregnancy.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H3937125\">",
"     <span class=\"h3\">",
"      Sinecatechins",
"     </span>",
"     &nbsp;&mdash;&nbsp;Sinecatechins (eg, Veregen&reg;) is a botanical product that can be self-administered. The exact mechanism of action of catechins is unknown, but they have both antioxidant and immune enhancing activity. The ointment is placed on each external wart three times each day for up to 16 weeks. It should not be used in the vagina or anus, in immunocompromised women, or in women with active herpes. It should be washed off of the skin before sexual contact or before inserting a tampon into the vagina, and it can weaken the latex in condoms and diaphragms.",
"    </p>",
"    <p>",
"     In trials of this therapy, 5 percent of users discontinued the drug due to side effects and almost 90 percent reported local application site reactions, some of which were severe (pruritus, erythema, pain, inflammation, ulceration, edema, burning, induration, vesicular rash).",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H12\">",
"     <span class=\"h2\">",
"      Surgical treatment",
"     </span>",
"     &nbsp;&mdash;&nbsp;Surgical treatments include treatments that remove the wart (called excision) and treatments that destroy (freeze, burn) the wart. These treatments are often used in combination. Some surgical treatments can be done in the office while others are done in the operating room. Surgical treatments may be recommended for:",
"    </p>",
"    <p>",
"     <ul class=\"bulletCompact-block\">",
"      <li>",
"       Warts that do not respond to medical therapy",
"      </li>",
"      <li>",
"       Large areas of warts, where medical therapy alone is often inadequate",
"      </li>",
"      <li>",
"       Warts involving the vagina, urethra, or anus",
"      </li>",
"      <li>",
"       Areas that have pre-cancerous changes",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H13\">",
"     <span class=\"h3\">",
"      Cryotherapy",
"     </span>",
"     &nbsp;&mdash;&nbsp;Cryotherapy uses a chemical to freeze the wart. The treatment can be done in the office, and does not usually require any anesthesia.",
"    </p>",
"    <p>",
"     Cryotherapy often causes pain during the procedure; other side effects can include skin irritation, swelling, blistering, and ulceration. Cryotherapy is not usually a first-line treatment. Cryotherapy can be used during pregnancy.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H14\">",
"     <span class=\"h3\">",
"      Electrocautery",
"     </span>",
"     &nbsp;&mdash;&nbsp;Electrocautery uses electrical energy to burn away warts. Treatment is usually done in an operating room using local anesthesia to prevent pain.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H15\">",
"     <span class=\"h3\">",
"      Excision",
"     </span>",
"     &nbsp;&mdash;&nbsp;Excision involves using surgery to remove the wart. Most people are treated in the operating room using anesthesia to prevent pain. Rarely, excision causes pain, scarring, and infection.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H16\">",
"     <span class=\"h3\">",
"      Laser",
"     </span>",
"     &nbsp;&mdash;&nbsp;Lasers produce light energy, which destroys warts. Physicians who perform laser treatment require specific training and specialized equipment. Laser treatment is done in the operating room using local anesthesia to prevent pain.",
"    </p>",
"    <p>",
"     Laser therapy may be recommended if you have multiple warts spread over a large area. Risks of laser surgery include scarring, pain, and changes in the skin (usually lightened color).",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H17\">",
"     <span class=\"h1\">",
"      GENITAL WARTS FOLLOW UP",
"     </span>",
"    </p>",
"    <p>",
"     Getting rid of warts does not necessarily mean that the virus causing the warts (HPV) is gone. If warts come back, they usually do so within three to six months of treatment. This problem is more common in women with a weakened immune system (such as diabetes, HIV, or certain medications).",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H18\">",
"     <span class=\"h1\">",
"      GENITAL WARTS PREVENTION",
"     </span>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H19\">",
"     <span class=\"h2\">",
"      HPV vaccine",
"     </span>",
"     &nbsp;&mdash;&nbsp;A vaccine, Gardasil&reg;, is available for prevention of genital warts. Gardasil&reg; helps prevent infection from four types of HPV (types 6, 11, 16, and 18), which helps to prevent most cases of cervical cancer (caused by HPV 16 and 18) and genital warts (caused by HPV 6 and 11).",
"    </p>",
"    <p>",
"     Another vaccine, Cervarix&reg;, helps prevent infection from two types of HPV (types 16 and 18), thus it helps to prevent most cases of cervical cancer, but not genital warts.",
"    </p>",
"    <p>",
"     Both vaccines are safe. An article about the HPV vaccine is available separately. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?37/45/38610?source=see_link\">",
"      \"Patient information: Human papillomavirus (HPV) vaccine (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H20\">",
"     <span class=\"h2\">",
"      Sexual contact",
"     </span>",
"     &nbsp;&mdash;&nbsp;Avoiding people who have genital warts or HPV can reduce your risk of becoming infected with HPV. However, from a practical standpoint this is difficult, as many people are infected with HPV and do not have any visible warts. Condoms do not provide complete protection against warts or HPV; areas not covered by the condom can spread HPV from one person to another.",
"    </p>",
"    <p>",
"     If you have genital warts or HPV and you are worried about infecting your sex partner, have an honest talk before you have sex. Explain that you have HPV and that it is very common and most people are asymptomatic. There is no test for looking for HPV on the vulva. There is a test to find HPV on the cervix, but this test is not useful for the type of HPV that causes vulvar warts. Cervical HPV and vulvar HPV are usually different.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H21\">",
"     <span class=\"h1\">",
"      WHERE TO GET MORE INFORMATION",
"     </span>",
"    </p>",
"    <p>",
"     Your healthcare provider is the best source of information for questions and concerns related to your medical problem.",
"    </p>",
"    <p>",
"     This article will be updated as needed on our web site (",
"     <a class=\"external\" href=\"file://www.uptodate.com/patients\">",
"      www.uptodate.com/patients",
"     </a>",
"     ). Related topics for patients, as well as selected articles written for healthcare professionals, are also available. Some of the most relevant are listed below.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H3498687937\">",
"     <span class=\"h2\">",
"      Patient level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H257222\">",
"     <span class=\"h3\">",
"      The Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;The Basics patient education pieces answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?16/13/16594?source=see_link\">",
"      Patient information: Genital warts (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?5/22/5475?source=see_link\">",
"      Patient information: Human papillomavirus (HPV) vaccine (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?1/57/1940?source=see_link\">",
"      Patient information: Screening for sexually transmitted diseases (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?9/61/10195?source=see_link\">",
"      Patient information: Syphilis (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?4/44/4803?source=see_link\">",
"      Patient information: Urethritis (The Basics)",
"     </a>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H257229\">",
"     <span class=\"h3\">",
"      Beyond the Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are best for patients who want in-depth information and are comfortable with some medical jargon.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?7/53/8019?source=see_link\">",
"      Patient information: Cervical cancer screening (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?37/45/38610?source=see_link\">",
"      Patient information: Human papillomavirus (HPV) vaccine (Beyond the Basics)",
"     </a>",
"     <br/>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H22\">",
"     <span class=\"h2\">",
"      Professional level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;Professional level articles are designed to keep doctors and other health professionals up-to-date on the latest medical findings. These articles are thorough, long, and complex, and they contain multiple references to the research on which they are based. Professional level articles are best for people who are comfortable with a lot of medical terminology and who want to read the same materials their doctors are reading.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/33/1562?source=see_link\">",
"      Anal intraepithelial neoplasia: Diagnosis, screening, prevention, and treatment",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/13/26840?source=see_link\">",
"      Carcinoma of the penis: Epidemiology, risk factors, staging, and prognosis",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/54/38762?source=see_link\">",
"      Clinical features, staging, and treatment of anal cancer",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/10/13480?source=see_link\">",
"      Clinical trials of human papillomavirus vaccines",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/38/23144?source=see_link\">",
"      Condylomata acuminata (anogenital warts)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/6/21610?source=see_link\">",
"      Epidemiology of human papillomavirus infections",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/17/19738?source=see_link\">",
"      Recommendations for the use of human papillomavirus vaccines",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/34/27178?source=see_link\">",
"      Treatment of vulvar and vaginal warts",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/53/26455?source=see_link\">",
"      Virology of human papillomavirus infections and the link to cancer",
"     </a>",
"     <br/>",
"     <br/>",
"     The following organizations also provide reliable health information.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Library of Medicine",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.nlm.nih.gov/medlineplus/healthtopics.html\">",
"      www.nlm.nih.gov/medlineplus/healthtopics.html",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       American Cancer Society",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.cancer.org/\">",
"      www.cancer.org",
"     </a>",
"     , search for HPV)",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National HPV and Cervical Cancer Public Education Campaign",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;Telephone: 1-866-280-6605",
"     <br/>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.cervicalcancercampaign.org/\">",
"      www.cervicalcancercampaign.org",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Institute of Allergy and Infectious Diseases",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.niaid.nih.gov/factsheets/stdhpv.htm\">",
"      www.niaid.nih.gov/factsheets/stdhpv.htm",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Center for Disease Control and Prevention",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.cdc.gov/std/HPV/STDFact-HPV.htm\">",
"      www.cdc.gov/std/HPV/STDFact-HPV.htm",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       American Social Health Association",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.ashastd.org/std-sti/hpv/genital-warts.html\">",
"      www.ashastd.org/std-sti/hpv/genital-warts.html",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     [",
"     <a class=\"abstract\" href=\"UTD.htm?3/60/4035/abstract/1-11\">",
"      1-11",
"     </a>",
"     ]",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 2, 2012.",
"  </div>",
"  <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"   <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"    Find",
"   </a>",
"   <a class=\"toolbutton printicon\" href=\"UTD.htm?3/60/4035?view=print\" title=\"Print This Topic\">",
"    Print",
"   </a>",
"  </div>",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <div id=\"patTopicRefHeader\">",
"    <div id=\"patTopicRefHeaderHeader\">",
"     References",
"    </div>",
"    <div id=\"patTopicRefHeaderTop\">",
"     <a href=\"#top\">",
"      <img alt=\"\" src=\"./../images/top_arrow.myextg\">",
"       Top",
"      </img>",
"     </a>",
"    </div>",
"   </div>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/60/4035/abstract/1\">",
"      Stone KM, Becker TM, Hadgu A, Kraus SJ. Treatment of external genital warts: a randomised clinical trial comparing podophyllin, cryotherapy, and electrodesiccation. Genitourin Med 1990; 66:16.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/60/4035/abstract/2\">",
"      Greenberg MD, Rutledge LH, Reid R, et al. A double-blind, randomized trial of 0.5% podofilox and placebo for the treatment of genital warts in women. Obstet Gynecol 1991; 77:735.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/60/4035/abstract/3\">",
"      Abdullah AN, Walzman M, Wade A. Treatment of external genital warts comparing cryotherapy (liquid nitrogen) and trichloroacetic acid. Sex Transm Dis 1993; 20:344.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/60/4035/abstract/4\">",
"      Beutner KR, Spruance SL, Hougham AJ, et al. Treatment of genital warts with an immune-response modifier (imiquimod). J Am Acad Dermatol 1998; 38:230.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/60/4035/abstract/5\">",
"      Eron, LJ, Judson, F, Tucker, S, et al. Interferon therapy for condylomata acuminata. NEJM 1059; 315:1059.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/60/4035/abstract/6\">",
"      Recurrent condylomata acuminata treated with recombinant interferon alpha-2a. A multicenter double-blind placebo-controlled clinical trial. Condylomata International Collaborative Study Group. Acta Derm Venereol 1993; 73:223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/60/4035/abstract/7\">",
"      Jensen SL. Comparison of podophyllin application with simple surgical excision in clearance and recurrence of perianal condylomata acuminata. Lancet 1985; 2:1146.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/60/4035/abstract/8\">",
"      Rader JS, Leake JF, Dillon MB, Rosenshein NB. Ultrasonic surgical aspiration in the treatment of vulvar disease. Obstet Gynecol 1991; 77:573.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/60/4035/abstract/9\">",
"      Koutsky LA, Ault KA, Wheeler CM, et al. A controlled trial of a human papillomavirus type 16 vaccine. N Engl J Med 2002; 347:1645.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/60/4035/abstract/10\">",
"      Harper DM, Franco EL, Wheeler C, et al. Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial. Lancet 2004; 364:1757.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/60/4035/abstract/11\">",
"      Harper DM, Franco EL, Wheeler CM, et al. Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial. Lancet 2006; 367:1247.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
" </div>",
" <!-- patTopicMiddle -->",
"</div>"].join("\n");
var script_f3_60_4035=[""].join("\n");
var outline_f3_60_4035=[" <div class=\"patTopicFancyTop\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <p>",
"    Contents of this article",
"   </p>",
"  </div>",
" </div>",
" <div class=\"patTopicFancySpacer\">",
" </div>",
" <div class=\"patTopicOutline\">",
"  <div class=\"rcbBottom\">",
"   <div class=\"rcbLeft\">",
"    <div class=\"rcbRight\">",
"     <div class=\"rcbBottomLeft\">",
"      <div class=\"rcbBottomRight rcbBottomRightBottomOnly\">",
"       <div id=\"outline\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          <a href=\"#H1\">",
"           GENITAL WARTS OVERVIEW",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H2\">",
"           CAUSES OF GENITAL WARTS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H3\">",
"           GENITAL WARTS SYMPTOMS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H4\">",
"           GENITAL WARTS DIAGNOSIS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H5\">",
"           GENITAL WARTS TREATMENT",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H17\">",
"           GENITAL WARTS FOLLOW UP",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H18\">",
"           GENITAL WARTS PREVENTION",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H21\">",
"           WHERE TO GET MORE INFORMATION",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#references\">",
"           REFERENCES",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"  </div>",
" </div>"].join("\n");
var title_f3_60_4036="Supracondylar extension fracture";
var content_f3_60_4036=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F54389&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F54389&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 536px\">",
"   <div class=\"ttl\">",
"    Extension supracondylar fractures",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 516px; height: 354px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Hyperextension forces. A) Most young children attempt to break their falls with the upper extremity extended. Because of the laxity of the ligaments, the elbow becomes locked into hyperextension. B) This converts the linear applied force (large arrow) to an anterior tension force. Posteriorly, the olecranon is forced into the depths of the olecranon fossa (small arrow). C) As the bending force continues, the distal humerus fails anteriorly in the supracondylar area. D) When the fracture is complete, the distal fragment becomes posteriorly displaced. The strong action of the triceps (large arrow) produces proximal displacement of the distal fragment.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Kasser JR, Beaty JH. Supracondylar fractures of the distal humerus. In: Rockwood and Wilkins' Fractures in Children, 5th ed, Beaty JH, Kasser JR (Eds), Lippincott Williams &amp; Wilkins 2001. Copyright &copy; 2001 Lippincott Williams &amp; Wilkins.",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.lww.com\">",
"      file://www.lww.com",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_60_4036=[""].join("\n");
var outline_f3_60_4036=null;
var title_f3_60_4037="Sites central venous access";
var content_f3_60_4037=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F81727&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F81727&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Sites for central venous access",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 450px; height: 621px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The three primary sites for central venous access in infants and children are the femoral vein, subclavian vein, and the internal jugular vein.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_60_4037=[""].join("\n");
var outline_f3_60_4037=null;
var title_f3_60_4038="Krabbe disease";
var content_f3_60_4038=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Krabbe disease",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?3/60/4038/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/60/4038/contributors\">",
"     Robert P Cruse, DO",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?3/60/4038/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/60/4038/contributors\">",
"     Marc C Patterson, MD, FRACP",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/60/4038/contributors\">",
"     Helen V Firth, DM, FRCP, DCH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?3/60/4038/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/60/4038/contributors\">",
"     John F Dashe, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?3/60/4038/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 12, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Krabbe disease (globoid cell leukodystrophy) is a rare autosomal recessive lysosomal storage disorder (",
"    <a class=\"graphic graphic_table graphicRef56567 \" href=\"UTD.htm?36/27/37308\">",
"     table 1",
"    </a>",
"    ) caused by the deficiency of galactocerebrosidase. This topic will review the clinical aspects of Krabbe disease. Other lysosomal storage disorders are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/49/27414?source=see_link\">",
"     \"Neurologic manifestations of Fabry disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/11/9402?source=see_link\">",
"     \"Gaucher disease: Pathogenesis, clinical manifestations, and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/27/42421?source=see_link\">",
"     \"Metachromatic leukodystrophy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/6/7274?source=see_link\">",
"     \"Clinical features and diagnosis of the mucopolysaccharidoses\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/16/35082?source=see_link\">",
"     \"Complications and management of the mucopolysaccharidoses\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/0/20489?source=see_link\">",
"     \"Overview of Niemann-Pick disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20034641\">",
"    <span class=\"h1\">",
"     PATHOPHYSIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Krabbe disease (globoid cell leukodystrophy) is a rare autosomal recessive disorder caused by the deficiency of the enzyme galactocerebrosidase (GALC), also known as galactosylceramidase. Galactocerebrosidase is responsible for the liposomal hydrolysis of galactolipids formed during white matter myelination. The pathologic changes in the peripheral and central nervous system (globoid cell formation and decreased myelin) appear to result from the toxic nature of accumulated psychosine (galactosylsphingosine) and galactocerebroside (galactosylceramide) that cannot be degraded because of the galactocerebrosidase deficiency.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     GENETICS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The galactosylceramidase gene (GALC), also known as the galactocerebrosidase gene, is located on chromosome 14q31 [",
"    <a class=\"abstract\" href=\"UTD.htm?3/60/4038/abstract/1\">",
"     1",
"    </a>",
"    ]. More than 70 GALC mutations, including numerous small deletions and insertions, have been identified in patients with all clinical types of Krabbe disease [",
"    <a class=\"abstract\" href=\"UTD.htm?3/60/4038/abstract/2\">",
"     2",
"    </a>",
"    ]. Some mutations result in the infantile type if found homozygous or with another severe mutation, and one mutation predicts a less severe phenotype.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A 30 kb deletion is particularly common [",
"      <a class=\"abstract\" href=\"UTD.htm?3/60/4038/abstract/2,3\">",
"       2,3",
"      </a>",
"      ]. This mutation makes up approximately 40 to 45 percent of the mutant alleles in infantile patients in northern Europe and is present in approximately 35 percent of the mutant alleles in infantile Mexican patients.",
"     </li>",
"     <li>",
"      Approximately one-half of patients with the juvenile or adult phenotype are heterozygous for the large 30 kb gene deletion [",
"      <a class=\"abstract\" href=\"UTD.htm?3/60/4038/abstract/4\">",
"       4",
"      </a>",
"      ]. Other mutations in these patients may occur in a low-activity GALC allele [",
"      <a class=\"abstract\" href=\"UTD.htm?3/60/4038/abstract/4\">",
"       4",
"      </a>",
"      ]. As an example, reported patients with at least one copy of the 809G mutation have had a juvenile or adult phenotype, regardless of the mutation in the second allele [",
"      <a class=\"abstract\" href=\"UTD.htm?3/60/4038/abstract/5\">",
"       5",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most patients with Krabbe disease present with symptoms within the first six months of life; approximately 10 percent present later in life, including adulthood. A peripheral motor sensory neuropathy occurs in all patients, but the early onset forms are dominated by symptoms related to central nervous system dysfunction.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Infantile onset",
"    </span>",
"    &nbsp;&mdash;&nbsp;Symptoms usually develop from ages two to five months with infantile onset Krabbe disease [",
"    <a class=\"abstract\" href=\"UTD.htm?3/60/4038/abstract/6\">",
"     6",
"    </a>",
"    ]. Manifestations include irritability, developmental delay or regression, limb spasticity, axial hypotonia, absent reflexes, optic atrophy, and microcephaly [",
"    <a class=\"abstract\" href=\"UTD.htm?3/60/4038/abstract/6-8\">",
"     6-8",
"    </a>",
"    ]. Seizures eventually appear, and tonic extensor spasms occur upon stimulation with light, sound, or touch. These children regress rapidly to a decerebrate condition, with most dying before reaching two years of age.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Juvenile onset",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with juvenile onset disease typically present with weakness, loss of skills, and vision loss. Late infantile and juvenile patients regress at an unpredictable rate, but all become severely incapacitated and die two to seven years after diagnosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Adult onset",
"    </span>",
"    &nbsp;&mdash;&nbsp;Adult onset disease may be manifested initially by loss of manual dexterity, burning paresthesias in the extremities, weakness, or predominantly peripheral motor sensory neuropathy with loss of distal sensation and muscle atrophy with scoliosis [",
"    <a class=\"abstract\" href=\"UTD.htm?3/60/4038/abstract/3,9\">",
"     3,9",
"    </a>",
"    ]. Some adolescents and adults have symptoms confined to weakness without intellectual deterioration, whereas others become bedridden and continue to deteriorate mentally and physically [",
"    <a class=\"abstract\" href=\"UTD.htm?3/60/4038/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20035154\">",
"    <span class=\"h2\">",
"     Neuroimaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;Brain MRI typically (but not always) shows generalized atrophy with increased T2 signal from the periventricular and deep cerebral white matter, predominantly involving the parieto-occipital lobes (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef52319 \" href=\"UTD.htm?34/63/35830\">",
"     image 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?3/60/4038/abstract/11\">",
"     11",
"    </a>",
"    ]. Cerebellar white matter (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef64081 \" href=\"UTD.htm?0/40/646\">",
"     image 2",
"    </a>",
"    ) and deep gray matter involvement are often present in early onset disease [",
"    <a class=\"abstract\" href=\"UTD.htm?3/60/4038/abstract/6,12\">",
"     6,12",
"    </a>",
"    ]. In juvenile and adult onset disease, brain MRI may show increased T2 signal involving the bilateral corticospinal tracts (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef71266 \" href=\"UTD.htm?16/21/16726\">",
"     image 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?3/60/4038/abstract/13\">",
"     13",
"    </a>",
"    ]. &nbsp;Head CT scan most often shows increased signal in the basal ganglia or thalamus. In one report of symptomatic children with early infantile Krabbe disease, MRI scans were abnormal in 32 of 42 (76 percent), and CT scans of the brain were abnormal in 10 of 15 (67 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?3/60/4038/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Electrodiagnostic studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Neurophysiologic studies are abnormal in a majority of children with infantile onset Krabbe disease. Nerve conduction studies (NCS) show marked slowing of both motor and sensory nerve conduction velocities in most patients with infantile onset, even in presymptomatic disease, and in 20 percent of those with late onset disease [",
"    <a class=\"abstract\" href=\"UTD.htm?3/60/4038/abstract/14,15\">",
"     14,15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the largest published series of 27 children with Krabbe disease ranging in age from one day to eight years who were evaluated with electrodiagnostic studies, the following observations were made [",
"    <a class=\"abstract\" href=\"UTD.htm?3/60/4038/abstract/16\">",
"     16",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Nerve conduction studies were abnormal in 25 (93 percent). Abnormalities were found most frequently with sural sensory responses, F-wave latencies, motor conduction velocities, and distal motor latencies (82, 85, 82, and 76 percent, respectively). No conduction block was seen in any child.",
"     </li>",
"     <li>",
"      In the 24 children with the early infantile form, NCS were abnormal in 23 (96 percent), and marked NCS abnormalities were found in three neonates less than one month old; the youngest was one day old and asymptomatic.",
"     </li>",
"     <li>",
"      Among nine children with normal electroencephalogram or evoked potential testing, NCS were abnormal in five (56 percent).",
"     </li>",
"     <li>",
"      The severity of abnormalities on NCS testing correlated with clinical disease severity. These results suggest that the severity of NCS abnormalities may reflect the degree of central nervous system involvement.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Symptomatic children frequently have abnormalities on brainstem and visual evoked potentials as well as electroencephalogram (EEG) [",
"    <a class=\"abstract\" href=\"UTD.htm?3/60/4038/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20035262\">",
"    <span class=\"h2\">",
"     Cerebrospinal fluid",
"    </span>",
"    &nbsp;&mdash;&nbsp;Elevated cerebrospinal fluid protein concentration is a characteristic but not universal feature of Krabbe disease, and is thought to occur because of the breakdown of myelin associated with the disorder. In a registry of 25 symptomatic children with early infantile Krabbe disease who had lumbar puncture, elevated CSF protein levels were present in 23 (92 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?3/60/4038/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20035255\">",
"    <span class=\"h2\">",
"     Pathology",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pathologically, peripheral nerve demyelination and periodic acid-Schiff-positive multinucleated globoid cells are present. Hypomyelination occurs in the early onset form and segmental demyelination in the late onset type. Electron microscopy shows curvilinear lamellar inclusions in Schwann cells and histiocytes. Pathologic findings in the CNS include globoid cells, generalized loss of myelin, and almost total loss of oligodendroglia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The definitive diagnosis of Krabbe disease is made by measurement of galactocerebrosidase activity in leukocytes isolated from whole blood or cultured skin fibroblasts [",
"    <a class=\"abstract\" href=\"UTD.htm?3/60/4038/abstract/17\">",
"     17",
"    </a>",
"    ]. Typical values in patients with Krabbe disease are &lt;5 percent of the normal value. The residual activity is not an indicator of clinical type or prognosis.",
"   </p>",
"   <p>",
"    In addition, molecular genetic testing is available to confirm the diagnosis of Krabbe disease [",
"    <a class=\"abstract\" href=\"UTD.htm?3/60/4038/abstract/2\">",
"     2",
"    </a>",
"    ], and is also useful for genetic counseling.",
"   </p>",
"   <p>",
"    A method for newborn screening uses tandem mass spectrometry to directly assay galactocerebrosidase in dried blood spots for the detection of Krabbe disease [",
"    <a class=\"abstract\" href=\"UTD.htm?3/60/4038/abstract/18\">",
"     18",
"    </a>",
"    ]. This screening technique is being implemented by at least one US state (New York) [",
"    <a class=\"abstract\" href=\"UTD.htm?3/60/4038/abstract/19,20\">",
"     19,20",
"    </a>",
"    ]. However, the utility of screening is limited because neither enzyme activity nor knowledge of the genetic mutation can reliably predict phenotype. In addition, the long-term benefit of umbilical cord blood transplantation is unknown. (See",
"    <a class=\"local\" href=\"#H9\">",
"     'Management'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Prenatal diagnosis for at-risk couples is performed by measuring GALC activity in a chorionic villi sample or cultured amniocytes [",
"    <a class=\"abstract\" href=\"UTD.htm?3/60/4038/abstract/17\">",
"     17",
"    </a>",
"    ]. Prenatal diagnosis can also be achieved by molecular genetic analysis if both disease-causing mutations are known [",
"    <a class=\"abstract\" href=\"UTD.htm?3/60/4038/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    All siblings of confirmed Krabbe disease cases should be tested preferably during the prenatal period or in the immediate new born period for GALC activity, and preferably with molecular genetic testing, particularly if the genetic profile of the proband is known. Older asymptomatic siblings who are galactocerebrosidase deficient should be observed closely, but these patients may not become symptomatic or require treatment because of heterogeneity.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;No proven therapeutic options currently are available for symptomatic patients with the infantile form of Krabbe disease. In such cases, supportive care is the only viable option to manage irritability and spasticity [",
"    <a class=\"abstract\" href=\"UTD.htm?3/60/4038/abstract/2\">",
"     2",
"    </a>",
"    ]. The available evidence, discussed in greater detail below, suggests but does not establish that hematopoietic stem cell transplantation is beneficial for the infantile form of Krabbe, but only if performed before the onset of symptoms, and for patients with juvenile onset Krabbe disease [",
"    <a class=\"abstract\" href=\"UTD.htm?3/60/4038/abstract/22,23\">",
"     22,23",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Hematopoietic stem cell transplantation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Preliminary studies have reported beneficial clinical effects using hematopoietic stem cell transplantation to treat the infantile form of Krabbe, but only if performed before the onset of symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?3/60/4038/abstract/23\">",
"     23",
"    </a>",
"    ]. The treatment of Krabbe disease using hematopoietic stem cells has become a safer procedure with the development of techniques such as accurate HLA typing, depletion of donor T lymphocytes, and umbilical cord blood. However, the stem cell transplantation requires myelosuppressive therapy and is not without potential risk. Furthermore, long-term benefit for this intervention has not been established; the median follow-up of published series is approximately three years.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      One report examined the effect of umbilical cord blood transplantation from unrelated donors in 11 asymptomatic (ages 12 to 44 days) and 14 symptomatic newborns (ages 142 to 352 days) with infantile Krabbe disease [",
"      <a class=\"abstract\" href=\"UTD.htm?3/60/4038/abstract/23\">",
"       23",
"      </a>",
"      ]. All patients received myeloablative chemotherapy prior to transplantation. The following observations were noted:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      At a median follow-up of three years, all 11 children who had transplantation as",
"      <strong>",
"       asymptomatic",
"      </strong>",
"      newborns remained alive and demonstrated normal progression of central myelination by MRI [",
"      <a class=\"abstract\" href=\"UTD.htm?3/60/4038/abstract/23\">",
"       23",
"      </a>",
"      ]. In 10 of these children who had neurocognitive evaluations after transplantation, all had age-appropriate language, and nine had age-appropriate cognitive function. Of some concern, four had mild to moderate delay in gross motor function. These findings contrasted with the disease progression seen in an untreated control group of registry patients, most of whom experienced overwhelming spasticity, blindness, and death by one or two years of age. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Infantile onset'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      At a median follow-up of 3.4 years, only 6 of 14 infants who were",
"      <strong>",
"       symptomatic",
"      </strong>",
"      at the time of transplantation had survived; the survival rate for this group was not statistically different from survival among the untreated controls [",
"      <a class=\"abstract\" href=\"UTD.htm?3/60/4038/abstract/23\">",
"       23",
"      </a>",
"      ]. None of the surviving patients from the symptomatic group demonstrated appreciable improvement in any domain of neurocognitive function.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In an earlier study, hematopoietic stem cell transplantation was performed in five children with Krabbe disease (one with asymptomatic infantile type and four with late onset disease) [",
"      <a class=\"abstract\" href=\"UTD.htm?3/60/4038/abstract/22\">",
"       22",
"      </a>",
"      ]. Engraftment occurred in all patients, and normal leukocyte galactocerebrosidase levels were restored. In the four patients with late onset disease, the CNS deterioration was reversed, whereas no signs or symptoms appeared in the patient with infantile onset disease. Brain MRI showed a decrease in signal intensity in three patients studied before and after transplantation.",
"     </li>",
"     <li>",
"      Hematopoietic stem cell transplantation may also improve peripheral nerve conduction abnormalities, especially if performed within the first month of life [",
"      <a class=\"abstract\" href=\"UTD.htm?3/60/4038/abstract/24\">",
"       24",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The advent of hematopoietic stem cell transplantation for infantile Krabbe disease presents a therapeutic dilemma, since the procedure appears to provide benefit only when performed in the presymptomatic stage. However, there is no reliable way to predict phenotype in early infantile Krabbe disease based upon low galactocerebrosidase activity or genotype, and some untreated children with low galactocerebrosidase activity and two genetic mutations in the New York State screening program have remained asymptomatic [",
"    <a class=\"abstract\" href=\"UTD.htm?3/60/4038/abstract/6\">",
"     6",
"    </a>",
"    ]. Early intervention with hematopoietic stem cell transplantation in these cases would likely have been considered &ldquo;successful&rdquo;. Furthermore, there have not been any documented cures of symptomatic patients, and no additional studies have confirmed the initial transplant data. Therefore, we inform potential candidates and their families of the option of hematopoietic stem cell transplantation, being careful to point out the uncertain benefit and potential risks of this therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20034632\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Krabbe disease (globoid cell leukodystrophy) is a rare autosomal recessive disorder caused by the deficiency of galactocerebrosidase. The pathologic changes in the peripheral and central nervous system (globoid cell formation and decreased myelin) result from the toxic nature of psychosine and the accumulation of galactocerebroside (galactosylceramide) that cannot be degraded because of the GALC deficiency. (See",
"      <a class=\"local\" href=\"#H20034641\">",
"       'Pathophysiology'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H2\">",
"       'Genetics'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Most patients with Krabbe disease present with symptoms within the first six months of life; approximately 10 percent present later in life, including adulthood. A peripheral motor sensory neuropathy occurs in all patients, but the early onset forms are dominated by symptoms related to central nervous system dysfunction. Infantile onset disease is associated with irritability, developmental delay or regression, limb spasticity, axial hypotonia, absent reflexes, optic atrophy, and microcephaly. Seizures and tonic extensor spasms eventually appear. Typically there is rapid regression to a decerebrate condition and death before two years of age. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The definitive diagnosis of Krabbe disease is made by measurement of GALC activity in leukocytes isolated from whole blood or cultured skin fibroblasts. Typical values in patients with Krabbe disease are &lt;5 percent of normal. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      No proven therapeutic options currently are available for patients with Krabbe disease. While preliminary evidence suggests that hematopoietic stem cell transplantation is beneficial for the infantile form if performed before the onset of symptoms, there is no reliable way to predict later phenotype for such infants, and some will have minimal or no symptoms without treatment. There is limited evidence that symptomatic children with the late onset (juvenile) form of Krabbe disease may benefit from transplantation even after the onset of symptoms. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Hematopoietic stem cell transplantation'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/60/4038/abstract/1\">",
"      Luzi P, Rafi MA, Wenger DA. Structure and organization of the human galactocerebrosidase (GALC) gene. Genomics 1995; 26:407.",
"     </a>",
"    </li>",
"    <li>",
"     Wenger DA. Krabbe disease. GeneReviews. www.ncbi.nlm.nih.gov/books/NBK1238/ (Accessed on December 14, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/60/4038/abstract/3\">",
"      Rafi MA, Luzi P, Chen YQ, Wenger DA. A large deletion together with a point mutation in the GALC gene is a common mutant allele in patients with infantile Krabbe disease. Hum Mol Genet 1995; 4:1285.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/60/4038/abstract/4\">",
"      De Gasperi R, Gama Sosa MA, Sartorato EL, et al. Molecular heterogeneity of late-onset forms of globoid-cell leukodystrophy. Am J Hum Genet 1996; 59:1233.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/60/4038/abstract/5\">",
"      Wenger DA, Rafi MA, Luzi P. Molecular genetics of Krabbe disease (globoid cell leukodystrophy): diagnostic and clinical implications. Hum Mutat 1997; 10:268.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/60/4038/abstract/6\">",
"      Duffner PK, Barczykowski A, Jalal K, et al. Early infantile Krabbe disease: results of the World-Wide Krabbe Registry. Pediatr Neurol 2011; 45:141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/60/4038/abstract/7\">",
"      Dunn HG, Lake BD, Dolman CL, Wilson J. The neuropathy of Krabbe's infantile cerebral sclerosis (globoid cell leucodystrophy). Brain 1969; 92:329.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/60/4038/abstract/8\">",
"      Duffner PK, Jalal K, Carter RL. The Hunter's Hope Krabbe family database. Pediatr Neurol 2009; 40:13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/60/4038/abstract/9\">",
"      Marks HG, Scavina MT, Kolodny EH, et al. Krabbe's disease presenting as a peripheral neuropathy. Muscle Nerve 1997; 20:1024.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/60/4038/abstract/10\">",
"      Kolodny EH, Raghavan S, Krivit W. Late-onset Krabbe disease (globoid cell leukodystrophy): clinical and biochemical features of 15 cases. Dev Neurosci 1991; 13:232.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/60/4038/abstract/11\">",
"      Schiffmann R, van der Knaap MS. Invited article: an MRI-based approach to the diagnosis of white matter disorders. Neurology 2009; 72:750.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/60/4038/abstract/12\">",
"      Loes DJ, Peters C, Krivit W. Globoid cell leukodystrophy: distinguishing early-onset from late-onset disease using a brain MR imaging scoring method. AJNR Am J Neuroradiol 1999; 20:316.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/60/4038/abstract/13\">",
"      Sehgal R, Sharma S, Sankhyan N, et al. Selective corticospinal tract involvement in late-onset Krabbe disease. Neurology 2011; 77:e20.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/60/4038/abstract/14\">",
"      Miller RG, Gutmann L, Lewis RA, Sumner AJ. Acquired versus familial demyelinative neuropathies in children. Muscle Nerve 1985; 8:205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/60/4038/abstract/15\">",
"      Husain AM, Altuwaijri M, Aldosari M. Krabbe disease: neurophysiologic studies and MRI correlations. Neurology 2004; 63:617.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/60/4038/abstract/16\">",
"      Siddiqi ZA, Sanders DB, Massey JM. Peripheral neuropathy in Krabbe disease: electrodiagnostic findings. Neurology 2006; 67:263.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/60/4038/abstract/17\">",
"      Wenger DA, Rafi MA, Luzi P, et al. Krabbe disease: genetic aspects and progress toward therapy. Mol Genet Metab 2000; 70:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/60/4038/abstract/18\">",
"      Li Y, Brockmann K, Turecek F, et al. Tandem mass spectrometry for the direct assay of enzymes in dried blood spots: application to newborn screening for Krabbe disease. Clin Chem 2004; 50:638.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/60/4038/abstract/19\">",
"      Duffner PK, Caggana M, Orsini JJ, et al. Newborn screening for Krabbe disease: the New York State model. Pediatr Neurol 2009; 40:245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/60/4038/abstract/20\">",
"      Steiner RD. Commentary on: \"Newborn screening for Krabbe Disease: the New York state model\" and \"the long-term outcomes of presymptomatic infants transplanted for Krabbe disease. A report of the workshop held on July 11 and 12, 2008, Holiday Valley, New York\". Genet Med 2009; 11:411.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/60/4038/abstract/21\">",
"      Kleijer WJ, Keulemans JL, van der Kraan M, et al. Prevalent mutations in the GALC gene of patients with Krabbe disease of Dutch and other European origin. J Inherit Metab Dis 1997; 20:587.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/60/4038/abstract/22\">",
"      Krivit W, Shapiro EG, Peters C, et al. Hematopoietic stem-cell transplantation in globoid-cell leukodystrophy. N Engl J Med 1998; 338:1119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/60/4038/abstract/23\">",
"      Escolar ML, Poe MD, Provenzale JM, et al. Transplantation of umbilical-cord blood in babies with infantile Krabbe's disease. N Engl J Med 2005; 352:2069.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/60/4038/abstract/24\">",
"      Siddiqi ZA, Sanders DB, Massey JM. Peripheral neuropathy in Krabbe disease: effect of hematopoietic stem cell transplantation. Neurology 2006; 67:268.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6188 Version 4.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-110.170.48.130-B1CD8C1B47-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_60_4038=[""].join("\n");
var outline_f3_60_4038=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H20034632\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20034641\">",
"      PATHOPHYSIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      GENETICS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Infantile onset",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Juvenile onset",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Adult onset",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20035154\">",
"      Neuroimaging",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Electrodiagnostic studies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20035262\">",
"      Cerebrospinal fluid",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20035255\">",
"      Pathology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Hematopoietic stem cell transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20034632\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/6188\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/6188|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?34/63/35830\" title=\"diagnostic image 1\">",
"      Brain MRI 2 year old with Krabbe disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?0/40/646\" title=\"diagnostic image 2\">",
"      Brain MRI 8 month old with Krabbe disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?16/21/16726\" title=\"diagnostic image 3\">",
"      Brain MRI 4 year old with Krabbe disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/6188|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?36/27/37308\" title=\"table 1\">",
"      Lysosomal storage disorders",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/6/7274?source=related_link\">",
"      Clinical features and diagnosis of the mucopolysaccharidoses",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/16/35082?source=related_link\">",
"      Complications and management of the mucopolysaccharidoses",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/11/9402?source=related_link\">",
"      Gaucher disease: Pathogenesis, clinical manifestations, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/27/42421?source=related_link\">",
"      Metachromatic leukodystrophy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/49/27414?source=related_link\">",
"      Neurologic manifestations of Fabry disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/0/20489?source=related_link\">",
"      Overview of Niemann-Pick disease",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f3_60_4039="Mutations PIs";
var content_f3_60_4039=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F79835&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F79835&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 618px\">",
"   <div class=\"ttl\">",
"    Mutations in the protease gene associated with resistance to protease inhibitors",
"    <sup>",
"     o,p,q",
"    </sup>",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 598px; height: 556px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reprinted with permission from: the International AIDS Society-USA. Johnson VA, Brun-V&eacute;zinet F, Clotet B, G&uuml;nthard HF, Kuritzkes DR, Pillay D, Schapiro JM, and Richman DD. Update of the Drug Resistance Mutations in HIV-1: December 2010. Topics in HIV Medicine 2010; 18(5):156-163. Updated information (and thorough explanatory notes) are available at",
"     <a href=\"file://www.iasusa.org\" target=\"_blank\">",
"      www.iasusa.org",
"     </a>",
"     .",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_60_4039=[""].join("\n");
var outline_f3_60_4039=null;
var title_f3_60_4040="Breast cysts: Clinical manifestations, diagnosis, and management";
var content_f3_60_4040=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Breast cysts: Clinical manifestations, diagnosis, and management",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?3/60/4040/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/60/4040/contributors\">",
"     Christine Laronga, MD, FACS",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/60/4040/contributors\">",
"     Sharon Tollin, PhD, ARNP-BC, OCN",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/60/4040/contributors\">",
"     Marjorie Thurlow, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?3/60/4040/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/60/4040/contributors\">",
"     Anees B Chagpar, MD, MSc, MA, MPH, FACS, FRCS(C)",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?3/60/4040/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/60/4040/contributors\">",
"     Rosemary B Duda, MD, MPH, FACS",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?3/60/4040/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 18, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;A breast cyst is a fluid-filled round or ovoid mass derived from the terminal duct lobular unit (TDLU) (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef63321 \" href=\"UTD.htm?41/50/42785\">",
"     image 1",
"    </a>",
"    ). Cysts begin as fluid accumulation in the TDLU because of distension and obstruction of the efferent ductule [",
"    <a class=\"abstract\" href=\"UTD.htm?3/60/4040/abstract/1\">",
"     1",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/10/20649?source=see_link&amp;anchor=H6#H6\">",
"     \"Breast development and morphology\", section on 'Lobule formation'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Breast cysts, which can present as a solitary mass or multiple masses, usually prompt women to seek medical attention because of the palpable mass or associated pain or discomfort. A breast cyst may be first identified on a clinical or self-breast examination, or as a mammographic density. Breast cysts may fluctuate in size, number, and magnitude of symptoms.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H202991655\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Breast cysts are influenced by hormonal function and fluctuation. Therefore, they occur during lobular development, menstrual cyclic changes, and lobular involution in premenopausal and perimenopausal women [",
"    <a class=\"abstract\" href=\"UTD.htm?3/60/4040/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Breast cysts are common masses found in premenopausal, perimenopausal, and postmenopausal women. In a prospective study of 2809 women at increased risk of breast cancer development, the American College of Radiology Imaging Network (ACRIN) 6666 protocol found that cysts were identified in 37.5 percent of all women screened, with the peak incidence between 35 and 50 years of age [",
"    <a class=\"abstract\" href=\"UTD.htm?3/60/4040/abstract/3\">",
"     3",
"    </a>",
"    ]. During this three-year screening study, cysts were identified more often in premenopausal women compared with postmenopausal women (65.1 versus 39.4 percent). Hormone replacement therapy (HRT) was used by 5.4 percent (n=73) of postmenopausal women, and 66 percent of HRT users were diagnosed with cysts.",
"   </p>",
"   <p>",
"    Symptomatic and asymptomatic small cysts (microcysts) are common in young premenopausal women [",
"    <a class=\"abstract\" href=\"UTD.htm?3/60/4040/abstract/4\">",
"     4",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/15/24825?source=see_link&amp;anchor=H18#H18\">",
"     \"Breast masses and other common breast problems\", section on 'Breast masses'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/52/11081?source=see_link&amp;anchor=H3#H3\">",
"     \"Overview of benign breast disease\", section on 'Nonproliferative breast lesions'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H100217503\">",
"    <span class=\"h1\">",
"     CLINICAL FEATURES",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H91862437\">",
"    <span class=\"h2\">",
"     Patient presentation",
"    </span>",
"    &nbsp;&mdash;&nbsp;A breast cyst can present as a painful or painless, often solitary, mass. The mass may be large (gross), small (microcysts), or a cluster of small microcysts. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/15/24825?source=see_link&amp;anchor=H3#H3\">",
"     \"Breast masses and other common breast problems\", section on 'Presenting symptoms'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Acute enlargement of cysts may cause severe, localized pain of sudden onset. Microcystic changes of the breast frequently cause pain",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    tenderness prior to the onset of menses, and sometimes pain persists throughout the menstrual cycle.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H91862472\">",
"    <span class=\"h2\">",
"     Physical examination findings",
"    </span>",
"    &nbsp;&mdash;&nbsp;Physical examination alone cannot definitively distinguish between a benign cyst, benign solid mass, and a malignancy. A large or small breast cyst can be palpated as a smooth, firm, discreet, and frequently tender mass. Cysts may present as a cluster of small masses or an ill-defined mass. The texture is variable, often described as similar to a grape, water-balloon, or even a hard mass. Some, but not all cysts have a sharp distinct border and are ballotable. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/15/24825?source=see_link&amp;anchor=H14#H14\">",
"     \"Breast masses and other common breast problems\", section on 'Physical examination'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/15/24825?source=see_link&amp;anchor=H18#H18\">",
"     \"Breast masses and other common breast problems\", section on 'Breast masses'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H91862589\">",
"    <span class=\"h2\">",
"     Imaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;Breast cysts can be evaluated by several imaging studies.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H91862703\">",
"    <span class=\"h3\">",
"     Ultrasonography",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ultrasonography is used to differentiate between a mass that is a fluid-filled, solid, or contains mixed elements.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H202993215\">",
"    <span class=\"h4\">",
"     Classification",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cysts are classified as simple, complicated, or complex based upon the characteristics identified by ultrasound evaluation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/35/39482?source=see_link\">",
"     \"Breast imaging: Mammography and ultrasonography\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H202992300\">",
"    <span class=\"h5\">",
"     Simple",
"    </span>",
"    &nbsp;&mdash;&nbsp;A simple cyst is well-circumscribed with ultrasonic features that include posterior acoustic enhancement, without internal echoes (anechoic), solid components, or Doppler signal (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef73503 \" href=\"UTD.htm?20/55/21360\">",
"     image 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_diagnosticimage graphicRef83700 \" href=\"UTD.htm?22/25/22932\">",
"     image 3",
"    </a>",
"    ). Simple cysts are, by definition, benign lesions.",
"   </p>",
"   <p>",
"    Clustered microcysts and cysts with thin septa are subsets of simple cysts. Clustered microcysts are a cluster of simple anechoic cysts, each smaller than 2 to 3 mm, without discrete solid components. Cysts with thin septa that are less than 0.5 mm in thickness are defined as simple cysts.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H202992307\">",
"    <span class=\"h5\">",
"     Complicated",
"    </span>",
"    &nbsp;&mdash;&nbsp;Complicated cysts are defined by ultrasound criteria as masses with homogenous low-level internal echoes due to echogenic debris, without solid components, thick walls, or thick septa, and without vascular flow (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef80160 \" href=\"UTD.htm?7/57/8087\">",
"     image 4",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?3/60/4040/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H202992314\">",
"    <span class=\"h5\">",
"     Complex",
"    </span>",
"    &nbsp;&mdash;&nbsp;Complex cysts are defined by ultrasound criteria as masses with thick walls",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    septa greater than 0.5 mm, presence of cystic and solid components, and absence of posterior wall enhancement (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef80160 \" href=\"UTD.htm?7/57/8087\">",
"     image 4",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?3/60/4040/abstract/6\">",
"     6",
"    </a>",
"    ]. The ultrasound appearance of complex cysts can demonstrate anechoic and echogenic components.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H202991771\">",
"    <span class=\"h4\">",
"     BI-RADS categories",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Breast Imaging Reporting and Data System (BI-RADS) final assessment categories used for reporting mammographic findings and recommendations are also applicable to ultrasound examinations [",
"    <a class=\"abstract\" href=\"UTD.htm?3/60/4040/abstract/7-10\">",
"     7-10",
"    </a>",
"    ]. Assessments are either incomplete (category 0) or final assessment categories (categories 1 through 6) (",
"    <a class=\"graphic graphic_table graphicRef66601 \" href=\"UTD.htm?38/19/39227\">",
"     table 1",
"    </a>",
"    ). The BI-RADS assessments are used to guide clinical decision making and the need for biopsy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/35/39482?source=see_link&amp;anchor=H13#H13\">",
"     \"Breast imaging: Mammography and ultrasonography\", section on 'Mammography quality control'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The BI-RADS classification criteria for ultrasound imaging of breast masses include [",
"    <a class=\"abstract\" href=\"UTD.htm?3/60/4040/abstract/8,9\">",
"     8,9",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Shape (ie, oval, round, lobular, irregular)",
"     </li>",
"     <li>",
"      Margin (ie, circumscribed, obscured, microlobulated, ill-defined, spiculated)",
"     </li>",
"     <li>",
"      Orientation (ie, parallel or not parallel to skin)",
"     </li>",
"     <li>",
"      Matrix echogenicity (ie, anechoic, hypoechoic, hyperechoic)",
"     </li>",
"     <li>",
"      Homogeneity (ie, homogeneous, heterogeneous)",
"     </li>",
"     <li>",
"      Attenuation (ie, indifferent, shadowing, enhancement)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H274795950\">",
"    <span class=\"h4\">",
"     Risk of malignancy",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is no increased risk of breast cancer detection in a mass that fulfills the ultrasound diagnostic criteria of a simple cyst [",
"    <a class=\"abstract\" href=\"UTD.htm?3/60/4040/abstract/4,11\">",
"     4,11",
"    </a>",
"    ], and breast cancer presenting as a complicated cyst is rare (&lt;1 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?3/60/4040/abstract/3,4,11\">",
"     3,4,11",
"    </a>",
"    ]. However, the risk of malignancy in a complex cyst generally ranges from &lt;1 to 23 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?3/60/4040/abstract/4,12-17\">",
"     4,12-17",
"    </a>",
"    ]. The wide range of malignant findings may be due, in part, to technical accuracy of ultrasound to differentiate solid from cystic components of breast masses and the interpretation of the ultrasound findings.",
"   </p>",
"   <p>",
"    Ultrasonographic features that increase the likelihood of malignancy in the complex cystic breast mass include thickened cyst wall, thick septations, mixed",
"    <span class=\"nowrap\">",
"     cystic/solid",
"    </span>",
"    components, lobulations, indeterminant classification, and hyperechogenicity [",
"    <a class=\"abstract\" href=\"UTD.htm?3/60/4040/abstract/4,13,16,17\">",
"     4,13,16,17",
"    </a>",
"    ]. The presence of two or more abnormal ultrasonographic criteria was associated with a 10- to 14-fold increase in breast cancer detected in the lesion [",
"    <a class=\"abstract\" href=\"UTD.htm?3/60/4040/abstract/13,16\">",
"     13,16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Incomplete resolution",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    bloody fluid in a complex cyst were also associated with malignant findings in a complex cyst [",
"    <a class=\"abstract\" href=\"UTD.htm?3/60/4040/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H91862889\">",
"    <span class=\"h3\">",
"     Mammography",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mammography depicts a large cyst (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef83701 \" href=\"UTD.htm?2/3/2101\">",
"     image 5",
"    </a>",
"    ) or a cluster of small cysts (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef83699 \" href=\"UTD.htm?42/54/43877\">",
"     image 6",
"    </a>",
"    ) as a density that has well defined or partially obscured borders. Small microcysts typically are not visualized on a mammogram. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/35/39482?source=see_link&amp;anchor=H27#H27\">",
"     \"Breast imaging: Mammography and ultrasonography\", section on 'Diagnostic mammogram'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H91862905\">",
"    <span class=\"h3\">",
"     MRI",
"    </span>",
"    &nbsp;&mdash;&nbsp;Magnetic resonance imaging (MRI) depicts a cyst as a round or oval sharply-defined mass (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef83851 \" href=\"UTD.htm?25/30/26085\">",
"     image 7",
"    </a>",
"    ). A cluster of cysts is similarly depicted (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef85530 \" href=\"UTD.htm?42/59/43957\">",
"     image 8",
"    </a>",
"    ). The typical cyst will appear as a bright, high signal intensity T2 fat-suppressed weighted image. After injection of gadolinium, a cyst appears as filling defect, sometimes with rim enhancement. If septations are present, they are nonenhancing [",
"    <a class=\"abstract\" href=\"UTD.htm?3/60/4040/abstract/18\">",
"     18",
"    </a>",
"    ]. The indications and findings on MRI of the breast are reviewed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/29/23002?source=see_link\">",
"     \"MRI of the breast and emerging technologies\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H100217511\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;A palpable or nonpalpable breast cyst may be simple, complicated, or complex.",
"   </p>",
"   <p>",
"    The diagnosis of a simple breast cyst is based upon fulfilling the ultrasound criteria for a simple cyst (see",
"    <a class=\"local\" href=\"#H202992300\">",
"     'Simple'",
"    </a>",
"    above) An alternative to an ultrasound for a palpable mass or confirmation of ultrasonographic findings of a breast cyst is the fine needle aspiration (FNA). A simple cyst aspirate is nonbloody and the cyst completely collapses. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/59/24504?source=see_link&amp;anchor=H2#H2\">",
"     \"Breast biopsy\", section on 'Fine needle aspiration biopsy'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/35/39482?source=see_link\">",
"     \"Breast imaging: Mammography and ultrasonography\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The diagnosis of complicated and complex breast cysts is based upon ultrasound assessment that identifies septa",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    solid components. (See",
"    <a class=\"local\" href=\"#H202992307\">",
"     'Complicated'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H202992314\">",
"     'Complex'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    An excisional biopsy is not required to diagnose a simple cyst, clustered cysts, or cysts with thin septa. The absolute indications for a surgical biopsy of a cystic lesion are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/59/24504?source=see_link&amp;anchor=H14#H14\">",
"     \"Breast biopsy\", section on 'Excisional biopsy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H100217559\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The differential of a breast cyst, whether identified on a self or clinical breast examination, or by an imaging study, includes benign and malignant lesions [",
"    <a class=\"abstract\" href=\"UTD.htm?3/60/4040/abstract/19,20\">",
"     19,20",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/15/24825?source=see_link\">",
"     \"Breast masses and other common breast problems\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/35/39482?source=see_link\">",
"     \"Breast imaging: Mammography and ultrasonography\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A mass that fulfills the ultrasonographic criteria for a simple cyst is a simple cyst. A FNA that identifies nonbloody fluid and results in complete collapse of the mass is also diagnostic of a simple cyst. No further diagnostic evaluation is required.",
"     </li>",
"     <li>",
"      The differential diagnosis of a complicated or complex cyst includes:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Abscess &ndash; A breast abscess presents with localized, painful inflammation of the breast associated with fever and malaise, along with a fluctuant, tender, palpable mass. Although this is primarily a clinical diagnosis, ultrasound imaging is helpful for confirmation of the diagnosis and for directed aspiration of the purulent drainage. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?9/17/9495?source=see_link&amp;anchor=H5#H5\">",
"       \"Breast abscess\", section on 'Clinical manifestations and diagnosis'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Hematoma &ndash; Hematoma is a collection of partially solidified blood that results from trauma or a prior surgical procedure of the breast. An ultrasound may reveal a complicated cystic lesion that may require an aspiration for confirmation.",
"     </li>",
"     <li>",
"      Fat necrosis &ndash; Fat necrosis of the breast is a benign condition that most commonly occurs as the result of breast trauma and generally can be confused with a malignancy on physical examination. It may contain partially liquified fat on the ultrasound assessment. Diagnosis can be confirmed by a fine needle aspiration or excisional biopsy. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?10/52/11081?source=see_link&amp;anchor=H21#H21\">",
"       \"Overview of benign breast disease\", section on 'Fat necrosis'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Galactocele &ndash; Galactoceles (milk retention cysts) are cystic collections of fluid, usually caused by an obstructed milk duct. These present as soft cystic masses on physical exam, but are not tender and are not associated with systemic findings. Ultrasound may show a complex mass. Diagnosis can be made on the basis of the clinical history and aspiration, which yields a milky substance. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?17/15/17658?source=see_link\">",
"       \"Common problems of breastfeeding and weaning\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Noninfectious disorder &ndash; Noninfectious disorders, including duct ectasia characterized by distension of subareolar ducts with fibrosis, benign inflammatory periductal mastitis, and a ruptured cyst or duct may present as a complex or complicated cyst on ultrasound imaging. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?0/53/857?source=see_link&amp;anchor=H8#H8\">",
"       \"Erythematous disorders of the breast\", section on 'Noninfectious mastitis'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Oil cyst (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef61168 \" href=\"UTD.htm?2/60/3016\">",
"       image 9",
"      </a>",
"      ) &ndash; An oil cyst contains a collection of liquified fat. If there is any question on the ultrasound, an aspiration can be performed to confirm a diagnosis. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?10/52/11081?source=see_link&amp;anchor=H21#H21\">",
"       \"Overview of benign breast disease\", section on 'Fat necrosis'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Malignancy &ndash; A colloidal breast cancer or a cyst wall cancer may have a similar appearance to a complicated or complex cyst on ultrasound assessment, mammogram,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      MRI. Apocrine papillary carcinoma can present as a complex cyst with a mural nodule on ultrasound [",
"      <a class=\"abstract\" href=\"UTD.htm?3/60/4040/abstract/21,22\">",
"       21,22",
"      </a>",
"      ]. Diagnosis can be established by a fine needle aspiration, core biopsy, or excisional biopsy. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?23/36/24138?source=see_link\">",
"       \"Diagnostic evaluation of women with suspected breast cancer\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H100217519\">",
"    <span class=\"h1\">",
"     MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Once a breast mass is identified as a cyst, either by a FNA or ultrasound, management depends upon the clinical findings",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    ultrasonographic features. An aspirate that is bloody or does not result in complete collapse of the mass requires further evaluation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H100220008\">",
"    <span class=\"h2\">",
"     Simple cyst",
"    </span>",
"    &nbsp;&mdash;&nbsp;A simple cyst is benign and no further intervention is necessary [",
"    <a class=\"abstract\" href=\"UTD.htm?3/60/4040/abstract/23,24\">",
"     23,24",
"    </a>",
"    ]. Clustered simple microcysts are also benign and no further intervention is required.",
"   </p>",
"   <p>",
"    Aspiration of a simple cyst should be considered in the following clinical settings:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Severe pain &ndash; A painful simple cyst can be aspirated for patient comfort, but most pain or discomfort subsides within days without aspiration.",
"     </li>",
"     <li>",
"      Obstruction of adjacent breast tissue &ndash; A gross (large) cyst that obscures breast tissue on a mammogram or clinical examination should be aspirated. The aspiration can be performed under ultrasonographic guidance with real-time imaging to assure complete collapse of the cyst [",
"      <a class=\"abstract\" href=\"UTD.htm?3/60/4040/abstract/25\">",
"       25",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Following aspiration of a cyst that completely disappears, no further management is required if there is concordance between the clinical examination and ultrasound results [",
"    <a class=\"abstract\" href=\"UTD.htm?3/60/4040/abstract/26\">",
"     26",
"    </a>",
"    ]. One short-term follow-up clinical breast examination",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    ultrasound in two to four months is performed to document clinical stability [",
"    <a class=\"abstract\" href=\"UTD.htm?3/60/4040/abstract/5\">",
"     5",
"    </a>",
"    ]. The patient can then resume routine annual screening [",
"    <a class=\"abstract\" href=\"UTD.htm?3/60/4040/abstract/15\">",
"     15",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/49/41754?source=see_link\">",
"     \"Screening for breast cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    If the aspirated mass does not completely resolve, further diagnostic evaluation is warranted, including an imaging (mammogram",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    ultrasound) and biopsy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/59/24504?source=see_link\">",
"     \"Breast biopsy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    If an aspirated cyst recurs, repeat ultrasound with a second attempt at aspiration is performed [",
"    <a class=\"abstract\" href=\"UTD.htm?3/60/4040/abstract/5\">",
"     5",
"    </a>",
"    ]. If a symptomatic simple breast cyst recurs multiple times, it can be difficult to assess whether the same cyst is recurring or a new cyst has formed. If the cyst recurs three or more times, another mammogram and ultrasound, and MRI if available, should be performed to further evaluate the area.",
"   </p>",
"   <p>",
"    Excisional biopsy is reserved for clinically or radiographically suspicious lesions and for patients who no longer desire repeat aspirations [",
"    <a class=\"abstract\" href=\"UTD.htm?3/60/4040/abstract/27\">",
"     27",
"    </a>",
"    ]. If an excision is performed, the cyst wall should remain intact and be completely removed. The site in the breast can be marked intraoperatively with metallic clips for future reference.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H100220260\">",
"    <span class=\"h2\">",
"     Complicated cyst",
"    </span>",
"    &nbsp;&mdash;&nbsp;A complicated cyst by ultrasound evaluation is confirmed as a benign breast lesion by image-guided fine needle aspiration, core biopsy, or excisional biopsy. An alternative approach is close observation by ultrasound imaging and mammography (if the lesion was visualized on mammography) and clinical examination every six months for two years to document stability [",
"    <a class=\"abstract\" href=\"UTD.htm?3/60/4040/abstract/11\">",
"     11",
"    </a>",
"    ]. Worrisome changes (eg, increase in size, development of a solid component) should be pursued by an image-guide FNA, core biopsy, or excisional breast biopsy [",
"    <a class=\"abstract\" href=\"UTD.htm?3/60/4040/abstract/5\">",
"     5",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/49/41754?source=see_link\">",
"     \"Screening for breast cancer\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/59/24504?source=see_link\">",
"     \"Breast biopsy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The choice of observation rather than FNA does require patient compliance with imaging recommendations. One study showed that 36 percent of patients who were recommended to have short-term follow-up of cystic lesions did not achieve two years of compliance [",
"    <a class=\"abstract\" href=\"UTD.htm?3/60/4040/abstract/28\">",
"     28",
"    </a>",
"    ]. For noncompliant patients or women uncomfortable with follow-up, FNA should be performed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H100220398\">",
"    <span class=\"h2\">",
"     Complex cyst",
"    </span>",
"    &nbsp;&mdash;&nbsp;A complex cyst identified by ultrasound must be confirmed to be a benign or malignant lesion by image-guided fine needle aspiration, core biopsy, or excisional biopsy [",
"    <a class=\"abstract\" href=\"UTD.htm?3/60/4040/abstract/17,29,30\">",
"     17,29,30",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H100217519\">",
"     'Management'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H9\">",
"     'Subsequent breast cancer risk'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/59/24504?source=see_link\">",
"     \"Breast biopsy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    If no fluid is obtained by a FNA, a core needle biopsy under image guidance should be performed. A sonographically-guided core biopsy is a safe and accurate technique for diagnosis of indeterminate or complex cystic breast lesions with a solid component [",
"    <a class=\"abstract\" href=\"UTD.htm?3/60/4040/abstract/31-33\">",
"     31-33",
"    </a>",
"    ]. When performing a core biopsy of a complex cystic breast lesion, it is essential to target the solid component with the first needle pass. Typically, a core needle biopsy consists of three to four biopsy samples. However, if the cystic portion is punctured with the first needle pass, the cystic component may collapse, making the solid component of the lesion difficult to identify sonographically.",
"   </p>",
"   <p>",
"    At the completion of all core biopsies, a metallic marker clip is deployed into the biopsy site to mark the area for future follow-up or surgical excision. If a core biopsy cannot be performed due to the position of the breast lesion or technical difficulty, a surgical biopsy with needle localization is indicated. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/59/24504?source=see_link&amp;anchor=H9#H9\">",
"     \"Breast biopsy\", section on 'Wire localization breast biopsy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Correlation of imaging and pathologic findings is essential [",
"    <a class=\"abstract\" href=\"UTD.htm?3/60/4040/abstract/34\">",
"     34",
"    </a>",
"    ]. If the findings on imaging and core biopsy pathology are discordant, surgical excision with needle localization is indicated. Benign histologic findings associated with complex cysts include a wide range of diagnoses and should be treated appropriately [",
"    <a class=\"abstract\" href=\"UTD.htm?3/60/4040/abstract/34,35\">",
"     34,35",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/52/11081?source=see_link\">",
"     \"Overview of benign breast disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    If the findings on imaging and core biopsy pathology are concordant and benign, follow-up includes a clinical breast examination and an imaging study every 6 to 12 months for one to two years to document stability [",
"    <a class=\"abstract\" href=\"UTD.htm?3/60/4040/abstract/5,26\">",
"     5,26",
"    </a>",
"    ]. Any changes in the biopsied lesion or growth of the lesion should lead to rebiopsy or excision [",
"    <a class=\"abstract\" href=\"UTD.htm?3/60/4040/abstract/5,33,36,37\">",
"     5,33,36,37",
"    </a>",
"    ]. A study of 156 patients who had a benign breast biopsy showed that 13 percent required a subsequent biopsy within two years [",
"    <a class=\"abstract\" href=\"UTD.htm?3/60/4040/abstract/37\">",
"     37",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     SUBSEQUENT BREAST CANCER RISK",
"    </span>",
"    &nbsp;&mdash;&nbsp;The overall risk of a subsequent breast cancer is not increased for women with a history of simple breast cysts [",
"    <a class=\"abstract\" href=\"UTD.htm?3/60/4040/abstract/35,38,39\">",
"     35,38,39",
"    </a>",
"    ]. In a retrospective review of 480 subsequent breast cancer diagnoses among 14,602 women with benign breast biopsies, simple cysts were not associated with subsequent breast cancer development [",
"    <a class=\"abstract\" href=\"UTD.htm?3/60/4040/abstract/38\">",
"     38",
"    </a>",
"    ]. For patients with complicated or complex cysts, the risk of a subsequent breast cancer is related to the findings from the biopsy. (See",
"    <a class=\"local\" href=\"#H100220260\">",
"     'Complicated cyst'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H100220398\">",
"     'Complex cyst'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The risk of a subsequent breast cancer developing in women with nonproliferative, proliferative, or atypical breast lesions is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/52/11081?source=see_link\">",
"     \"Overview of benign breast disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?5/62/6115?source=see_link\">",
"       \"Patient information: Common breast problems (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?5/56/6018?source=see_link\">",
"       \"Patient information: Common breast problems (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Breast cysts are fluid-filled, round or ovoid masses. Breast cysts can present as symptomatic gross palpable masses or as microcysts, usually found as an abnormality on an imaging exam. Cysts usually prompt women to seek medical attention because of a palpable mass or associated discomfort. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Breast cysts are classified according to their sonographic appearance, which helps guide clinical management. (See",
"      <a class=\"local\" href=\"#H202993215\">",
"       'Classification'",
"      </a>",
"      above.) &nbsp;",
"     </li>",
"     <li>",
"      Simple cysts, clustered microcysts, and cysts with thin septa are considered benign and no intervention is needed. Fine needle aspiration (FNA) can be performed if the cyst is symptomatic (painful) or obscures adjacent breast tissue. (See",
"      <a class=\"local\" href=\"#H100220008\">",
"       'Simple cyst'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      If a symptomatic simple breast cyst recurs several times after aspiration, another mammogram and ultrasound should be performed to evaluate the area again. Excision is reserved for suspicious lesions or for patients who no longer desire repeat aspirations. (See",
"      <a class=\"local\" href=\"#H100220008\">",
"       'Simple cyst'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Complicated cysts are rarely malignant, but should be aspirated to confirm diagnosis or followed with imaging and examination every six months for two years to document stability. Image-guided FNA or biopsy is indicated if the lesion increases in size or changes in characteristics on repeat imaging. (See",
"      <a class=\"local\" href=\"#H100220260\">",
"       'Complicated cyst'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Complex cysts should be biopsied, particularly those with thickened cyst walls",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      septa, and solid components. (See",
"      <a class=\"local\" href=\"#H274795950\">",
"       'Risk of malignancy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Surgical intervention is indicated for complex cysts that are not amenable to core needle biopsy and when pathology results from a core biopsy are discordant, atypical, indeterminate, or reveal a malignancy. (See",
"      <a class=\"local\" href=\"#H100220398\">",
"       'Complex cyst'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/60/4040/abstract/1\">",
"      Courtillot C, Plu-Bureau G, Binart N, et al. Benign breast diseases. J Mammary Gland Biol Neoplasia 2005; 10:325.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/60/4040/abstract/2\">",
"      Hughes LE, Mansel RE, Webster DJ. Aberrations of normal development and involution (ANDI): a new perspective on pathogenesis and nomenclature of benign breast disorders. Lancet 1987; 2:1316.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/60/4040/abstract/3\">",
"      Berg WA, Sechtin AG, Marques H, Zhang Z. Cystic breast masses and the ACRIN 6666 experience. Radiol Clin North Am 2010; 48:931.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/60/4040/abstract/4\">",
"      Berg WA, Campassi CI, Ioffe OB. Cystic lesions of the breast: sonographic-pathologic correlation. Radiology 2003; 227:183.",
"     </a>",
"    </li>",
"    <li>",
"     National Comprehensive Cancer Network (NCCN) guidelines. Available at: www.nccn.org (Accessed on May 15, 2012).",
"    </li>",
"    <li>",
"     Berg, WA, Birdwell, RL, Kennedy, A, et al. Diagnostic Imaging: Breast. Elsevier, Philadelphia 2007.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/60/4040/abstract/7\">",
"      Kim EK, Ko KH, Oh KK, et al. Clinical application of the BI-RADS final assessment to breast sonography in conjunction with mammography. AJR Am J Roentgenol 2008; 190:1209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/60/4040/abstract/8\">",
"      Heinig J, Witteler R, Schmitz R, et al. Accuracy of classification of breast ultrasound findings based on criteria used for BI-RADS. Ultrasound Obstet Gynecol 2008; 32:573.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/60/4040/abstract/9\">",
"      Hong AS, Rosen EL, Soo MS, Baker JA. BI-RADS for sonography: positive and negative predictive values of sonographic features. AJR Am J Roentgenol 2005; 184:1260.",
"     </a>",
"    </li>",
"    <li>",
"     American College of Radiology (ACR) Breast Imaging Reporting and Data System (BI-RADS) Atlas. Reston, VA: American College of Radiology, 2003.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/60/4040/abstract/11\">",
"      Daly CP, Bailey JE, Klein KA, Helvie MA. Complicated breast cysts on sonography: is aspiration necessary to exclude malignancy? Acad Radiol 2008; 15:610.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/60/4040/abstract/12\">",
"      Dixon JM, McDonald C, Elton RA, Miller WR. Risk of breast cancer in women with palpable breast cysts: a prospective study. Edinburgh Breast Group. Lancet 1999; 353:1742.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/60/4040/abstract/13\">",
"      Tea MK, Grimm C, Fink-Retter A, et al. The validity of complex breast cysts after surgery. Am J Surg 2009; 197:199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/60/4040/abstract/14\">",
"      Louie L, Velez N, Earnest D, Staren ED. Management of nonpalpable ultrasound-indeterminate breast lesions. Surgery 2003; 134:667.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/60/4040/abstract/15\">",
"      Chang YW, Kwon KH, Goo DE, et al. Sonographic differentiation of benign and malignant cystic lesions of the breast. J Ultrasound Med 2007; 26:47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/60/4040/abstract/16\">",
"      Tea MK, Grimm C, Heinz-Peer G, et al. The predictive value of suspicious sonographic characteristics in atypical cyst-like breast lesions. Breast 2011; 20:165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/60/4040/abstract/17\">",
"      Houssami N, Irwig L, Ung O. Review of complex breast cysts: implications for cancer detection and clinical practice. ANZ J Surg 2005; 75:1080.",
"     </a>",
"    </li>",
"    <li>",
"     Glassman L and Hazewinkel. Breast - MRI. 2009. radiologyassistant.nl.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/60/4040/abstract/19\">",
"      Cardenosa, G. Cysts, cystic lesions, and papillary lesions. Ultrasound Clinics 2007; 1:617.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/60/4040/abstract/20\">",
"      Hogge JP, Robinson RE, Magnant CM, Zuurbier RA. The mammographic spectrum of fat necrosis of the breast. Radiographics 1995; 15:1347.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/60/4040/abstract/21\">",
"      Rodr&iacute;guez MC, Secades AL, Angulo JM. Best cases from the AFIP: intracystic papillary carcinoma of the breast. Radiographics 2010; 30:2021.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/60/4040/abstract/22\">",
"      Seal M, Wilson C, Naus GJ, et al. Encapsulated apocrine papillary carcinoma of the breast--a tumour of uncertain malignant potential: report of five cases. Virchows Arch 2009; 455:477.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/60/4040/abstract/23\">",
"      Guray M, Sahin AA. Benign breast diseases: classification, diagnosis, and management. Oncologist 2006; 11:435.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/60/4040/abstract/24\">",
"      O'Malley FP, Bane AL. The spectrum of apocrine lesions of the breast. Adv Anat Pathol 2004; 11:1.",
"     </a>",
"    </li>",
"    <li>",
"     Reynolds, HE, Dershaw, DD. Fine-needle aspiration and cyst aspiration. In: Imaging-Guided Interventional Breast Techniques, Dershaw, DD (Ed), New York 2003. p.145.",
"    </li>",
"    <li>",
"     NCCN Guidelines Version 1/2011 Breast Cancer Screening and Diagnosis nccn.org/professionals/physician_gls/pdf/breast-screening/pdf (Accessed on July 02, 2012).",
"    </li>",
"    <li>",
"     Bleicher, RJ. Management of the palpable breast mass. In: Diseases of the Breast, 4th ed, Harris, JR, Lippman, ME, Morrow, M, Osborne, CK (Eds). Lippincott, Philadelphia 2010.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/60/4040/abstract/28\">",
"      Berg WA. Sonographically depicted breast clustered microcysts: is follow-up appropriate? AJR Am J Roentgenol 2005; 185:952.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/60/4040/abstract/29\">",
"      Vargas HI, Vargas MP, Gonzalez KD, et al. Outcomes of sonography-based management of breast cysts. Am J Surg 2004; 188:443.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/60/4040/abstract/30\">",
"      Omori LM, Hisa N, Ohkuma K, et al. Breast masses with mixed cystic-solid sonographic appearance. J Clin Ultrasound 1993; 21:489.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/60/4040/abstract/31\">",
"      Chuo CB, Corder AP. Core biopsy vs fine needle aspiration cytology in a symptomatic breast clinic. Eur J Surg Oncol 2003; 29:374.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/60/4040/abstract/32\">",
"      Philpotts LE, Hooley RJ, Lee CH. Comparison of automated versus vacuum-assisted biopsy methods for sonographically guided core biopsy of the breast. AJR Am J Roentgenol 2003; 180:347.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/60/4040/abstract/33\">",
"      Youk JH, Kim EK, Kim MJ, Oh KK. Sonographically guided 14-gauge core needle biopsy of breast masses: a review of 2,420 cases with long-term follow-up. AJR Am J Roentgenol 2008; 190:202.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/60/4040/abstract/34\">",
"      Doshi DJ, March DE, Crisi GM, Coughlin BF. Complex cystic breast masses: diagnostic approach and imaging-pathologic correlation. Radiographics 2007; 27 Suppl 1:S53.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/60/4040/abstract/35\">",
"      Dupont WD, Page DL. Risk factors for breast cancer in women with proliferative breast disease. N Engl J Med 1985; 312:146.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/60/4040/abstract/36\">",
"      Bhate RD, Chakravorty A, Ebbs SR. Management of breast cysts revisited. Int J Clin Pract 2007; 61:195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/60/4040/abstract/37\">",
"      Shin S, Schneider HB, Cole FJ Jr, Laronga C. Follow-up recommendations for benign breast biopsies. Breast J 2006; 12:413.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/60/4040/abstract/38\">",
"      Ashbeck EL, Rosenberg RD, Stauber PM, Key CR. Benign breast biopsy diagnosis and subsequent risk of breast cancer. Cancer Epidemiol Biomarkers Prev 2007; 16:467.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/60/4040/abstract/39\">",
"      Chun J, Joseph KA, El-Tamer M, et al. Cohort study of women at risk for breast cancer and gross cystic disease. Am J Surg 2005; 190:583.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 799 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-14.112.150.12-587BC34546-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_60_4040=[""].join("\n");
var outline_f3_60_4040=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H14\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H202991655\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H100217503\">",
"      CLINICAL FEATURES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H91862437\">",
"      Patient presentation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H91862472\">",
"      Physical examination findings",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H91862589\">",
"      Imaging",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H91862703\">",
"      - Ultrasonography",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H202993215\">",
"      Classification",
"     </a>",
"    </li>",
"    <li class=\"dashItem2\">",
"     <a class=\"outlineLink\" href=\"#H202992300\">",
"      - Simple",
"     </a>",
"    </li>",
"    <li class=\"dashItem2\">",
"     <a class=\"outlineLink\" href=\"#H202992307\">",
"      - Complicated",
"     </a>",
"    </li>",
"    <li class=\"dashItem2\">",
"     <a class=\"outlineLink\" href=\"#H202992314\">",
"      - Complex",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H202991771\">",
"      BI-RADS categories",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H274795950\">",
"      Risk of malignancy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H91862889\">",
"      - Mammography",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H91862905\">",
"      - MRI",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H100217511\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H100217559\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H100217519\">",
"      MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H100220008\">",
"      Simple cyst",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H100220260\">",
"      Complicated cyst",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H100220398\">",
"      Complex cyst",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      SUBSEQUENT BREAST CANCER RISK",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"SURG/799\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"SURG/799|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?41/50/42785\" title=\"diagnostic image 1\">",
"      Benign breast cysts",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?20/55/21360\" title=\"diagnostic image 2\">",
"      Simple cyst",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?22/25/22932\" title=\"diagnostic image 3\">",
"      Breast cyst ultrasound - pear shaped",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?7/57/8087\" title=\"diagnostic image 4\">",
"      Complex complicated cysts",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?2/3/2101\" title=\"diagnostic image 5\">",
"      Mammographic image of a density - large cyst",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?42/54/43877\" title=\"diagnostic image 6\">",
"      Breast clustered cysts mammogram and ultrasound",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?25/30/26085\" title=\"diagnostic image 7\">",
"      Large cyst imaged on breast MRI",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?42/59/43957\" title=\"diagnostic image 8\">",
"      MRI cluster of breast cysts",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?2/60/3016\" title=\"diagnostic image 9\">",
"      Ultrasound oil cyst",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"SURG/799|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?38/19/39227\" title=\"table 1\">",
"      BIRADS mammography categories",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/17/9495?source=related_link\">",
"      Breast abscess",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/59/24504?source=related_link\">",
"      Breast biopsy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/10/20649?source=related_link\">",
"      Breast development and morphology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/35/39482?source=related_link\">",
"      Breast imaging: Mammography and ultrasonography",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/15/24825?source=related_link\">",
"      Breast masses and other common breast problems",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/15/17658?source=related_link\">",
"      Common problems of breastfeeding and weaning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/36/24138?source=related_link\">",
"      Diagnostic evaluation of women with suspected breast cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/53/857?source=related_link\">",
"      Erythematous disorders of the breast",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/29/23002?source=related_link\">",
"      MRI of the breast and emerging technologies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/52/11081?source=related_link\">",
"      Overview of benign breast disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?5/56/6018?source=related_link\">",
"      Patient information: Common breast problems (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?5/62/6115?source=related_link\">",
"      Patient information: Common breast problems (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/49/41754?source=related_link\">",
"      Screening for breast cancer",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f3_60_4041="Clinical course and management of monoclonal gammopathy of undetermined significance";
var content_f3_60_4041=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Clinical course and management of monoclonal gammopathy of undetermined significance",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?3/60/4041/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/60/4041/contributors\">",
"     S Vincent Rajkumar, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?3/60/4041/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/60/4041/contributors\">",
"     Robert A Kyle, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?3/60/4041/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/60/4041/contributors\">",
"     Rebecca F Connor, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?3/60/4041/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 5, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H20641026\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Monoclonal gammopathy of undetermined significance (MGUS) is an asymptomatic premalignant clonal plasma cell or lymphoplasmacytic proliferative disorder.",
"   </p>",
"   <p>",
"    MGUS occurs in over 3 percent of the general population over the age of 50 and is typically detected as an incidental finding when patients undergo a protein electrophoresis as part of an evaluation for a wide variety of clinical symptoms and disorders (eg, peripheral neuropathy, vasculitis, hemolytic anemia, skin rashes, hypercalcemia, or elevated erythrocyte sedimentation rate).",
"   </p>",
"   <p>",
"    The clinical course and management of patients with MGUS will be discussed here [",
"    <a class=\"abstract\" href=\"UTD.htm?3/60/4041/abstract/1-4\">",
"     1-4",
"    </a>",
"    ]. The diagnosis of MGUS, recognition of serum or urinary monoclonal proteins and the clinical features, laboratory manifestations, and diagnosis of multiple myeloma and other plasma cell dyscrasias are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/59/15290?source=see_link\">",
"     \"Diagnosis of monoclonal gammopathy of undetermined significance\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/58/10154?source=see_link\">",
"     \"Recognition of monoclonal proteins\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/13/35034?source=see_link\">",
"     \"Clinical features, laboratory manifestations, and diagnosis of multiple myeloma\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/47/762?source=see_link\">",
"     \"Epidemiology, pathogenesis, clinical manifestations and diagnosis of Waldenstr&ouml;m macroglobulinemia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/62/35815?source=see_link\">",
"     \"Pathogenesis of immunoglobulin light chain (AL) amyloidosis and light and heavy chain deposition diseases\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22390998\">",
"    <span class=\"h1\">",
"     CLINICAL COURSE",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22391006\">",
"    <span class=\"h2\">",
"     Disease progression",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are three distinct clinical types of MGUS, each with a small risk of progressing through a unique intermediate (more advanced) premalignant stage and then to a malignant plasma cell dyscrasia or lymphoproliferative disorder [",
"    <a class=\"abstract\" href=\"UTD.htm?3/60/4041/abstract/5-9\">",
"     5-9",
"    </a>",
"    ]. Conversely, two large longitudinal studies have suggested that virtually all patients diagnosed with multiple myeloma (MM) had a preceding MGUS, with 75 percent having a detectible M-protein &ge;8 years prior to the diagnosis of MM [",
"    <a class=\"abstract\" href=\"UTD.htm?3/60/4041/abstract/8,9\">",
"     8,9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Non-IgM MGUS (IgG, IgA, or IgD MGUS) is the most common subtype of MGUS [",
"      <a class=\"abstract\" href=\"UTD.htm?3/60/4041/abstract/10\">",
"       10",
"      </a>",
"      ]. A minority of cases will progress to the more advanced premalignant stage smoldering (asymptomatic) MM and to symptomatic MM. Less frequently, these patients progress to AL amyloidosis, light chain deposition disease, or another lymphoproliferative disorder.",
"     </li>",
"     <li>",
"      IgM MGUS accounts for approximately 15 percent of MGUS cases. IgM MGUS can progress to smoldering Waldenstrom macroglobulinemia and to symptomatic Waldenstrom macroglobulinemia [",
"      <a class=\"abstract\" href=\"UTD.htm?3/60/4041/abstract/11\">",
"       11",
"      </a>",
"      ]. Infrequently, IgM MGUS can progress to IgM multiple myeloma.",
"     </li>",
"     <li>",
"      Light chain MGUS (LC-MGUS) is a unique subtype of MGUS in which the secreted monoclonal protein lacks the immunoglobulin heavy chain component. LC-MGUS may progress to idiopathic Bence Jones proteinuria, light chain MM, AL amyloidosis, or light chain deposition disease [",
"      <a class=\"abstract\" href=\"UTD.htm?3/60/4041/abstract/6\">",
"       6",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Studies that provide the majority of information regarding the risk of progression of MGUS did not distinguish between these three clinical subtypes. The generic term MGUS used in most studies only includes patients with non-IgM MGUS and IgM MGUS; LC-MGUS is a newly defined entity. In general, patients with MGUS progress to more advanced disease at a rate of 1 percent per year. When compared with non-IgM MGUS, the rate may be slightly higher for IgM MGUS and slightly lower for light chain MGUS. The following sections describe information on the rate of disease progression. Clinically, patients may be stratified by risk of progression based upon the presence or absence of adverse risk factors. (See",
"    <a class=\"local\" href=\"#H22391048\">",
"     'Risk stratification'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22391013\">",
"    <span class=\"h3\">",
"     MGUS",
"    </span>",
"    &nbsp;&mdash;&nbsp;MGUS (non-IgM and IgM) is defined by the presence of a serum monoclonal protein (M-protein), at a concentration &lt;3",
"    <span class=\"nowrap\">",
"     g/dL,",
"    </span>",
"    bone marrow with &lt;10 percent monoclonal plasma cells, if done, and absence of end organ damage (lytic bone lesions, anemia, hypercalcemia, renal insufficiency, hyperviscosity) related to the proliferative process. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/59/15290?source=see_link&amp;anchor=H90176118#H90176118\">",
"     \"Diagnosis of monoclonal gammopathy of undetermined significance\", section on 'Non-IgM MGUS'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    As described above, patients with MGUS progress to more advanced disease at a rate of 1 percent per year. The following describes the clinical course of MGUS derived from the long-term follow-up of 1384 patients with MGUS (11,009 person-years), during which time 70 percent of the patients died [",
"    <a class=\"abstract\" href=\"UTD.htm?3/60/4041/abstract/10\">",
"     10",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      115 persons (8.3 percent) developed MM, macroglobulinemia (WM), amyloidosis, or a malignant lymphoproliferative disorder. The cumulative probability of progression to one of those disorders at 10, 20, and 25 years was 10, 21, and 26 percent, respectively, for a rate of progression of approximately 1 percent per year.",
"     </li>",
"     <li>",
"      The number of patients progressing to a plasma cell neoplasm or a related disorder was 7.3 times that expected in the general population. The risks of developing MM, WM, primary amyloid, or lymphoma were increased by factors of 25, 46, 8.4, and 2.4, respectively. The risk of progression did not increase with age or duration of MGUS.",
"     </li>",
"     <li>",
"      32 (2.3 percent) had a serum M-protein concentration of &ge;3.0",
"      <span class=\"nowrap\">",
"       g/dL",
"      </span>",
"      or bone marrow plasma cells &gt;10 percent during follow-up without developing overt MM (ie, smoldering MM); it is presumed that most of these patients would progress to MM or a related disease if they had survived long enough.",
"     </li>",
"     <li>",
"      Only six patients (0.4 percent) had a measurable monoclonal protein that later disappeared without apparent cause. In 39 patients, the monoclonal protein disappeared after treatment for MM, lymphoma, or another disease (eg, immune thrombocytopenia (ITP), vasculitis, etc.).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Another series from the same institution of 241 patients with MGUS followed for a median period of 13.7 years (range: 0 to 39 years) noted [",
"    <a class=\"abstract\" href=\"UTD.htm?3/60/4041/abstract/12\">",
"     12",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients were diagnosed with MGUS at a median age of 64 years; median survival (13.7 years) was only slightly shorter than that of a comparable United States population (15.5 years)",
"     </li>",
"     <li>",
"      The rate of progression to MM, WM, amyloidosis, or malignant lymphoproliferative disorder was 1.5 percent per year (",
"      <a class=\"graphic graphic_figure graphicRef56429 \" href=\"UTD.htm?8/36/8781\">",
"       figure 1",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?3/60/4041/abstract/12\">",
"       12",
"      </a>",
"      ]. The median interval between the diagnosis of MGUS and one of these complications was 10.4 years (range: 1 to 32 years).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Similar rates of progression have been noted in other studies [",
"    <a class=\"abstract\" href=\"UTD.htm?3/60/4041/abstract/13-18\">",
"     13-18",
"    </a>",
"    ]. In a prospective hospital-based Dutch cohort study in 213 newly-diagnosed patients with definite MGUS (bone marrow biopsy and radiographically confirmed) and a median age of 72, the overall rate of malignant progression was 5 percent at 10 years [",
"    <a class=\"abstract\" href=\"UTD.htm?3/60/4041/abstract/19\">",
"     19",
"    </a>",
"    ]. Limitations on follow-up time and cohort size make full interpretation of these results difficult.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22391020\">",
"    <span class=\"h3\">",
"     IgM MGUS",
"    </span>",
"    &nbsp;&mdash;&nbsp;IgM MGUS is a subtype of MGUS comprising approximately 15 percent of all patients with MGUS [",
"    <a class=\"abstract\" href=\"UTD.htm?3/60/4041/abstract/10,20,21\">",
"     10,20,21",
"    </a>",
"    ] and over 30 percent of patients with an IgM paraprotein [",
"    <a class=\"abstract\" href=\"UTD.htm?3/60/4041/abstract/22\">",
"     22",
"    </a>",
"    ]. IgM MGUS can progress to smoldering Waldenstrom macroglobulinemia and then to symptomatic Waldenstrom macroglobulinemia at a rate of approximately 1.5 percent per year [",
"    <a class=\"abstract\" href=\"UTD.htm?3/60/4041/abstract/11\">",
"     11",
"    </a>",
"    ]. Infrequently, IgM MGUS can progress to IgM multiple myeloma. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/59/15290?source=see_link&amp;anchor=H174976281#H174976281\">",
"     \"Diagnosis of monoclonal gammopathy of undetermined significance\", section on 'IgM MGUS'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    From 1960 through 1994 IgM MGUS was diagnosed in 213 Mayo Clinic patients who resided in the 11 counties of southeastern Minnesota [",
"    <a class=\"abstract\" href=\"UTD.htm?3/60/4041/abstract/11\">",
"     11",
"    </a>",
"    ]. The age and sex distribution, mean M-protein concentrations, the involved light chain class, and incidences of anemia and thrombocytopenia for these 213 patients were similar to those reported from larger series of patients with MGUS of all M-protein types [",
"    <a class=\"abstract\" href=\"UTD.htm?3/60/4041/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      After a median follow-up of 6.3 years, non-Hodgkin lymphoma (17 patients), Waldenstrom macroglobulinemia (6 patients), chronic lymphocytic leukemia (3 patients), or amyloidosis (3 patients) developed in 29 patients (14 percent), with relative risk factors (as compared with the IOWA SEER registry) of 15, 262, 6, and 16, respectively.",
"     </li>",
"     <li>",
"      The risk for progression to a lymphoma or related malignancy was directly related to the concentration of serum M-protein at the time of diagnosis of MGUS. It was 14, 26, 34, and 41 percent for M-protein concentrations of &le;0.5, 1.5, 2.0, and &gt;2.5",
"      <span class=\"nowrap\">",
"       g/dL,",
"      </span>",
"      respectively.",
"     </li>",
"     <li>",
"      The rate of progression to a lymphoma or related malignancy increased gradually over the period of observation, averaging 1.5 percent per year (",
"      <a class=\"graphic graphic_figure graphicRef81878 \" href=\"UTD.htm?8/12/8398\">",
"       figure 2",
"      </a>",
"      ). This risk persisted even after 20 years of follow-up. The risk was higher than that seen in a larger series including all patients with MGUS from Mayo Clinic (1 percent per year).",
"     </li>",
"     <li>",
"      On multivariate analysis, only a higher initial concentration of the serum M-protein and a lower serum albumin at diagnosis were independent predictors of progression.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In an Italian study of 217 patients with IgM MGUS, higher serum concentrations of serum IgM, male sex, and a lower level of hemoglobin were independent predictors of progression [",
"    <a class=\"abstract\" href=\"UTD.htm?3/60/4041/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22391027\">",
"    <span class=\"h3\">",
"     Light chain MGUS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Light chain MGUS (LC-MGUS) is defined by the presence of an abnormal serum free light chain ratio (&lt;0.26 or &gt;1.65), increased level of the involved free light chain above the reference range, no monoclonal immunoglobulin heavy chain (IgG, IgA, IgD, or IgM), bone marrow with &lt;10 percent monoclonal plasma cells, if done, and absence of end organ damage (lytic bone lesions, anemia, hypercalcemia, renal insufficiency, hyperviscosity) related to the proliferative process. LC-MGUS may progress through idiopathic Bence Jones proteinuria to light chain multiple myeloma (MM), AL amyloidosis, or light chain deposition disease. The estimated risk of progression is 0.3 percent per year [",
"    <a class=\"abstract\" href=\"UTD.htm?3/60/4041/abstract/6\">",
"     6",
"    </a>",
"    ]. Once idiopathic Bence Jones proteinuria is identified, the rate of progression is higher. In one series of seven patients with idiopathic Bence Jones proteinuria, only three had a benign course after an 8 to 12 year follow-up [",
"    <a class=\"abstract\" href=\"UTD.htm?3/60/4041/abstract/24\">",
"     24",
"    </a>",
"    ]. The other five patients progressed to symptomatic or asymptomatic MM, accompanied by amyloidosis in one. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/59/15290?source=see_link&amp;anchor=H90176125#H90176125\">",
"     \"Diagnosis of monoclonal gammopathy of undetermined significance\", section on 'Light-chain MGUS'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22391034\">",
"    <span class=\"h2\">",
"     Survival",
"    </span>",
"    &nbsp;&mdash;&nbsp;While the probability of progression of MGUS at 25 years is 25 to 30 percent, the median age at diagnosis is 65 to 70 years and the probability of progressing during a patient&rsquo;s lifetime is approximately 10 percent due to a high rate of death from competing causes [",
"    <a class=\"abstract\" href=\"UTD.htm?3/60/4041/abstract/25\">",
"     25",
"    </a>",
"    ]. For this reason, the median survival of patients with MGUS is expected to be only slightly shorter than that of age-matched controls.",
"   </p>",
"   <p>",
"    Studies that have investigated the survival of patients with MGUS have had mixed results:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a series of 241 patients with MGUS followed for a median period of 13.7 years noted the median survival (13.7 years) was only slightly shorter than that of a comparable United States population (15.5 years) [",
"      <a class=\"abstract\" href=\"UTD.htm?3/60/4041/abstract/12\">",
"       12",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A study from Sweden indicated that patients with MGUS have a significantly reduced life expectancy when compared with the general population, and an excess risk of dying not only from well-described malignant transformations (eg, multiple myeloma, Waldenstrom macroglobulinemia, amyloidosis), but also from bacterial infections as well as heart, liver, and renal diseases [",
"      <a class=\"abstract\" href=\"UTD.htm?3/60/4041/abstract/26\">",
"       26",
"      </a>",
"      ]. The mechanisms for the latter are unclear, and may be related to the underlying conditions leading to the initial diagnosis of MGUS.",
"     </li>",
"     <li>",
"      A single-center retrospective study of 1400 patients with MGUS reported that patients with an M-protein &lt;1.5",
"      <span class=\"nowrap\">",
"       g/dL",
"      </span>",
"      had the same life expectancy as the general population [",
"      <a class=\"abstract\" href=\"UTD.htm?3/60/4041/abstract/27\">",
"       27",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22391041\">",
"    <span class=\"h1\">",
"     MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The management of a patient with MGUS requires an understanding of the risk of progression to symptomatic disease requiring therapy. It is paramount to deliver the appropriate balance of information about this asymptomatic disorder that has a small chance of progression to a more serious disorder [",
"    <a class=\"abstract\" href=\"UTD.htm?3/60/4041/abstract/3\">",
"     3",
"    </a>",
"    ]. Patients and their families need appropriate information and support concerning the clinical and psychological ramifications of a diagnosis of MGUS.",
"   </p>",
"   <p>",
"    Patients with MGUS should be monitored for disease progression and for potential complications. Not all persons with MGUS have the same risk of disease progression. The risk of progression to a serious disease ranges widely from 0.6 to 3.4",
"    <span class=\"nowrap\">",
"     percent/year",
"    </span>",
"    according to the initial value of serum monoclonal protein [",
"    <a class=\"abstract\" href=\"UTD.htm?3/60/4041/abstract/10,28-30\">",
"     10,28-30",
"    </a>",
"    ], or from 0.25 to 2.9",
"    <span class=\"nowrap\">",
"     percent/year",
"    </span>",
"    according to a risk stratification model [",
"    <a class=\"abstract\" href=\"UTD.htm?3/60/4041/abstract/4,31\">",
"     4,31",
"    </a>",
"    ]. There are a variety of acceptable monitoring schedules for patients with MGUS. Our approach uses a risk stratification system to provide more intensive monitoring for patients more likely to progress.",
"   </p>",
"   <p>",
"    There is no known role for chemotherapy in the management of MGUS. Only a minority of patients will progress to symptomatic disease and there is no data that treatment of asymptomatic disease effects mortality. A number of trials are ongoing to determine if the early use of drugs and other agents (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/25/16793?source=see_link\">",
"     lenalidomide",
"    </a>",
"    , bisphosphonates) can delay the progression of MGUS",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    smoldering multiple myeloma.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22391048\">",
"    <span class=\"h2\">",
"     Risk stratification",
"    </span>",
"    &nbsp;&mdash;&nbsp;As described above, patients with MGUS progress to a symptomatic plasma cell proliferative disorder or lymphoproliferative disorder at a rate of 1 percent per year. No single factor can differentiate a patient with MGUS who will have a benign clinical course from one in whom a malignant plasma cell or lymphoproliferative disorder will eventually develop. Numerous studies have investigated potential predictors of disease progression. Of these, three adverse risk factors have been combined to create a risk-stratification model that is useful in predicting the risk of progression of MGUS (non-IgM and IgM) to MM or a related malignancy:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Serum monoclonal protein level &ge;1.5",
"      <span class=\"nowrap\">",
"       g/dL",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?3/60/4041/abstract/10,28-30\">",
"       10,28-30",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Non-IgG MGUS (ie, IgA, IgM, IgD MGUS)",
"     </li>",
"     <li>",
"      Abnormal serum free light chain ratio (ie, ratio of kappa to lambda free light chains &lt;0.26 or &gt;1.65) [",
"      <a class=\"abstract\" href=\"UTD.htm?3/60/4041/abstract/31,32\">",
"       31,32",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The absolute risk of disease progression over 20 years for patients with various combinations of risk factors is [",
"    <a class=\"abstract\" href=\"UTD.htm?3/60/4041/abstract/4,31\">",
"     4,31",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      3 risk factors (high-risk MGUS) &mdash; 58 percent",
"     </li>",
"     <li>",
"      2 risk factors (high-intermediate risk MGUS) &mdash; 37 percent",
"     </li>",
"     <li>",
"      1 risk factor (low-intermediate risk MGUS) &mdash; 21 percent",
"     </li>",
"     <li>",
"      no risk factors (low-risk MGUS) &mdash; 5 percent",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Other studies support the use of these factors as predictors of progression. As examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A study in Southeastern Minnesota revealed that the initial concentration of the serum monoclonal protein was the most important risk factor for progression to plasma cell malignancy [",
"      <a class=\"abstract\" href=\"UTD.htm?3/60/4041/abstract/10\">",
"       10",
"      </a>",
"      ]. Progression to MM or a related cancer at 10 years was 6, 7, 11, 20, 24, and 34 percent for values of &le;0.5, 1.0, 1.5, 2.0, 2.5, and 3.0",
"      <span class=\"nowrap\">",
"       g/dL,",
"      </span>",
"      respectively.",
"     </li>",
"     <li>",
"      A retrospective case control study, the presence of an abnormal (monoclonal)",
"      <span class=\"nowrap\">",
"       kappa/lambda",
"      </span>",
"      free light chain ratio in the serum was associated with a significantly higher risk of disease progression (relative risk 2.5, 95% CI 1.6-4.0) [",
"      <a class=\"abstract\" href=\"UTD.htm?3/60/4041/abstract/32\">",
"       32",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a large cohort study involving 1148 patients, the risk of progression in patients with an abnormal free light chain ratio was significantly higher compared with patients with a normal ratio (hazard ratio, 3.5; 95% CI 2.3-5.5) [",
"      <a class=\"abstract\" href=\"UTD.htm?3/60/4041/abstract/31\">",
"       31",
"      </a>",
"      ]. This effect was independent of the size and type of the serum M protein.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Other factors may predict progression, but are not used in the risk stratification model, including: urine free light chains, increasing percentage of bone marrow plasma cells and malignant bone marrow plasma cell immunophenotype, and increased markers of bone turnover [",
"    <a class=\"abstract\" href=\"UTD.htm?3/60/4041/abstract/28-30,33-41\">",
"     28-30,33-41",
"    </a>",
"    ]. Risk factors for progression of LC-MGUS have not been defined yet.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3221500\">",
"    <span class=\"h2\">",
"     Monitoring for progression",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with MGUS should be followed over time with history and physical examination looking for signs and symptoms of progressive disease [",
"    <a class=\"abstract\" href=\"UTD.htm?3/60/4041/abstract/3\">",
"     3",
"    </a>",
"    ]. The role of laboratory testing in the longitudinal care of patients with MGUS is less clear. Most experts agree that all patients should undergo laboratory evaluation for disease progression six months after diagnosis with serum and urinary M-protein, complete blood count, creatinine, electrolytes, and serum calcium [",
"    <a class=\"abstract\" href=\"UTD.htm?3/60/4041/abstract/30\">",
"     30",
"    </a>",
"    ]. While some experts incorporate periodic laboratory testing into the routine follow-up of all patients, we use the risk stratification system described above to identify patients for whom laboratory testing is most likely to provide value:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with low-risk MGUS (serum M protein &le;1.5",
"      <span class=\"nowrap\">",
"       g/dL,",
"      </span>",
"      IgG subtype, and normal serum free light chain ratio) have a risk of progression of only 5 percent over 20 years, and may be followed with history and physical examination alone [",
"      <a class=\"abstract\" href=\"UTD.htm?3/60/4041/abstract/31,42\">",
"       31,42",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      All other patients are followed with annual serum and urinary M-protein, complete blood count, creatinine, and serum calcium.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The following signs or symptoms should be considered &lsquo;red flags&rsquo; that necessitate further investigation:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Bone pain",
"     </li>",
"     <li>",
"      <span class=\"nowrap\">",
"       Fatigue/generalized",
"      </span>",
"      weakness",
"     </li>",
"     <li>",
"      Constitutional &ldquo;B&rdquo; symptoms (unintentional weight loss, fever, night sweats)",
"     </li>",
"     <li>",
"      Neurologic symptoms (neuropathy, headache, dizziness, loss of",
"      <span class=\"nowrap\">",
"       vision/hearing)",
"      </span>",
"     </li>",
"     <li>",
"      Bleeding",
"     </li>",
"     <li>",
"      Symptoms suggestive of amyloid (macroglossia, nephrotic range proteinuria, restrictive cardiomyopathy)",
"     </li>",
"     <li>",
"      Lymphadenopathy, hepatomegaly, or splenomegaly",
"     </li>",
"     <li>",
"      Abnormal laboratory findings: Anemia, elevated creatinine, hypercalcemia",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The evolution from MGUS to multiple myeloma (MM) may be abrupt [",
"    <a class=\"abstract\" href=\"UTD.htm?3/60/4041/abstract/42,43\">",
"     42,43",
"    </a>",
"    ]. As a result, patients should be advised to obtain medical evaluation promptly if clinical symptoms occur. This risk stratified follow-up places a high value on minimizing undue psychological and financial stress on patients unlikely to progress and places a low value on the unknown benefit of the small chance of detecting disease progression early through laboratory testing.",
"   </p>",
"   <p>",
"    The efficacy of periodic monitoring was evaluated in a single-institution retrospective analysis of 116 patients with MGUS who later developed MM [",
"    <a class=\"abstract\" href=\"UTD.htm?3/60/4041/abstract/42\">",
"     42",
"    </a>",
"    ]. Patients evaluated at least every two years were considered to have optimal follow-up. Of the 80 patients with optimal follow-up, disease progression was identified by routine laboratory follow-up in only 13 patients (16 percent). Disease progression to symptomatic MM was identified in the rest of the cases by:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Serious MM-related complications (45 percent)",
"     </li>",
"     <li>",
"      Diagnostic work-up of less serious symptoms reported by the patient (25 percent)",
"     </li>",
"     <li>",
"      Incidental finding in the context of workup of another condition (11 percent)",
"     </li>",
"     <li>",
"      Unknown (3 percent)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In patients with high-risk MGUS (serum M protein &ge;1.5",
"    <span class=\"nowrap\">",
"     g/dL",
"    </span>",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    non-IgG MGUS), disease progression was identified by routine laboratory follow-up in 21 percent. This study suggests that close follow-up of the general population of patients with MGUS may not achieve its purpose of identifying the progression to MM prior to an adverse MM-related complication. It also demonstrates that most patients who progress to MM will have symptoms that prompt further investigation. However, patients with high-risk MGUS have a higher rate of transformation and a greater chance of having progression identified by routine periodic testing before a serious MM-related complication occurs.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3221507\">",
"    <span class=\"h2\">",
"     Monitoring for complications",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3221515\">",
"    <span class=\"h3\">",
"     Fracture",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with MGUS have an increased risk of axial (skull,",
"    <span class=\"nowrap\">",
"     vertebral/pelvis,",
"    </span>",
"    and",
"    <span class=\"nowrap\">",
"     sternum/costae),",
"    </span>",
"    but not peripheral (arm and leg), bone fractures [",
"    <a class=\"abstract\" href=\"UTD.htm?3/60/4041/abstract/44-46\">",
"     44-46",
"    </a>",
"    ], with the highest risk being noted in those with reduced lumbar bone mineral density [",
"    <a class=\"abstract\" href=\"UTD.htm?3/60/4041/abstract/47\">",
"     47",
"    </a>",
"    ]. The pathophysiologic basis for this finding is unclear, although both an imbalance between bone resorption and bone formation and altered bone microstructure have been postulated [",
"    <a class=\"abstract\" href=\"UTD.htm?3/60/4041/abstract/47-49\">",
"     47-49",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The largest population-based study evaluated fracture risk in 5326 patients with MGUS and 20,161 matched controls from Sweden [",
"    <a class=\"abstract\" href=\"UTD.htm?3/60/4041/abstract/46\">",
"     46",
"    </a>",
"    ]. Patients with MGUS had an increased risk of fracture at five years (hazard ratio [HR] = 1.74, 95% CI 1.58 to 1.92) and 10 years (HR = 1.61, 95% CI 1.49 to 1.74). This increased risk was greatest for axial fractures. The risk of fracture did not differ by isotype (ie, IgG versus IgA) or M protein concentration at diagnosis. Fracture did not predict for disease progression to multiple myeloma or Waldenstrom macroglobulinemia. &nbsp;",
"   </p>",
"   <p>",
"    Patients with MGUS should be evaluated for osteoporosis and osteopenia with a dual energy X-ray absorptiometry (DEXA) scan and have their vitamin D and calcium intake optimized [",
"    <a class=\"abstract\" href=\"UTD.htm?3/60/4041/abstract/50\">",
"     50",
"    </a>",
"    ]. Prophylactic bisphosphonates have not been proven to be beneficial for patients with MGUS. Bisphosphonates should be used in these patients only if they have another indication for their use, such as osteoporosis or osteopenia on bone mineral density studies. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/56/40842?source=see_link\">",
"     \"Bisphosphonates in the management of osteoporosis in postmenopausal women\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3221522\">",
"    <span class=\"h3\">",
"     Thromboembolic disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of studies have reported an increased incidence of venous thromboembolic disease (VTE) and arterial thrombosis in patients with MGUS [",
"    <a class=\"abstract\" href=\"UTD.htm?3/60/4041/abstract/51-56\">",
"     51-56",
"    </a>",
"    ]. While the mechanisms involving this increased incidence are unclear, a hypercoagulable state secondary to an ongoing clonal plasma cell activity has been suggested for patients with MGUS, multiple myeloma, Waldenstrom macroglobulinemia, and systemic amyloidosis [",
"    <a class=\"abstract\" href=\"UTD.htm?3/60/4041/abstract/55,57\">",
"     55,57",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31491539\">",
"    <span class=\"h3\">",
"     Second malignancies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Persons with MGUS or multiple myeloma have a higher incidence of developing second cancers [",
"    <a class=\"abstract\" href=\"UTD.htm?3/60/4041/abstract/58\">",
"     58",
"    </a>",
"    ]. We recommend that patients with MGUS be encouraged to participate in age-appropriate cancer screening programs. No additional cancer screening has been recommended for this population.",
"   </p>",
"   <p>",
"    In a large series, persons with MGUS were reported to have excessive rates of acute myeloid",
"    <span class=\"nowrap\">",
"     leukemia/myelodysplastic",
"    </span>",
"    syndrome (SIR 8.01; 95% CI 5.40-11.43) and nonhematologic malignancy (SIR 1.56; 95% CI 1.44-1.68) when compared with the general population [",
"    <a class=\"abstract\" href=\"UTD.htm?3/60/4041/abstract/59\">",
"     59",
"    </a>",
"    ]. However, the general population in this study was not screened for the presence or absence of MGUS. The association seen is likely spurious; patients who are ill enough to be evaluated for MGUS are likely to have more medical problems and cancers than patients who never have the need for such a test. These study flaws are systematic biases, and therefore cannot be rectified and are likely to be amplified by large sample sizes. In asymptomatic conditions such as MGUS, true associations can be demonstrated only if all persons are tested uniformly for the presence or absence of the condition.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?16/23/16754?source=see_link\">",
"       \"Patient information: Monoclonal gammopathy of undetermined significance (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22391063\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Monoclonal gammopathy of undetermined significance (MGUS) is an asymptomatic premalignant clonal plasma cell or lymphoplasmacytic proliferative disorder. MGUS occurs in over 3 percent of the general population over the age of 50 and is typically detected as an incidental finding when patients undergo a protein electrophoresis as part of an evaluation for a wide variety of clinical symptoms and disorders.",
"     </li>",
"     <li>",
"      There are three distinct clinical types of MGUS, each with a risk of progressing through a unique intermediate (more advanced) premalignant stage and then to a malignant plasma cell dyscrasia or lymphoproliferative disorder (see",
"      <a class=\"local\" href=\"#H22391006\">",
"       'Disease progression'",
"      </a>",
"      above):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Non-IgM MGUS (IgG, IgA, or IgD MGUS) is the most common subtype of MGUS. It has the potential to progress to smoldering (asymptomatic) multiple myeloma and symptomatic multiple myeloma. Less frequently, these patients progress to AL amyloidosis, light chain deposition disease, or another lymphoproliferative disorder.",
"     </li>",
"     <li>",
"      IgM MGUS accounts for approximately 15 percent of MGUS cases. It is considered separately from non-IgM MGUS because it has the potential to progress to smoldering Waldenstrom macroglobulinemia and symptomatic Waldenstrom macroglobulinemia. Infrequently, IgM MGUS can progress to IgM multiple myeloma.",
"     </li>",
"     <li>",
"      Light chain MGUS is a unique subtype of MGUS in which the secreted monoclonal protein lacks the immunoglobulin heavy chain component. It may progress to idiopathic Bence Jones proteinuria, light chain multiple myeloma, or AL amyloidosis.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with MGUS progress to more advanced disease at a rate of 1 percent per year. When compared with non-IgM MGUS, the rate may be slightly higher for IgM MGUS and slightly lower for light chain MGUS. (See",
"      <a class=\"local\" href=\"#H22391006\">",
"       'Disease progression'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The median survival of patients with MGUS is only slightly shorter than that of age-matched controls. (See",
"      <a class=\"local\" href=\"#H22391034\">",
"       'Survival'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      No treatment is required for patients with MGUS. Patients with MGUS should be followed over time with history and physical examination looking for signs and symptoms of progressive disease. All patients should undergo laboratory evaluation for disease progression six months after diagnosis with serum and urinary M-protein, complete blood count, creatinine, and serum calcium. While some experts incorporate periodic laboratory testing into the routine follow-up of all patients, we use a risk stratification system to identify patients for whom laboratory testing is most likely to provide value:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Patients with low-risk non-IgM MGUS (serum M protein &le;1.5",
"      <span class=\"nowrap\">",
"       g/dL,",
"      </span>",
"      IgG subtype, and normal serum free light chain ratio) may be followed with history and physical examination alone. They have a risk of progression of only 5 percent over 20 years.",
"     </li>",
"     <li>",
"      All other patients are followed with annual serum and urinary M-protein, complete blood count, creatinine, and serum calcium in addition to a history and physical examination.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The evolution from MGUS to advanced disease may be abrupt. As a result, patients should be advised to obtain medical evaluation promptly if clinical symptoms occur. (See",
"      <a class=\"local\" href=\"#H3221500\">",
"       'Monitoring for progression'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with MGUS are at increased risk of fracture and thromboembolic disease. Patients with MGUS should be evaluated for osteoporosis with a dual energy X-ray absorptiometry (DEXA) scan and have their vitamin D and calcium intake optimized. If osteoporosis is present, then treatment with bisphosphonates may be considered at the same dosing and schedule used for osteoporosis in patients without MGUS. (See",
"      <a class=\"local\" href=\"#H3221515\">",
"       'Fracture'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/60/4041/abstract/1\">",
"      Kyle RA, Rajkumar SV. Monoclonal gammopathy of undetermined significance. Br J Haematol 2006; 134:573.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/60/4041/abstract/2\">",
"      Kyle RA, Rajkumar SV. Monoclonal gammopathy of undetermined significance and smouldering multiple myeloma: emphasis on risk factors for progression. Br J Haematol 2007; 139:730.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/60/4041/abstract/3\">",
"      Bird J, Behrens J, Westin J, et al. UK Myeloma Forum (UKMF) and Nordic Myeloma Study Group (NMSG): guidelines for the investigation of newly detected M-proteins and the management of monoclonal gammopathy of undetermined significance (MGUS). Br J Haematol 2009; 147:22.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/60/4041/abstract/4\">",
"      Kyle RA, Durie BG, Rajkumar SV, et al. Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management. Leukemia 2010; 24:1121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/60/4041/abstract/5\">",
"      Rajkumar SV, Kyle RA, Buadi FK. Advances in the diagnosis, classification, risk stratification, and management of monoclonal gammopathy of undetermined significance: implications for recategorizing disease entities in the presence of evolving scientific evidence. Mayo Clin Proc 2010; 85:945.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/60/4041/abstract/6\">",
"      Dispenzieri A, Katzmann JA, Kyle RA, et al. Prevalence and risk of progression of light-chain monoclonal gammopathy of undetermined significance: a retrospective population-based cohort study. Lancet 2010; 375:1721.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/60/4041/abstract/7\">",
"      Kyle RA, Gertz MA, Witzig TE, et al. Review of 1027 patients with newly diagnosed multiple myeloma. Mayo Clin Proc 2003; 78:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/60/4041/abstract/8\">",
"      Landgren O, Kyle RA, Pfeiffer RM, et al. Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective study. Blood 2009; 113:5412.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/60/4041/abstract/9\">",
"      Weiss BM, Abadie J, Verma P, et al. A monoclonal gammopathy precedes multiple myeloma in most patients. Blood 2009; 113:5418.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/60/4041/abstract/10\">",
"      Kyle RA, Therneau TM, Rajkumar SV, et al. A long-term study of prognosis in monoclonal gammopathy of undetermined significance. N Engl J Med 2002; 346:564.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/60/4041/abstract/11\">",
"      Kyle RA, Therneau TM, Rajkumar SV, et al. Long-term follow-up of IgM monoclonal gammopathy of undetermined significance. Blood 2003; 102:3759.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/60/4041/abstract/12\">",
"      Kyle RA, Therneau TM, Rajkumar SV, et al. Long-term follow-up of 241 patients with monoclonal gammopathy of undetermined significance: the original Mayo Clinic series 25 years later. Mayo Clin Proc 2004; 79:859.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/60/4041/abstract/13\">",
"      Axelsson U. A 20-year follow-up study of 64 subjects with M-components. Acta Med Scand 1986; 219:519.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/60/4041/abstract/14\">",
"      Neriishi K, Nakashima E, Suzuki G. Monoclonal gammopathy of undetermined significance in atomic bomb survivors: incidence and transformation to multiple myeloma. Br J Haematol 2003; 121:405.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/60/4041/abstract/15\">",
"      Paladini G, Fogher M, Mazzanti G, et al. [Idiopathic monoclonal gammopathy. Long-term study of 313 cases]. Recenti Prog Med 1989; 80:123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/60/4041/abstract/16\">",
"      Giraldo MP, Rubio-F&eacute;lix D, Perella M, et al. [Monoclonal gammopathies of undetermined significance. Clinical course and biological aspects of 397 cases]. Sangre (Barc) 1991; 36:377.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/60/4041/abstract/17\">",
"      Gregersen H, Ibsen J, Mellemkjoer L, et al. Mortality and causes of death in patients with monoclonal gammopathy of undetermined significance. Br J Haematol 2001; 112:353.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/60/4041/abstract/18\">",
"      Gregersen H, Mellemkjaer L, Salling Ibsen J, et al. Cancer risk in patients with monoclonal gammopathy of undetermined significance. Am J Hematol 2000; 63:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/60/4041/abstract/19\">",
"      Schaar CG, le Cessie S, Snijder S, et al. Long-term follow-up of a population based cohort with monoclonal proteinaemia. Br J Haematol 2009; 144:176.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/60/4041/abstract/20\">",
"      Kyle RA, Therneau TM, Rajkumar SV, et al. Prevalence of monoclonal gammopathy of undetermined significance. N Engl J Med 2006; 354:1362.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/60/4041/abstract/21\">",
"      McMaster ML, Caporaso N. Waldenstr&ouml;m macroglobulinaemia and IgM monoclonal gammopathy of undetermined significance: emerging understanding of a potential precursor condition. Br J Haematol 2007; 139:663.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/60/4041/abstract/22\">",
"      Gobbi PG, Baldini L, Broglia C, et al. Prognostic validation of the international classification of immunoglobulin M gammopathies: a survival advantage for patients with immunoglobulin M monoclonal gammopathy of undetermined significance? Clin Cancer Res 2005; 11:1786.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/60/4041/abstract/23\">",
"      Baldini L, Goldaniga M, Guffanti A, et al. Immunoglobulin M monoclonal gammopathies of undetermined significance and indolent Waldenstrom's macroglobulinemia recognize the same determinants of evolution into symptomatic lymphoid disorders: proposal for a common prognostic scoring system. J Clin Oncol 2005; 23:4662.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/60/4041/abstract/24\">",
"      Kyle RA, Greipp PR. \"Idiopathic\" Bence Jones proteinuria: long-term follow-up in seven patients. N Engl J Med 1982; 306:564.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/60/4041/abstract/25\">",
"      Blad&eacute; J, Rosi&ntilde;ol L, Cibeira MT, de Larrea CF. Pathogenesis and progression of monoclonal gammopathy of undetermined significance. Leukemia 2008; 22:1651.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/60/4041/abstract/26\">",
"      Kristinsson SY, Bj&ouml;rkholm M, Andersson TM, et al. Patterns of survival and causes of death following a diagnosis of monoclonal gammopathy of undetermined significance: a population-based study. Haematologica 2009; 94:1714.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/60/4041/abstract/27\">",
"      Varettoni M, Corso A, Cocito F, et al. Changing pattern of presentation in monoclonal gammopathy of undetermined significance: a single-center experience with 1400 patients. Medicine (Baltimore) 2010; 89:211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/60/4041/abstract/28\">",
"      Baldini L, Guffanti A, Cesana BM, et al. Role of different hematologic variables in defining the risk of malignant transformation in monoclonal gammopathy. Blood 1996; 87:912.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/60/4041/abstract/29\">",
"      Cesana C, Klersy C, Barbarano L, et al. Prognostic factors for malignant transformation in monoclonal gammopathy of undetermined significance and smoldering multiple myeloma. J Clin Oncol 2002; 20:1625.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/60/4041/abstract/30\">",
"      Rosi&ntilde;ol L, Cibeira MT, Montoto S, et al. Monoclonal gammopathy of undetermined significance: predictors of malignant transformation and recognition of an evolving type characterized by a progressive increase in M protein size. Mayo Clin Proc 2007; 82:428.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/60/4041/abstract/31\">",
"      Rajkumar SV, Kyle RA, Therneau TM, et al. Serum free light chain ratio is an independent risk factor for progression in monoclonal gammopathy of undetermined significance. Blood 2005; 106:812.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/60/4041/abstract/32\">",
"      Rajkumar SV, Kyle RA, Therneau TM, et al. Presence of monoclonal free light chains in the serum predicts risk of progression in monoclonal gammopathy of undetermined significance. Br J Haematol 2004; 127:308.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/60/4041/abstract/33\">",
"      Kumar S, Rajkumar SV, Kyle RA, et al. Prognostic value of circulating plasma cells in monoclonal gammopathy of undetermined significance. J Clin Oncol 2005; 23:5668.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/60/4041/abstract/34\">",
"      Rossi F, Petrucci MT, Guffanti A, et al. Proposal and validation of prognostic scoring systems for IgG and IgA monoclonal gammopathies of undetermined significance. Clin Cancer Res 2009; 15:4439.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/60/4041/abstract/35\">",
"      P&eacute;rez-Persona E, Vidriales MB, Mateo G, et al. New criteria to identify risk of progression in monoclonal gammopathy of uncertain significance and smoldering multiple myeloma based on multiparameter flow cytometry analysis of bone marrow plasma cells. Blood 2007; 110:2586.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/60/4041/abstract/36\">",
"      Paiva B, Vidriales MB, Mateo G, et al. The persistence of immunophenotypically normal residual bone marrow plasma cells at diagnosis identifies a good prognostic subgroup of symptomatic multiple myeloma patients. Blood 2009; 114:4369.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/60/4041/abstract/37\">",
"      Mateo G, Montalb&aacute;n MA, Vidriales MB, et al. Prognostic value of immunophenotyping in multiple myeloma: a study by the PETHEMA/GEM cooperative study groups on patients uniformly treated with high-dose therapy. J Clin Oncol 2008; 26:2737.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/60/4041/abstract/38\">",
"      P&eacute;rez-Persona E, Mateo G, Garc&iacute;a-Sanz R, et al. Risk of progression in smouldering myeloma and monoclonal gammopathies of unknown significance: comparative analysis of the evolution of monoclonal component and multiparameter flow cytometry of bone marrow plasma cells. Br J Haematol 2010; 148:110.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/60/4041/abstract/39\">",
"      Raja KR, Kovarova L, Hajek R. Review of phenotypic markers used in flow cytometric analysis of MGUS and MM, and applicability of flow cytometry in other plasma cell disorders. Br J Haematol 2010; 149:334.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/60/4041/abstract/40\">",
"      Pecherstorfer M, Seibel MJ, Woitge HW, et al. Bone resorption in multiple myeloma and in monoclonal gammopathy of undetermined significance: quantification by urinary pyridinium cross-links of collagen. Blood 1997; 90:3743.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/60/4041/abstract/41\">",
"      Mailankody S, Mena E, Yuan CM, et al. Molecular and biologic markers of progression in monoclonal gammopathy of undetermined significance to multiple myeloma. Leuk Lymphoma 2010; 51:2159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/60/4041/abstract/42\">",
"      Bianchi G, Kyle RA, Colby CL, et al. Impact of optimal follow-up of monoclonal gammopathy of undetermined significance on early diagnosis and prevention of myeloma-related complications. Blood 2010; 116:2019.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/60/4041/abstract/43\">",
"      Kyle RA. \"Benign\" monoclonal gammopathy--after 20 to 35 years of follow-up. Mayo Clin Proc 1993; 68:26.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/60/4041/abstract/44\">",
"      Melton LJ 3rd, Rajkumar SV, Khosla S, et al. Fracture risk in monoclonal gammopathy of undetermined significance. J Bone Miner Res 2004; 19:25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/60/4041/abstract/45\">",
"      Gregersen H, Jensen P, Gislum M, et al. Fracture risk in patients with monoclonal gammopathy of undetermined significance. Br J Haematol 2006; 135:62.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/60/4041/abstract/46\">",
"      Kristinsson SY, Tang M, Pfeiffer RM, et al. Monoclonal gammopathy of undetermined significance and risk of skeletal fractures: a population-based study. Blood 2010; 116:2651.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/60/4041/abstract/47\">",
"      Pepe J, Petrucci MT, Nofroni I, et al. Lumbar bone mineral density as the major factor determining increased prevalence of vertebral fractures in monoclonal gammopathy of undetermined significance. Br J Haematol 2006; 134:485.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/60/4041/abstract/48\">",
"      Politou M, Terpos E, Anagnostopoulos A, et al. Role of receptor activator of nuclear factor-kappa B ligand (RANKL), osteoprotegerin and macrophage protein 1-alpha (MIP-1a) in monoclonal gammopathy of undetermined significance (MGUS). Br J Haematol 2004; 126:686.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/60/4041/abstract/49\">",
"      Ng AC, Khosla S, Charatcharoenwitthaya N, et al. Bone microstructural changes revealed by high-resolution peripheral quantitative computed tomography imaging and elevated DKK1 and MIP-1&alpha; levels in patients with MGUS. Blood 2011; 118:6529.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/60/4041/abstract/50\">",
"      Berenson JR, Anderson KC, Audell RA, et al. Monoclonal gammopathy of undetermined significance: a consensus statement. Br J Haematol 2010; 150:28.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/60/4041/abstract/51\">",
"      Sallah S, Husain A, Wan J, et al. The risk of venous thromboembolic disease in patients with monoclonal gammopathy of undetermined significance. Ann Oncol 2004; 15:1490.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/60/4041/abstract/52\">",
"      Srkalovic G, Cameron MG, Rybicki L, et al. Monoclonal gammopathy of undetermined significance and multiple myeloma are associated with an increased incidence of venothromboembolic disease. Cancer 2004; 101:558.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/60/4041/abstract/53\">",
"      Kristinsson SY, Fears TR, Gridley G, et al. Deep vein thrombosis after monoclonal gammopathy of undetermined significance and multiple myeloma. Blood 2008; 112:3582.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/60/4041/abstract/54\">",
"      Muslimani AA, Spiro TP, Chaudhry AA, et al. Venous thromboembolism in patients with monoclonal gammopathy of undetermined significance. Clin Adv Hematol Oncol 2009; 7:827.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/60/4041/abstract/55\">",
"      Kristinsson SY, Pfeiffer RM, Bj&ouml;rkholm M, et al. Arterial and venous thrombosis in monoclonal gammopathy of undetermined significance and multiple myeloma: a population-based study. Blood 2010; 115:4991.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/60/4041/abstract/56\">",
"      Gregersen H, N&oslash;rgaard M, Severinsen MT, et al. Monoclonal gammopathy of undetermined significance and risk of venous thromboembolism. Eur J Haematol 2011; 86:129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/60/4041/abstract/57\">",
"      Auwerda JJ, Sonneveld P, de Maat MP, Leebeek FW. Prothrombotic coagulation abnormalities in patients with paraprotein-producing B-cell disorders. Clin Lymphoma Myeloma 2007; 7:462.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/60/4041/abstract/58\">",
"      Thomas A, Mailankody S, Korde N, et al. Second malignancies after multiple myeloma: from 1960s to 2010s. Blood 2012; 119:2731.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/60/4041/abstract/59\">",
"      Mailankody S, Pfeiffer RM, Kristinsson SY, et al. Risk of acute myeloid leukemia and myelodysplastic syndromes after multiple myeloma and its precursor disease (MGUS). Blood 2011; 118:4086.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 15772 Version 16.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-61.234.146.186-A1721555EE-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_60_4041=[""].join("\n");
var outline_f3_60_4041=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H22391063\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20641026\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22390998\">",
"      CLINICAL COURSE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22391006\">",
"      Disease progression",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22391013\">",
"      - MGUS",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22391020\">",
"      - IgM MGUS",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22391027\">",
"      - Light chain MGUS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22391034\">",
"      Survival",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22391041\">",
"      MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22391048\">",
"      Risk stratification",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3221500\">",
"      Monitoring for progression",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3221507\">",
"      Monitoring for complications",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H3221515\">",
"      - Fracture",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H3221522\">",
"      - Thromboembolic disease",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H31491539\">",
"      - Second malignancies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22391063\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"HEME/15772\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/15772|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?8/36/8781\" title=\"figure 1\">",
"      Course of MGUS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?8/12/8398\" title=\"figure 2\">",
"      Progression IgM MGUS",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/56/40842?source=related_link\">",
"      Bisphosphonates in the management of osteoporosis in postmenopausal women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/13/35034?source=related_link\">",
"      Clinical features, laboratory manifestations, and diagnosis of multiple myeloma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/59/15290?source=related_link\">",
"      Diagnosis of monoclonal gammopathy of undetermined significance",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/47/762?source=related_link\">",
"      Epidemiology, pathogenesis, clinical manifestations and diagnosis of Waldenstr&ouml;m macroglobulinemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/62/35815?source=related_link\">",
"      Pathogenesis of immunoglobulin light chain (AL) amyloidosis and light and heavy chain deposition diseases",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?16/23/16754?source=related_link\">",
"      Patient information: Monoclonal gammopathy of undetermined significance (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/58/10154?source=related_link\">",
"      Recognition of monoclonal proteins",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f3_60_4042="Midazolam: Drug information";
var content_f3_60_4042=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Midazolam: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?4/6/4197?source=see_link\">",
"    see \"Midazolam: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?0/46/746?source=see_link\">",
"    see \"Midazolam: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F5709086\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F196443\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-Midazolam&reg;;",
"     </li>",
"     <li>",
"      Midazolam Injection",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F196489\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Benzodiazepine",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F196447\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     The dose of midazolam needs to be individualized based on the patient's age, underlying diseases, and concurrent medications. Consider reducing dose by 20% to 50% in elderly, chronically ill, or debilitated patients and those receiving opioids or other CNS depressants.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      Preoperative/preprocedural sedation:",
"     </b>",
"     Healthy adults &lt;60 years:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      I.M.:",
"     </i>",
"     0.07-0.08 mg/kg 30-60 minutes prior to surgery/procedure; usual dose: 5 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      I.V.:",
"     </i>",
"     0.02-0.04 mg/kg; repeat every 5 minutes as needed to desired effect or up to 0.1-0.2 mg/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Intranasal (unlabeled route):",
"     </i>",
"     0.1 mg/kg; administer 10-20 minutes prior to surgery/procedure (Uygur-Bayrami&ccedil;li, 2002).",
"     <b>",
"      Note:",
"     </b>",
"     Use 5 mg/mL injectable concentrated solution to deliver dose. Due to the low pH of the solution, burning upon administration is likely to occur.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Conscious sedation:",
"     </b>",
"     I.V.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Manufacturer's labeling:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Healthy adults &lt;60 years:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Initial: Some patients respond to doses as low as 1 mg; no more than 2.5 mg should be administered over a period of 2 minutes. Additional doses of midazolam may be administered after a 2-minute waiting period and evaluation of sedation after each dose increment. A total dose &gt;5 mg is generally not needed.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Maintenance: 25% of dose used to reach sedative effect",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Adults &ge;60 years, debilitated, or chronically ill: Refer to geriatric dosing.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Alternate recommendations: American Society for Gastrointestinal Endoscopy: Initial: 0.5-2 mg slow I.V. over at least 2 minutes; slowly titrate to effect by repeating doses every 2-3 minutes if needed; usual total dose: 2.5-5 mg (Waring, 2003)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Anesthesia:",
"     </b>",
"     I.V.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Induction:",
"     </i>",
"     Adults &lt;55 years:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Unpremedicated patients: 0.3-0.35 mg/kg over 20-30 seconds; after 2 minutes, may repeat if necessary at 25% of initial dose every 2 minutes, up to a total dose of 0.6 mg/kg in resistant cases",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Premedicated patients: Usual dosage range: 0.05-0.2 mg/kg (Barash, 2009; Miller, 2010). Use of 0.2 mg/kg administered over 5-10 seconds has been shown to safely produce anesthesia within 30 seconds (Samuelson, 1981) and is recommended for ASA physical status P1 and P2 patients. When used with other anesthetic drugs (ie, co-induction), the dose is &lt;0.1 mg/kg (Miller, 2010).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     ASA physical status &gt;P3 or debilitation: Reduce dose by at least 20% (Miller, 2010).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Maintenance:",
"     </i>",
"     0.05 mg/kg as needed (Miller, 2010), or continuous infusion 0.015-0.06 mg/kg/",
"     <b>",
"      hour",
"     </b>",
"     (0.25-1",
"     <b>",
"      mcg",
"     </b>",
"     /kg/minute) (Barash, 2009; Miller, 2010)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Sedation in mechanically-ventilated patients:",
"     </b>",
"     I.V.:  Initial dose: 0.01-0.05 mg/kg (~0.5-4 mg); may repeat at 5- to 15-minute intervals until adequate sedation achieved; maintenance infusion: 0.02-0.1 mg/kg/",
"     <b>",
"      hour",
"     </b>",
"     (0.3-1.7",
"     <b>",
"      mcg",
"     </b>",
"     /kg/minute). Titrate to reach desired level of sedation. Titration to maintain a light rather than a deep level of sedation is recommended unless clinically contraindicated (Barr, 2013). May consider a trial of daily awakening; if agitated after discontinuation of drip, then restart at 50% of the previous dose (Kress, 2000).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Status epilepticus refractory to standard therapy (unlabeled use):",
"     </b>",
"     I.V.:",
"     <b>",
"      Note:",
"     </b>",
"     Intubation required; adjust dose based on hemodynamics, seizure activity, and EEG. 0.15-0.3 mg/kg (usual dose: 5-15 mg); may repeat every 10-15 minutes as needed",
"     <b>",
"      or",
"     </b>",
"     0.2 mg/kg bolus followed by a continuous  infusion of 0.05-0.6 mg/kg/",
"     <b>",
"      hour",
"     </b>",
"     (0.83-10",
"     <b>",
"      mcg",
"     </b>",
"     /kg/minute) (Lowenstein, 2005; Meierkord, 2010)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Status epilepticus, prehospital treatment (unlabeled use):",
"     </b>",
"     I.V.:",
"     <b>",
"      Note:",
"     </b>",
"     Administered by paramedics when convulsions last &gt;5 minutes",
"     <b>",
"      or",
"     </b>",
"     if convulsions are occurring after having intermittent seizures without regaining consciousness for &gt;5 minutes: 10 mg once (Silbergleit, 2012)",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F196467\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?0/46/746?source=see_link\">",
"      see \"Midazolam: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     The dose of midazolam needs to be individualized based on the patient's age, underlying diseases, and concurrent medications. Decrease dose (by ~30%) if opioids or other CNS depressants are administered concomitantly. Children &lt;6 years may require higher doses and closer monitoring than older children; calculate dose based on ideal body weight.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      Conscious sedation for procedures or preoperative sedation:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Oral, rectal:",
"     </i>",
"     0.5-0.75 mg/kg as a single dose preprocedure (maximum: 20 mg); administer 20-30 minutes prior to procedure. Children &lt;6 years or less cooperative patients may require as much as 1 mg/kg as a single dose; 0.25 mg/kg may suffice for children 6-16 years of age (Bozkurt, 2007).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Intranasal (unlabeled route):",
"     </i>",
"     0.2-0.5 mg/kg (maximum total dose: 10 mg or 5 mg per nare); may be administered 10-20 minutes prior to procedure (Bozkurt, 2007; Chiaretti, 2011).",
"     <b>",
"      Note:",
"     </b>",
"     Use 5 mg/mL injectable concentrated solution to deliver dose. Due to the low pH of the solution, burning upon administration is likely to occur.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      I.M.:",
"     </i>",
"     0.1-0.15 mg/kg 30-60 minutes before surgery or procedure; range: 0.05-0.15 mg/kg; doses up to 0.5 mg/kg have been used in more anxious patients; maximum total dose: 10 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      I.V.:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Infants &lt;6 months: Limited information is available in nonintubated infants; dosing recommendations not clear; infants &lt;6 months are at higher risk for airway obstruction and hypoventilation; titrate dose in small increments to desired effect",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Infants 6 months to Children 5 years: Initial: 0.05-0.1 mg/kg; total dose of 0.6 mg/kg may be required; maximum total dose: 6 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Children 6-12 years: Initial: 0.025-0.05 mg/kg; total doses of 0.4 mg/kg may be required; maximum total dose: 10 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Children 12-16 years: Dose as adults; maximum total dose: 10 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Conscious sedation during mechanical ventilation:",
"     </b>",
"     I.V.: Children: Loading dose: 0.05-0.2 mg/kg, followed by initial continuous infusion: 0.06-0.12 mg/kg/",
"     <b>",
"      hour",
"     </b>",
"     (1-2",
"     <b>",
"      mcg",
"     </b>",
"     /kg/minute); range in clinical trials: 0.024-0.564 mg/kg/",
"     <b>",
"      hour",
"     </b>",
"     (0.4-9.4",
"     <b>",
"      mcg",
"     </b>",
"     /kg/minute) (Hartman, 2009)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Status epilepticus refractory to standard therapy (unlabeled use):",
"     </b>",
"     I.V.:",
"     <b>",
"      Note:",
"     </b>",
"     Intubation required; adjust dose based on hemodynamics, seizure activity, and EEG. Infants &gt;2 months and Children: Loading dose: 0.15 mg/kg followed by a continuous infusion of 0.06 mg/kg/",
"     <b>",
"      hour",
"     </b>",
"     (1",
"     <b>",
"      mcg",
"     </b>",
"     /kg/minute); titrate dose upward every 5 minutes until clinical seizure activity is controlled; mean infusion rate required in 24 children was 0.14 mg/kg/",
"     <b>",
"      hour",
"     </b>",
"     (2.3",
"     <b>",
"      mcg",
"     </b>",
"     /kg/minute) with a range of 0.06-1.1 mg/kg/",
"     <b>",
"      hour",
"     </b>",
"     (1-18.3",
"     <b>",
"      mcg",
"     </b>",
"     /kg/minute) (Rivera, 1993).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     A more aggressive approach has been demonstrated to provide control of status epilepticus within 30 minutes of initiation: Loading dose: 0.5 mg/kg followed by 0.12 mg/kg/",
"     <b>",
"      hour",
"     </b>",
"     (2",
"     <b>",
"      mcg",
"     </b>",
"     /kg/minute). If seizures persist or recur, administer 0.5 mg/kg bolus with an increase in the infusion rate to 0.24 mg/kg/",
"     <b>",
"      hour",
"     </b>",
"     (4",
"     <b>",
"      mcg",
"     </b>",
"     /kg/minute); if seizures continue to persist/recur, administer 0.1 mg/kg bolus and increase infusion to 0.48 mg/kg/",
"     <b>",
"      hour",
"     </b>",
"     (8",
"     <b>",
"      mcg",
"     </b>",
"     /kg/minute); continue to repeat this last incremental increase until seizure control or a maximum dose of 1.44 mg/kg/",
"     <b>",
"      hour",
"     </b>",
"     (24",
"     <b>",
"      mcg",
"     </b>",
"     /kg/minute) is reached; do not allow &gt;5 minutes to elapse between each dose increment while seizures persist (dose range within clinical trial: 0.12-1.92 mg/kg/",
"     <b>",
"      hour",
"     </b>",
"     or 2-32",
"     <b>",
"      mcg",
"     </b>",
"     /kg/minute) (Morrison, 2006).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Status epilepticus, prehospital treatment (unlabeled use; Silbergleit, 2012):",
"     </b>",
"     I.M.:",
"     <b>",
"      Note:",
"     </b>",
"     Administered by paramedics when convulsions last &gt;5 minutes",
"     <b>",
"      or",
"     </b>",
"     if convulsions are occurring after having intermittent seizures without regaining consciousness for &gt;5 minutes. I.M.: Children and Adolescents:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     13-40 kg: 5 mg once",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &gt;40 kg: Refer to adult dosing",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F196448\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The dose of midazolam needs to be individualized based on the patient's age, underlying diseases, and concurrent medications. Consider reducing dose by 20% to 50% in elderly, chronically ill, or debilitated patients and those receiving opioids or other CNS depressants.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      Anesthesia:",
"     </b>",
"     I.V.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Induction: Adults &gt;55 years:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;text-align:justify;\">",
"     Unpremedicated patients: Initial dose: 0.3 mg/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;text-align:justify;\">",
"     Premedicated patients: Reduce dose by at least 20% (Miller, 2010).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Maintenance: Refer to adult dosing.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     <b>",
"      Conscious sedation:",
"     </b>",
"     I.V.: Initial: 0.5 mg slow I.V.; give no more than 1.5 mg in a 2-minute period; if additional titration is needed, give no more than 1 mg over 2 minutes, waiting another 2 or more minutes to evaluate sedative effect; a total dose of &gt;3.5 mg is rarely necessary",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     <b>",
"      Preoperative/preprocedural sedation:",
"     </b>",
"     Adults &gt;60 years (without concomitant opioid administration): I.M.: 2-3 mg (or 0.02-0.05 mg/kg) 30-60 minutes prior to surgery/procedure; some may only require 1 mg (or 0.01 mg/kg) if anticipated intensity and duration of sedation is less critical.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F196449\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     There are no dosage adjustments provided in manufacturer's labeling; however, patients with renal failure receiving a continuous infusion cannot adequately eliminate the active hydroxylated metabolites (eg, 1-hydroxymidazolam) contributing to prolonged sedation sometimes for days after discontinuation (Spina, 2007).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Intermittent hemodialysis: Supplemental dose is not necessary.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Continuous venovenous hemofiltration (CVVH): Unconjugated 1-hydroxymidazolam not effectively removed; 1-hydroxymidazolamglucuronide effectively removed; sieving coefficient = 0.45 (Swart, 2005).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Peritoneal dialysis: Significant drug removal is unlikely based on physiochemical characteristics.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F13134499\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Severe hepatic impairment (eg, cirrhosis):",
"     <b>",
"      Note:",
"     </b>",
"     Use with caution in patients with any degree of hepatic impairment; patients with hepatic encephalopathy likely to be more sensitive to midazolam.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Single dose (eg, induction): No dosage adjustment recommended; patients with hepatic impairment may be more sensitive compared to patients without hepatic impairment; anticipate longer duration of action (MacGilchrist, 1986; Trouvin, 1988).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Multiple dosing or continuous infusion: Expect longer duration of action and accumulation; based on patient response, dosage reduction likely to be necessary (Trouvin, 1988).",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F196415\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution: 1 mg/mL (2 mL, 5 mL, 10 mL); 5 mg/mL (1 mL, 2 mL, 5 mL, 10 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution [preservative free]: 1 mg/mL (2 mL, 5 mL); 5 mg/mL (1 mL, 2 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Syrup, oral: 2 mg/mL (118 mL)",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F196399\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block csi drugH1Div\" id=\"F196491\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Controlled Substance",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C-IV",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F196419\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Intranasal:",
"     <b>",
"      Note:",
"     </b>",
"     Due to the low pH of the solution, burning upon administration is likely to occur. Use of an atomizer, such as the MAD 300 Mucosal Atomizer which attaches to a tuberculin syringe, can reduce irritation. If possible, based upon dose to be administered, use higher concentration injectable solution to minimize volume administered intranasal. Smaller volume will reduce irritation and swallowing of administered dose. The maximum recommended dose volume per nare is 1 mL.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Using the 5 mg/mL injectable solution, draw up desired dose with a 1-3 mL needleless syringe; may attach a nasal mucosal atomization device prior to delivering dose. Deliver half of the total dose volume (of the 5 mg/mL concentration) into the first nare using the atomizer device or by dripping slowly into nostril, then deliver the other half of the dose into the second nare.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Oral: Do not mix with any liquid (such as grapefruit juice) prior to administration",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Parenteral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     I.M.: Administer deep I.M. into large muscle.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     I.V.: Administer by slow I.V. injection over at least 2-5 minutes at a concentration of 1-5 mg/mL or by I.V. infusion. For induction of anesthesia, administer I.V. bolus over 5-30 seconds. Continuous infusions should be administered via an infusion pump.",
"    </p>",
"   </div>",
"   <div class=\"block uica drugH1Div\" id=\"F14472924\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Usual Infusion Concentrations: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      I.V. infusion:",
"     </b>",
"     100 mg in 100 mL (concentration: 1 mg/mL) of D",
"     <sub>",
"      5",
"     </sub>",
"     W or NS",
"    </p>",
"   </div>",
"   <div class=\"block uicp drugH1Div\" id=\"F14472925\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Usual Infusion Concentrations: Pediatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      I.V. infusion:",
"     </b>",
"     0.5 mg/mL",
"     <b>",
"      or",
"     </b>",
"     1 mg/mL",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F196496\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Stable in D",
"     <sub>",
"      5",
"     </sub>",
"     NS, D",
"     <sub>",
"      5",
"     </sub>",
"     W, NS;",
"     <b>",
"      incompatible",
"     </b>",
"     with LR.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Y-site administration: Compatible:",
"     </b>",
"     Abciximab, amikacin, amiodarone, anidulafungin, argatroban, atracurium, bivalirudin, calcium gluconate, caspofungin, cefazolin, cimetidine, ciprofloxacin, cisatracurium, clindamycin, digoxin, diltiazem, doripenem, epinephrine, eptifibatide, erythromycin lactobionate, esmolol, etomidate, famotidine, fenoldopam, fentanyl, fluconazole, gentamicin, heparin, hetastarch in lactate electrolyte injection (Hextend&reg;), hydromorphone, insulin (regular), labetalol, linezolid, lorazepam, methadone, metronidazole, milrinone, morphine, nicardipine, nitroglycerin, nitroprusside, norepinephrine, palonosetron, pancuronium, piperacillin, ranitidine, remifentanil, sufentanil, theophylline, tirofiban, tobramycin, vancomycin, vecuronium.",
"     <b>",
"      Incompatible:",
"     </b>",
"     Albumin, amphotericin B cholesteryl sulfate complex, ampicillin, bumetanide, butorphanol, cefepime, ceftazidime, cefuroxime, dexamethasone sodium succinate, drotrecogin alfa, foscarnet, fosphenytoin, furosemide, hydrocortisone sodium succinate, imipenem/cilastatin, methotrexate, micafungin, nafcillin, sodium bicarbonate, thiopental,  trimethoprim/sulfamethoxazole.",
"     <b>",
"      Variable (consult detailed reference):",
"     </b>",
"     Cefotaxime, clonidine, dobutamine, haloperidol, methylprednisolone sodium succinate, metoclopramide, pantoprazole, potassium chloride, propofol.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Compatibility in syringe: Compatible:",
"     </b>",
"     Alfentanil, atracurium, atropine, buprenorphine, butorphanol, chlorpromazine, cimetidine, diphenhydramine, dopamine, droperidol, fentanyl, glycopyrrolate, hydromorphone, hydroxyzine, ketamine, meperidine, metoclopramide, morphine, nalbuphine, ondansetron, promethazine, rocuronium, scopolamine, sufentanil, trimethobenzamide.",
"     <b>",
"      Incompatible:",
"     </b>",
"     Dimenhydrinate, heparin, pantoprazole, pentobarbital, prochlorperazine edisylate, ranitidine.",
"     <b>",
"      Variable (consult detailed reference):",
"     </b>",
"     Dexamethasone sodium phosphate, methylprednisolone sodium succinate.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F196418\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Preoperative sedation; moderate sedation prior to diagnostic or radiographic procedures; ICU sedation (continuous infusion); induction and maintenance of general anesthesia",
"    </p>",
"   </div>",
"   <div class=\"block usu drugH1Div\" id=\"F196485\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use - Unlabeled",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Anxiety, status epilepticus, conscious sedation (intranasal route)",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F196498\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Versed may be confused with VePesid, Vistaril&reg;",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      High alert medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       The Institute for Safe Medication Practices (ISMP) includes this medication among its list of drugs which have a heightened risk of causing significant patient harm when used in error.",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F196487\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     As reported in adults unless otherwise noted:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &gt;10%: Respiratory: Decreased tidal volume and/or respiratory rate decrease, apnea (3% children)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Hypotension (3% children)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Drowsiness (1%), oversedation, headache (1%), seizure-like activity (1% children)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Nausea (3%), vomiting (3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Local: Pain and local reactions at injection site (4% I.M., 5% I.V.; severity less than diazepam)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Myoclonic jerks (preterm infants)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ocular: Nystagmus (1% children)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Cough (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miscellaneous: Physical and psychological dependence with prolonged use, hiccups (4%, 1% children), paradoxical reaction (2% children)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &lt;1% (Limited to important or life-threatening): Agitation, amnesia, bigeminy, bronchospasm, emergence delirium, euphoria, hallucinations, laryngospasm, rash",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F196422\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to midazolam or any component of the formulation; intrathecal or epidural injection of parenteral forms containing preservatives (ie, benzyl alcohol); acute narrow-angle glaucoma; concurrent use of potent inhibitors of CYP3A4 (amprenavir, atazanavir, or ritonavir)",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Per respective protease inhibitor manufacturer's labeling: Concurrent use of oral midazolam with amprenavir, atazanavir, darunavir, indinavir, lopinavir-ritonavir, nelfinavir, ritonavir, saquinavir, tipranavir and concurrent use of oral or injectable midazolam with fosamprenavir",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F196403\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Anterograde amnesia: Benzodiazepines have been associated with anterograde amnesia.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; CNS depression: May cause CNS depression, which may impair physical or mental abilities; patients must be cautioned about performing tasks which require mental alertness (eg, operating machinery or driving). A minimum of 1 day should elapse after midazolam administration before attempting these tasks.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypotension: May cause hypotension; hemodynamic events are more common in pediatric patients or patients with hemodynamic instability. Hypotension may occur more frequently in patients who have received opioid analgesics.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Paradoxical reactions: Paradoxical reactions, including hyperactive or aggressive behavior, have been reported with benzodiazepines, particularly in adolescent/pediatric or psychiatric patients; may consider treatment with flumazenil (Massanari, 1997).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Respiratory depression:",
"     <b>",
"      [U.S. Boxed Warning]: May cause severe respiratory depression, respiratory arrest, or apnea. Use with extreme caution, particularly in noncritical care settings.",
"     </b>",
"     Appropriate resuscitative equipment and qualified personnel must be available for administration and monitoring. Initial dosing must be cautiously titrated and individualized, particularly in elderly or debilitated patients, patients with hepatic impairment (including alcoholics), or in renal impairment, particularly if other CNS depressants (including opiates) are used concurrently.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Heart failure (HF): Use with caution in patients with HF.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Impaired gag reflex: Use with caution in patients with an impaired gag reflex.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Use with caution in patients with renal impairment; half-life of midazolam and metabolites may be prolonged.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Respiratory disease: Use with caution in patients with respiratory disease.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; CNS depressants/psychoactive medications: Use with caution in patients receiving other CNS depressants or psychoactive medication; effects with other sedative drugs or ethanol may be potentiated.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; CYP3A4 Inhibitors: Use with caution in patients receiving CYP3A4 inhibitors; may result in more intense and prolonged sedation; consider reducing midazolam dose and anticipate potential for prolongation and intensity of effect. The concurrent use of all protease inhibitors is contraindicated with oral midazolam per their respective manufacturer&rsquo;s labeling. The concurrent use of fosamprenavir is contraindicated with both oral and parenteral forms of midazolam. Of note, a sixfold higher incidence of severe prolonged sedation has been noted in HIV-positive patients receiving I.V. midazolam for sedation during inpatient bronchoscopy as compared to those not receiving antiretroviral agents (Hsu, 2012).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Debilitated patients:",
"     <b>",
"      [U.S. Boxed Warning]: Initial doses in debilitated patients should be conservative; start at the lower end of dosing range.",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Elderly:",
"     <b>",
"      [U.S. Boxed Warning]: Initial doses in elderly should be conservative; start at the lower end of dosing range.",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Fall risk: Use with extreme caution in patients who are at risk of falls; benzodiazepines have been associated with falls and traumatic injury.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Obese patients: Use with caution in obese patients; may have prolonged action when discontinued.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Neonates:",
"     <b>",
"      [U.S. Boxed Warning]: Do not administer by rapid I.V. injection in neonates; severe hypotension and seizures have been reported; risk may be increased with concomitant fentanyl use.",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Dosage form specific issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Benzyl alcohol: Some parenteral dosage forms may contain benzyl alcohol which has been associated with &ldquo;gasping syndrome&rdquo; in neonates.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Appropriate use: Does not have analgesic, antidepressant, or antipsychotic properties. Does not protect against increases in heart rate or blood pressure during intubation. Should not be used in shock, coma, or acute alcohol intoxication.  Avoid intra-arterial administration or extravasation of parenteral formulation. Use during upper airway procedures may increase risk of hypoventilation. Prolonged responses have been noted following extended administration by continuous infusion (possibly due to metabolite accumulation) or in the presence of drugs which inhibit midazolam metabolism.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cherry flavoring: Some formulations may contain cherry flavoring.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Withdrawal: Rebound or withdrawal symptoms may occur following abrupt discontinuation or large decreases in dose. Use caution when reducing dose or withdrawing therapy; decrease slowly and monitor for withdrawal symptoms. Flumazenil may cause withdrawal in patients receiving long-term benzodiazepine therapy.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F196481\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP2B6 (minor), CYP3A4 (major);",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential;",
"     <b>",
"      Inhibits",
"     </b>",
"     CYP2C8 (weak), CYP2C9 (weak), CYP3A4 (weak)",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F196408\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alcohol (Ethyl): CNS Depressants may enhance the CNS depressant effect of Alcohol (Ethyl).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antifungal Agents (Azole Derivatives, Systemic): May decrease the metabolism of Benzodiazepines (metabolized by oxidation). Management: The following combinations are specifically contraindicated: itraconazole with alprazolam, estazolam, oral midazolam, or triazolam; ketoconazole with alprazolam, estazolam, or triazolam.  Consider initial dose reductions of other benzodiazepines.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aprepitant: May increase the serum concentration of Benzodiazepines (metabolized by oxidation).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP3A4 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.  Management: Monitor for increased aripiprazole pharmacologic effects. Aripiprazole dose adjustments may or may not be required based on concomitant therapy and/or indication. Consult full interaction monograph for specific recommendations.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     AtorvaSTATin: May increase the serum concentration of Midazolam.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Azelastine (Nasal): CNS Depressants may enhance the CNS depressant effect of Azelastine (Nasal).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Boceprevir: May increase the serum concentration of Midazolam.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Buprenorphine: CNS Depressants may enhance the CNS depressant effect of Buprenorphine.  Management: Consider reduced doses of CNS depressants used in combination with buprenorphine.  Consider avoiding other CNS depressants in patients thought to be at high risk of buprenorphine overuse or self-injection.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcium Channel Blockers (Nondihydropyridine): May decrease the metabolism of Benzodiazepines (metabolized by oxidation).",
"     <b>",
"      Exceptions:",
"     </b>",
"     Bepridil [Off Market].",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CarBAMazepine: May increase the metabolism of Benzodiazepines (metabolized by oxidation).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cimetidine: May decrease the metabolism of Benzodiazepines (metabolized by oxidation).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CloZAPine: Benzodiazepines may enhance the adverse/toxic effect of CloZAPine.  Management: Consider decreasing the dose of (or possibly discontinuing) benzodiazepines prior to initiating clozapine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CNS Depressants: May enhance the adverse/toxic effect of other CNS Depressants.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levocabastine (Nasal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cobicistat: May increase the serum concentration of Midazolam. Management: Oral midazolam is contraindicated with the elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate combination product.  IV midazolam should only be used with caution, close monitoring, and consideration of lower IV midazolam doses.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Conivaptan: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Contraceptives (Estrogens): May decrease the metabolism of Benzodiazepines (metabolized by oxidation).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Contraceptives (Progestins): May increase the serum concentration of Benzodiazepines (metabolized by oxidation).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inducers (Strong): May increase the metabolism of CYP3A4 Substrates. Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Moderate): May decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Strong): May decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dasatinib: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Droperidol: May enhance the CNS depressant effect of CNS Depressants. Management: Consider dose reductions of droperidol or of other CNS agents (e.g., opioids, barbiturates) with concomitant use.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Efavirenz: May increase the serum concentration of Midazolam.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fosaprepitant: May increase the serum concentration of Benzodiazepines (metabolized by oxidation). Specifically, the active metabolite aprepitant is likely responsible for this effect.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fosphenytoin: Benzodiazepines may increase the serum concentration of Fosphenytoin. Short-term exposure to benzodiazepines may not present as much risk as chronic therapy.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ginkgo Biloba: May decrease the serum concentration of Midazolam.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Grapefruit Juice: May decrease the metabolism of Benzodiazepines (metabolized by oxidation).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     HydrOXYzine: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Isoniazid: May decrease the metabolism of Benzodiazepines (metabolized by oxidation).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Itraconazole: May increase the serum concentration of Midazolam. Management: Oral midazolam is contraindicated.  Use intravenous midazolam with great caution in patients receiving itraconazole, employing reduced initial doses whenever possible and monitoring closely for enhanced and prolonged effects.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivacaftor: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ketoconazole (Systemic): May increase the serum concentration of Midazolam.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lomitapide: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Lomitapide.  Management: Limit the maximum adult dose of lomitapide to 30 mg daily when used in combination with any weak CYP3A4 inhibitor.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Macrolide Antibiotics: May decrease the metabolism of Benzodiazepines (metabolized by oxidation).",
"     <b>",
"      Exceptions:",
"     </b>",
"     Azithromycin (Systemic); Fidaxomicin; Spiramycin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Magnesium Sulfate: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methotrimeprazine: CNS Depressants may enhance the CNS depressant effect of Methotrimeprazine. Methotrimeprazine may enhance the CNS depressant effect of CNS Depressants.  Management: Reduce adult dose of CNS depressant agents by 50% with initiation of concomitant methotrimeprazine therapy. Further CNS depressant dosage adjustments should be initiated only after clinically effective methotrimeprazine dose is established.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metyrosine: CNS Depressants may enhance the sedative effect of Metyrosine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May increase the serum concentration of CYP3A4 Substrates. Management: Minimize doses of CYP3A4 substrates, and monitor for increased concentrations/toxicity, during and 2 weeks following treatment with mifepristone. Avoid cyclosporine, dihydroergotamine, ergotamine, fentanyl, pimozide, quinidine, sirolimus, and tacrolimus.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mirtazapine: CNS Depressants may enhance the CNS depressant effect of Mirtazapine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     OLANZapine: May enhance the adverse/toxic effect of Benzodiazepines. Management: Avoid concomitant use of parenteral benzodiazepines and IM olanzapine due to risks of additive adverse events (e.g., cardiorespiratory depression). Olanzapine prescribing information provides no specific recommendations regarding oral administration.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Paraldehyde: CNS Depressants may enhance the CNS depressant effect of Paraldehyde.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Perampanel: May enhance the CNS depressant effect of CNS Depressants. Management: Patients taking perampanel with any other drug that has CNS depressant activities should avoid complex and high-risk activities, particularly those such as driving that require alertness and coordination, until they have experience using the combination.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phenytoin: Benzodiazepines may increase the serum concentration of Phenytoin. Short-term exposure to benzodiazepines may not present as much risk as chronic therapy.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimozide: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Pimozide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pramipexole: CNS Depressants may enhance the sedative effect of Pramipexole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Propofol: Midazolam may increase the serum concentration of Propofol. Propofol may increase the serum concentration of Midazolam.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Protease Inhibitors: May increase the serum concentration of Midazolam. Management: Oral midazolam contraindicated with all protease inhibitors.  IV midazolam contraindicated with fosamprenavir and nelfinavir; other protease inhibitors recommend caution, close monitoring, and consideration of lower IV midazolam doses with concurrent use.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Proton Pump Inhibitors: May increase the serum concentration of Benzodiazepines (metabolized by oxidation).",
"     <b>",
"      Exceptions:",
"     </b>",
"     Lansoprazole; Pantoprazole; RABEprazole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rifamycin Derivatives: May increase the metabolism of Benzodiazepines (metabolized by oxidation).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ROPINIRole: CNS Depressants may enhance the sedative effect of ROPINIRole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rotigotine: CNS Depressants may enhance the sedative effect of Rotigotine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Selective Serotonin Reuptake Inhibitors: May decrease the metabolism of Benzodiazepines (metabolized by oxidation).",
"     <b>",
"      Exceptions:",
"     </b>",
"     Citalopram; Escitalopram; PARoxetine; Sertraline.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Selective Serotonin Reuptake Inhibitors: CNS Depressants may enhance the adverse/toxic effect of Selective Serotonin Reuptake Inhibitors. Specifically, the risk of psychomotor impairment may be enhanced.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Oxybate: Benzodiazepines may enhance the CNS depressant effect of Sodium Oxybate.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     St Johns Wort: May increase the metabolism of Benzodiazepines (metabolized by oxidation).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Telaprevir: May increase the serum concentration of Midazolam. Management: Use of oral midazolam with telaprevir is contraindicated.  IV midazolam use may pose a lower risk, but dose reductions should be considered and patients should be monitored closely for signs/symptoms of toxicity.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Theophylline Derivatives: May diminish the therapeutic effect of Benzodiazepines.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tocilizumab: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Yohimbine: May diminish the therapeutic effect of Antianxiety Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Zolpidem: CNS Depressants may enhance the CNS depressant effect of Zolpidem.  Management: Reduce the Intermezzo brand sublingual zolpidem dose to 1.75 mg for men who are also receiving other CNS depressants.  No such dose change is recommended for women.  Avoid use with other CNS depressants at bedtime; avoid use with alcohol.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F196439\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ethanol: Ethanol may increase CNS depression. Management: Avoid ethanol.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Food: Grapefruit juice may increase serum concentrations of midazolam. Management: Avoid concurrent use of grapefruit juice with oral midazolam.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Herb/Nutraceutical: St John's wort may decrease midazolam levels and increase CNS depression; valerian, kava kava, and gotu kola may increase CNS depression. Management: Avoid concurrent use with St John's wort, valerian, kava kava, and gotu kola.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F196410\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     D (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F196425\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events were not observed in animal teratology studies. Midazolam has been found to cross the human placenta and can be detected in the serum of the umbilical vein and artery, as well as the amniotic fluid. Teratogenic effects have been observed with some benzodiazepines; however, additional studies are needed. The incidence of premature birth and low birth weights may be increased following maternal use of benzodiazepines; hypoglycemia and respiratory problems in the neonate may occur following exposure late in pregnancy. Neonatal withdrawal symptoms may occur within days to weeks after birth and &ldquo;floppy infant syndrome&rdquo; (which also includes withdrawal symptoms) have been reported with some benzodiazepines.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F196453\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Enters breast milk/use caution (AAP rates &ldquo;of concern&rdquo;; AAP 2001 update pending)",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F11229384\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Midazolam and hydroxymidazolam can be detected in breast milk. Based on information from two women, 2-3 months postpartum, the half-life of midazolam in breast milk is ~1 hour. Milk concentrations were below the limit of detection (&lt;5 nmol/L) 4 hours after a single maternal dose of midazolam 15 mg. Drowsiness, lethargy, or weight loss in nursing infants have been observed in case reports following maternal use of some benzodiazepines.",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F196426\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Avoid grapefruit juice with oral syrup.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16323409\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Midazolam HCl Injection)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1 mg/mL (5 mL): $3.23",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2 mg/2 mL (2 mL): $1.20",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     5 mg/5 mL (5 mL): $1.50",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     5 mg/mL (1 mL): $1.56",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10 mg/10 mL (10 mL): $2.52",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10 mg/2 mL (2 mL): $1.50",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     25 mg/5 mL (5 mL): $6.30",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     50 mg/10 mL (10 mL): $11.04",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Syrup",
"     </b>",
"     (Midazolam HCl Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2 mg/mL (118 mL): $127.15",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F196412\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Respiratory and cardiovascular status, blood pressure, blood pressure monitor required during I.V. administration",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Critically-ill patients: Monitor depth of sedation with either the Richmond Agitation-Sedation Scale (RASS) or Sedation-Agitation Scale (SAS) (Barr, 2013)",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F196427\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Anespar (ID);",
"     </li>",
"     <li>",
"      Buccolam (GB);",
"     </li>",
"     <li>",
"      Dalam (AR);",
"     </li>",
"     <li>",
"      Domi (MY);",
"     </li>",
"     <li>",
"      Doricum (VE);",
"     </li>",
"     <li>",
"      Dormicum (AE, AR, AT, BB, BD, BE, BF, BG, BH, BJ, BM, BS, BZ, CH, CI, CO, CY, CZ, DE, DK, EC, EE, EG, ES, ET, FI, GH, GM, GN, GR, GY, HK, HR, HU, ID, IQ, IR, JM, JO, JP, KE, KP, KW, LB, LR, LU, LY, MA, ML, MR, MT, MU, MW, MX, NE, NG, NL, NO, OM, PH, PK, PL, PT, PY, QA, RU, SA, SC, SD, SE, SG, SK, SL, SN, SR, SY, TH, TN, TR, TT, TW, TZ, UG, UY, YE, ZM, ZW);",
"     </li>",
"     <li>",
"      Dormicum[inj.] (HR);",
"     </li>",
"     <li>",
"      Dormonid (BR, CN, PE);",
"     </li>",
"     <li>",
"      Fortanest (ID);",
"     </li>",
"     <li>",
"      Fulsed (CL, IN);",
"     </li>",
"     <li>",
"      Hipnoz (ID);",
"     </li>",
"     <li>",
"      Hypnofast (HK);",
"     </li>",
"     <li>",
"      Hypnovel (AU, BE, CO, CR, DO, FR, GB, GT, HN, IE, NI, NZ, PA, SV);",
"     </li>",
"     <li>",
"      Hypozam (PH);",
"     </li>",
"     <li>",
"      Ipnovel (IT);",
"     </li>",
"     <li>",
"      Midacum (ZA);",
"     </li>",
"     <li>",
"      Midazo (TW);",
"     </li>",
"     <li>",
"      Midolam (IL);",
"     </li>",
"     <li>",
"      Midozor (MX);",
"     </li>",
"     <li>",
"      Miloz (ID);",
"     </li>",
"     <li>",
"      Omida (TW);",
"     </li>",
"     <li>",
"      Relacum (MX);",
"     </li>",
"     <li>",
"      Sedacum (ID);",
"     </li>",
"     <li>",
"      Sedoz (PH);",
"     </li>",
"     <li>",
"      Uzolam (TW);",
"     </li>",
"     <li>",
"      Versed (FR)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F196402\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Binds to stereospecific benzodiazepine receptors on the postsynaptic GABA neuron at several sites within the central nervous system, including the limbic system, reticular formation. Enhancement of the inhibitory effect of GABA on neuronal excitability results by increased neuronal membrane permeability to chloride ions. This shift in chloride ions results in hyperpolarization (a less excitable state) and stabilization.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F196421\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of action: I.M.: Sedation: ~15 minutes; I.V.: 3-5 minutes; Oral: 10-20 minutes; Intranasal: Children: 4-8 minutes (Lee-Kim, 2004)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Peak effect: I.M.: 0.5-1 hour",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Duration: I.M.: Up to 6 hours; Mean: 2 hours; Intranasal: Children: 18-41 minutes (Lee-Kim, 2004); I.V.: Single dose: &lt;2 hours (dose-dependent) (Fragen, 1997); Cirrhosis: Up to 6 hours (MacGilcrhist, 1986)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Oral: Rapid",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: V",
"     <sub>",
"      d",
"     </sub>",
"     : 1-3.1 L/kg; increased in females, elderly, and obesity",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: ~97%; in patients with cirrhosis, protein binding is reduced with a free fraction of ~5% (Trouvin, 1988)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Extensively hepatic CYP3A4; 60% to 70% of biotransformed midazolam is the active metabolite 1-hydroxy-midazolam (or alpha-hydroxymidazolam)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Bioavailability: Oral: 40% to 50% (Kanto, 1985), ~36% (children); I.M.: &gt;90%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: 2-6 hours; prolonged in cirrhosis, congestive heart failure, obesity, renal failure, and elderly.",
"     <b>",
"      Note:",
"     </b>",
"     In patients with renal failure, reduced elimination of active hydroxylated metabolites leads to drug accumulation and prolonged sedation.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: I.V.: Urine (primarily as glucuronide conjugates of the hydroxylated metabolites); Oral: Urine (~90% within 24 hours; primarily [60% to 70%] as glucuronide conjugates of the hydroxylated metabolites; &lt;0.03% as unchanged drug); feces (~2% to 10% over 5 days) (Kanto, 1985; Smith, 1981)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Abernathy DR and Greenblatt DJ, &ldquo;Drug Disposition in Obese Humans. An Update,&rdquo;",
"      <i>",
"       Clin Pharmacokinet",
"      </i>",
"      , 1986, 11(3):199-213.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Adrian ER, &ldquo;Intranasal Versed&reg;: The Future of Pediatric Conscious Sedation,&rdquo;",
"      <i>",
"       Pediatr Nurs",
"      </i>",
"      , 1994, 20(3):287-92.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Allonen H, Ziegler, G, and Klotz U, &ldquo;Midazolam Kinetics,&rdquo;",
"      <i>",
"       Clin Pharmacol Ther",
"      </i>",
"      , 1981, 30(5):653-61.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      al-Rakaf H, Bello LL, Turkustani A, et al, \"Intra-Nasal Midazolam in Conscious Sedation of Young Paediatric Dental Patients,\"",
"      <i>",
"       Int J Paediatr Dent",
"      </i>",
"      , 2001, 11(1):33-40.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?3/60/4042/abstract-text/11309871/pubmed\" id=\"11309871\" target=\"_blank\">",
"        11309871",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      American Academy of Pediatrics Committee on Drugs, \"Transfer of Drugs and Other Chemicals Into Human Milk,&rdquo;",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2001, 108(3):776-89.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?3/60/4042/abstract-text/11533352/pubmed\" id=\"11533352\" target=\"_blank\">",
"        11533352",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Arcos J, &ldquo;Midazolam-Induced Ventricular Irritability,&rdquo;",
"      <i>",
"       Anesthesiology",
"      </i>",
"      , 1987, 67(4):612.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Ashton H, &ldquo;Guidelines for the Rational Use of Benzodiazepines. When and What to Use,&rdquo;",
"      <i>",
"       Drugs",
"      </i>",
"      , 1994, 48(1):25-40.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Bailey PL, Pace NL, Ashburn MA, et al, &ldquo;Frequent Hypoxemia and Apnea After Sedation With Midazolam and Fentanyl,&rdquo;",
"      <i>",
"       Anesthesiology",
"      </i>",
"      , 1990, 73(5):826-30.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?3/60/4042/abstract-text/2122773/pubmed\" id=\"2122773\" target=\"_blank\">",
"        2122773",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Barash PG, Cullen BF, Stoelting RK, et al, eds,",
"      <i>",
"       Clinical Anesthesia",
"      </i>",
"      , 6th ed, Philadelphia, PA; Lippincott Williams &amp; Wilkins, 2009.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Barr J, Fraser GL, Puntillo K, et al, &ldquo;Clinical Practice Guidelines for the Management of Pain, Agitation, and Delirium in Adult Patients in the Intensive Care Unit,&rdquo;",
"      <i>",
"       Crit Care Med",
"      </i>",
"      , 2013, 41(1):263-306.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?3/60/4042/abstract-text/23269131/pubmed\" id=\"23269131\" target=\"_blank\">",
"        23269131",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Bergman U, Rosa FW, Baum C, et al, \"Effects of Exposure to Benzodiazepine During Fetal Life,\"",
"      <i>",
"       Lancet",
"      </i>",
"      , 1992, 340(8821):694-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?3/60/4042/abstract-text/1355799/pubmed\" id=\"1355799\" target=\"_blank\">",
"        1355799",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Booker PD, Beechey A, and Lloyd-Thomas AR, &ldquo;Sedation of Children Requiring Artificial Ventilation Using an Infusion of Midazolam,&rdquo;",
"      <i>",
"       Br J Anaesth",
"      </i>",
"      , 1986, 58(10):1104-8.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Bozkurt P, \"Premedication of the Pediatric Patient - Anesthesia for the Uncooperative Child,\"",
"      <i>",
"       Curr Opin Anaesthesiol",
"      </i>",
"      , 2007, 20(3):211-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?3/60/4042/abstract-text/17479023/pubmed\" id=\"17479023\" target=\"_blank\">",
"        17479023",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Burtin P, Jacqz-Aigrain E, Girard P, et al, &ldquo;Population Pharmacokinetics of Midazolam in Neonates,&rdquo;",
"      <i>",
"       Clin Pharmacol Ther",
"      </i>",
"      , 1994, 56(6 Pt 1):615-25.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Chiaretti A, Barone G, Rigante D, et al, \"Intranasal Lidocaine and Midazolam for Procedural Sedation in Children,\"",
"      <i>",
"       Arch Dis Child",
"      </i>",
"      , 2011, 96(2):160-3.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?3/60/4042/abstract-text/21030365/pubmed\" id=\"21030365\" target=\"_blank\">",
"        21030365",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Davis PJ, Tome JA, and McGowan FX Jr, &ldquo;Preanesthetic Medication With Intranasal Midazolam for Brief Surgical Procedures,&rdquo;",
"      <i>",
"       Anesthesiology",
"      </i>",
"      , 1995, 82(1):2-5.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Dellinger RP, Levy MM, Rhodes A, et al, &ldquo;Surviving Sepsis Campaign: International Guidelines for Management of Severe Sepsis and Septic Shock, 2012,&rdquo;",
"      <i>",
"       Crit Care Med",
"      </i>",
"      , 2013, 41(2):580-637.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?3/60/4042/abstract-text/23353941/pubmed\" id=\"23353941\" target=\"_blank\">",
"        23353941",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Doyle WL and Perrin L, &ldquo;Emergence Delirium in a Child Given Oral Midazolam for Conscious Sedation,&rdquo;",
"      <i>",
"       Ann Emerg Med",
"      </i>",
"      , 1994, 24(6):1173-5.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Fragen RJ, &ldquo;Pharmacokinetics and Pharmacodynamics of Midazolam Given via Continuous Intravenous Infusion in Intensive Care Units,&rdquo;",
"      <i>",
"       Clin Ther",
"      </i>",
"      , 1997, 19(3):405-19.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?3/60/4042/abstract-text/9220206/pubmed\" id=\"9220206\" target=\"_blank\">",
"        9220206",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Fraser G, &ldquo;Intranasal Midazolam,&rdquo;",
"      <i>",
"       Hosp Pharm",
"      </i>",
"      , 1992, 27:73-4.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hartman ME, McCrory DC, and Schulman SR, &ldquo;Efficacy of Sedation Regimens to Facilitate Mechanical Ventilation in the Pediatric Intensive Care Unit: A Systematic Review,&rdquo;",
"      <i>",
"       Pediatr Crit Care Med",
"      </i>",
"      , 2009, 10(2):246-55.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hegenbarth MA and the American Academy of Pediatrics Committee on Drugs, &ldquo;Preparing for Pediatric Emergencies: Drugs to Consider,&rdquo;",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2008, 121(2):433-43.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?3/60/4042/abstract-text/18245435/pubmed\" id=\"18245435\" target=\"_blank\">",
"        18245435",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hsu AJ, Carson KA, Yung R, et al, &ldquo;Severe Prolonged Sedation Associated with Coadministration of Protease Inhibitors and Intravenous Midazolam During Bronchoscopy,&rdquo;",
"      <i>",
"       Pharmacotherapy",
"      </i>",
"      , 2012, 32(6):538-45.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?3/60/4042/abstract-text/22488554/pubmed\" id=\"22488554\" target=\"_blank\">",
"        22488554",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hughes J, Gill A, Leach HJ, et al, &ldquo;A Prospective Study of the Adverse Effects of Midazolam on Withdrawal in Critically Ill Children,&rdquo;",
"      <i>",
"       Acta Paediatr",
"      </i>",
"      , 1994, 83(11):1194-9.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Iqbal MM, Sobhan T, Ryals T, et al, \"Effects of Commonly Used Benzodiazepines on the Fetus, the Neonate, and the Nursing Infant,\"",
"      <i>",
"       Psychiatr Serv",
"      </i>",
"      , 2002, 53(1):39-49.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?3/60/4042/abstract-text/11773648/pubmed\" id=\"11773648\" target=\"_blank\">",
"        11773648",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Institute for Safe Medication Practice (ISMP) and Vermont Oxford Network, &ldquo;Standard Concentrations of Neonatal Drug Infusions,&rdquo; 2011.  Available at https://www.ismp.org/Tools/PediatricConcentrations.pdf",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Jacqz-Algrain E, Daoud P, Burtin P, et al, &ldquo;Placebo-Controlled Trial of Midazolam Sedation in Mechanically Ventilated Newborn Babies,&rdquo;",
"      <i>",
"       Lancet",
"      </i>",
"      , 1994, 344(8923):646-50.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Johnson E, Briskie D, Majewski R, et al, \"The Physiologic and Behavioral Effects of Oral and Intranasal Midazolam in Pediatric Dental Patients,\"",
"      <i>",
"       Pediatr Dent",
"      </i>",
"      , 2010, 32(3):229-38.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?3/60/4042/abstract-text/20557707/pubmed\" id=\"20557707\" target=\"_blank\">",
"        20557707",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      K&auml;lvi&auml;inen R, &ldquo;Status Epilepticus Treatment Guidelines,&rdquo;",
"      <i>",
"       Epilepsia",
"      </i>",
"      , 2007, 48(Suppl 8):99-102.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?3/60/4042/abstract-text/18330014/pubmed\" id=\"18330014\" target=\"_blank\">",
"        18330014",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kanto J, &ldquo;Midazolam: The First Water-soluble Benzodiazepine-Pharmacology, Pharmacokinetics and Efficacy in Insomnia and Anesthesia,&rdquo;",
"      <i>",
"       Pharmacotherapy",
"      </i>",
"      , 1985, 5(3):138-55.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?3/60/4042/abstract-text/3161005/pubmed\" id=\"3161005\" target=\"_blank\">",
"        3161005",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kanto J, Aaltonen L, Himberg JJ, et al, &ldquo;Midazolam as an Intravenous Induction Agent in the Elderly: A Clinical and Pharmacokinetic Study,&rdquo;",
"      <i>",
"       Anesth Analg",
"      </i>",
"      , 1986, 65(1):15-20.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?3/60/4042/abstract-text/2934006/pubmed\" id=\"2934006\" target=\"_blank\">",
"        2934006",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kress JP, Pohlman AS, O&rsquo;Connor MF, et al, &ldquo;Daily Interruption of Sedative Infusions in Critically Ill Patients Undergoing Mechanical Ventilation,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2000, 342(20):1471-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?3/60/4042/abstract-text/10816184/pubmed\" id=\"10816184\" target=\"_blank\">",
"        10816184",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kupietzky A and Houpt MI, &ldquo;Midazolam: A Review of Its Use for Conscious Sedation of Children,&rdquo;",
"      <i>",
"       Pediatr Dent",
"      </i>",
"      , 1993, 15(4):237-41.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lee-Kim SJ, Fadavi S, Punwani I, et al, \"Nasal Versus Oral Midazolam Sedation for Pediatric Dental Patients,\"",
"      <i>",
"       J Dent Child (Chic)",
"      </i>",
"      , 2004, 71(2):126-30.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?3/60/4042/abstract-text/15587094/pubmed\" id=\"15587094\" target=\"_blank\">",
"        15587094",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lowenstein DH, &ldquo;Treatment Options for Status Epilepticus,&rdquo;",
"      <i>",
"       Curr Opin Pharmacol",
"      </i>",
"      , 2005, 5(3):334-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?3/60/4042/abstract-text/15907922/pubmed\" id=\"15907922\" target=\"_blank\">",
"        15907922",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lugo RA, Fishbein M, Nahata MC, et al, &ldquo;Complication of Intranasal Midazolam,&rdquo;",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 1993, 92(4):638.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      MacGilchrist AJ, Birnie GG, Cook A, et al, &ldquo;Pharmacokinetics and Pharmacodynamics of Intravenous Midazolam in Patients With Severe Alcoholic Cirrhosis,&rdquo;",
"      <i>",
"       Gut",
"      </i>",
"      , 1986, 27(2):190-5.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Magny JF, Zupan V, Dehan M, et al, &ldquo;Midazolam and Myoclonus in Neonate,&rdquo;",
"      <i>",
"       Eur J Pediatr",
"      </i>",
"      , 1994, 153(5):389-90.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Malinovsky JM, Populaire C, Cozian A, et al, &ldquo;Premedication With Midazolam in Children, Effect of Intranasal, Rectal and Oral Routes on Plasma Midazolam Concentrations,&rdquo;",
"      <i>",
"       Anaesthesia",
"      </i>",
"      , 1995, 50(4):351-4.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Massanari M, Novitsky J, and Reinstein LJ, &ldquo;Paradoxical Reactions in Children Associated With Midazolam Use During Endoscopy,&rdquo;",
"      <i>",
"       Clin Pediatr (Phila)",
"      </i>",
"      , 1997, 36(12):681-4.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Matheson I, Lunde PK, Bredesen JE, et al, \"Midazolam and Nitrazepam in the Maternity Ward: Milk Concentrations and Clinical Effects,\"",
"      <i>",
"       Br J Clin Pharmacol",
"      </i>",
"      , 1990, 30(6):787-93.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?3/60/4042/abstract-text/2288825/pubmed\" id=\"2288825\" target=\"_blank\">",
"        2288825",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      McMullin ST, Schaiff RA, and Dietzen DJ, &ldquo;Stability of Midazolam Hydrochloride in Polyvinyl Chloride Bags Under Fluorescent Light,&rdquo;",
"      <i>",
"       Am J Hosp Pharm",
"      </i>",
"      , 1995, 52(18), 2018-20.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Meierkord H, Boon P, Engelsen B, et al, \"EFNS Guideline on the Management of Status Epilepticus in Adults,\"",
"      <i>",
"       Eur J Neurol",
"      </i>",
"      , 2010, 17(3):348-55.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?3/60/4042/abstract-text/20050893/pubmed\" id=\"20050893\" target=\"_blank\">",
"        20050893",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Miller RD,",
"      <i>",
"       Miller&rsquo;s Anesthesia",
"      </i>",
"      ,  7th ed, Philadelphia PA: Churchill Livingstone, 2010.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Mokhlesi B, Leikin JB, Murray P, et al, &ldquo;Adult Toxicology in Critical Care: Part II: Specific Poisonings,&rdquo;",
"      <i>",
"       Chest",
"      </i>",
"      , 2003, 123(3):897-922.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Morrison G, Gibbons E, and Whitehouse WP, \"High-Dose Midazolam Therapy for Refractory Status Epilepticus in Children,\"",
"      <i>",
"       Intensive Care Med",
"      </i>",
"      , 2006, 32(12):2070-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?3/60/4042/abstract-text/16977485/pubmed\" id=\"16977485\" target=\"_blank\">",
"        16977485",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Murray MJ, De Ruyter ML, and Harrison BA, &ldquo;Opioids &amp; Benzodiazepines,&rdquo;",
"      <i>",
"       Crit Care Clin",
"      </i>",
"      , 1995, 11(4):849-73.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Nordt SP and Clark RF, &ldquo;Midazolam: A Review of Therapeutic Uses and Toxicity,&rdquo;",
"      <i>",
"       J Emerg Med",
"      </i>",
"      , 1997, 15(3):357-65.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?3/60/4042/abstract-text/9258787/pubmed\" id=\"9258787\" target=\"_blank\">",
"        9258787",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Phillips MS, &ldquo;Standardizing I.V. Infusion Concentrations: National Survey Results,&rdquo;",
"      <i>",
"       Am J Health Syst Pharm",
"      </i>",
"      , 2011, 68(22):2176-82.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?3/60/4042/abstract-text/22058104/pubmed\" id=\"22058104\" target=\"_blank\">",
"        22058104",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Rita L, Seleny FL, Mazurek A, et al, &ldquo;Intramuscular Midazolam for Pediatric Preanesthetic Sedation: A Double-Blind Controlled Study With Morphine,&rdquo;",
"      <i>",
"       Anesthesiology",
"      </i>",
"      , 1985, 63(5):528-31.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Riva J, Lejbusiewicz G, Papa M, et al, &ldquo;Oral Premedication With Midazolam in Paediatric Anaesthesia. Effects on Sedation and Gastric Contents,&rdquo;",
"      <i>",
"       Paediatr Anaesth",
"      </i>",
"      , 1997, 7(3):191-6.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Rivera R, Segnini M, Baltodano A, et al, &ldquo;Midazolam in the Treatment of Status Epilepticus in Children,&rdquo;",
"      <i>",
"       Crit Care Med",
"      </i>",
"      , 1993, 21(7):991-4.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Samuelson PN, Reves JG, Kouchoukos NT, et al, &ldquo;Hemodynamic Responses to Anesthetic Induction With Midazolam or Diazepam in Patients With Ischemic Heart Disease,&rdquo;",
"      <i>",
"       Anesth Analg",
"      </i>",
"      , 1981, 60(11):802-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?3/60/4042/abstract-text/7197492/pubmed\" id=\"7197492\" target=\"_blank\">",
"        7197492",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Servin F, Enriquez I, Fournet M, et al, &ldquo;Pharmacokinetics of Midazolam Used as an Intravenous Induction Agent for Patients Over 80 Years of Age,&rdquo;",
"      <i>",
"       Eur J Anaesthesiol",
"      </i>",
"      , 1987, 4(1):1-7.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Shah I and Deshmukh CT, &ldquo;Intramuscular Midazolam vs Intravenous Diazepam for Acute Seizures,&rdquo;",
"      <i>",
"       Indian J Pediatr",
"      </i>",
"      , 2005, 72(8):667-70.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?3/60/4042/abstract-text/16131771/pubmed\" id=\"16131771\" target=\"_blank\">",
"        16131771",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Silbergleit R, Durkalski V, Lowenstein D, et al, \"Intramuscular Versus Intravenous Therapy for Prehospital Status Epilepticus,\"",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2012, 366(7):591-600.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?3/60/4042/abstract-text/22335736/pubmed\" id=\"22335736\" target=\"_blank\">",
"        22335736",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Silvasi DL, Rosen DA, and Rosen KR, &ldquo;Continuous Intravenous Midazolam Infusion for Sedation in the Pediatric Intensive Care Unit,&rdquo;",
"      <i>",
"       Anesth Analg",
"      </i>",
"      , 1988, 67(3):286-8.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Smith MT, Eadie MJ, and Brophy TO, &ldquo;The Pharmacokinetics of Midazolam in Man,&rdquo;",
"      <i>",
"       Eur J Clin Pharmaocl",
"      </i>",
"      , 1981, 19(4):271-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?3/60/4042/abstract-text/6116606/pubmed\" id=\"6116606\" target=\"_blank\">",
"        6116606",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Spina SP and Ensom MHH, &ldquo;Clinical Pharmacokinetic Monitoring of Midazolam in Critically Ill Patients,&rdquo;",
"      <i>",
"       Pharmacotherapy",
"      </i>",
"      , 2007, 27(3):389-98.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?3/60/4042/abstract-text/17316150/pubmed\" id=\"17316150\" target=\"_blank\">",
"        17316150",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Swart EL, de Jongh J, Zuideveld KP, et al, &ldquo;Population Pharmacokinetics of Lorazepam and Midazolam and Their Metabolites in Intensive Care Patients on Continuous Venovenous Hemofiltration,&rdquo;",
"      <i>",
"       Am J Kidney Dis",
"      </i>",
"      , 45(2):360-71.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?3/60/4042/abstract-text/15685515/pubmed\" id=\"15685515\" target=\"_blank\">",
"        15685515",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Towne AR and DeLorenzo RJ, &ldquo;Use of Intramuscular Midazolam for Status Epilepticus,&rdquo;",
"      <i>",
"       J Emerg Med",
"      </i>",
"      , 1999, 17(2):323-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?3/60/4042/abstract-text/10195494/pubmed\" id=\"10195494\" target=\"_blank\">",
"        10195494",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Trouvin J H, Farinotti R, Haberer JP, et al, &ldquo;Pharmacokinetics of Midazolam in Anaesthetized Cirrhotic Patients,&rdquo;",
"      <i>",
"       Br J Anaesth",
"      </i>",
"      , 1988, 60(7):762-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?3/60/4042/abstract-text/3395535/pubmed\" id=\"3395535\" target=\"_blank\">",
"        3395535",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Uygur-Bayrami&ccedil;li O, Dabak R, Kuzucuoglu T, et al, \"Sedation With Intranasal Midazolam in Adults Undergoing Upper Gastrointestinal Endoscopy,\"",
"      <i>",
"       J Clin Gastroenterol",
"      </i>",
"      , 2002, 35(2):133-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?3/60/4042/abstract-text/12172357/pubmed\" id=\"12172357\" target=\"_blank\">",
"        12172357",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Votey SR, Bosse GM, Bayer MJ, et al, &ldquo;Flumazenil: A New Benzodiazepine Antagonist,&rdquo;",
"      <i>",
"       Ann Emerg Med",
"      </i>",
"      , 1991, 20(2):181-8.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Waring JP, Baron TH, Hirota WK, et al, &ldquo;Guidelines for Conscious Sedation and Monitoring During Gastrointestinal Endoscopy,&rdquo;",
"      <i>",
"       Gastrointest Endosc",
"      </i>",
"      , 2003, 58(3):317-22.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?3/60/4042/abstract-text/14528201/pubmed\" id=\"14528201\" target=\"_blank\">",
"        14528201",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Wikner BN, Stiller CO, Bergman U, et al, \"Use of Benzodiazepines and Benzodiazepine Receptor Agonists During Pregnancy: Neonatal Outcome and Congenital Malformations,\"",
"      <i>",
"       Pharmacoepidemiol Drug Saf",
"      </i>",
"      , 2007, 16(11):1203-10.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?3/60/4042/abstract-text/17894421/pubmed\" id=\"17894421\" target=\"_blank\">",
"        17894421",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Zeltzer LK, Altman A, Cohen D, et al, &ldquo;American Academy of Pediatrics Report of the Subcommittee on the Management of Pain Associated With Procedures in Children With Cancer,&rdquo;",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 1990, 86(5 Pt 2):826-31.",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9650 Version 52.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-61.234.146.186-C5D28A4D55-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_60_4042=[""].join("\n");
var outline_f3_60_4042=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5709086\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F196443\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F196489\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F196447\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F196467\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F196448\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F196449\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13134499\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F196415\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F196399\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F196491\">",
"      Controlled Substance",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F196419\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14472924\">",
"      Usual Infusion Concentrations: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14472925\">",
"      Usual Infusion Concentrations: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F196496\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F196418\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F196485\">",
"      Use - Unlabeled",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F196498\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F196487\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F196422\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F196403\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F196481\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F196408\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F196439\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F196410\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F196425\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F196453\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11229384\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F196426\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16323409\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F196412\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F196427\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F196402\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F196421\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9650\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9650|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?4/6/4197?source=related_link\">",
"      Midazolam: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?0/46/746?source=related_link\">",
"      Midazolam: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f3_60_4043="Bowel wall layers on ultrasound";
var content_f3_60_4043=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F74168&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F74168&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Bowel wall layers on ultrasound",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Layer echogenicity",
"       </td>",
"       <td class=\"subtitle1\">",
"        Anatomic structure",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Lumen",
"       </td>",
"       <td>",
"        Echo-poor (fluid)/echo-rich (air) depending on content",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Luminal echo-rich layer",
"       </td>",
"       <td>",
"        Echo-line between lumen and mucosa",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Luminal echo-poor layer",
"       </td>",
"       <td>",
"        Mucosa",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Echo-rich layer",
"       </td>",
"       <td>",
"        Submucosa",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Echo-poor layer",
"       </td>",
"       <td>",
"        Muscularis propria",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Echo-rich layer",
"       </td>",
"       <td>",
"        Serosa",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_60_4043=[""].join("\n");
var outline_f3_60_4043=null;
var title_f3_60_4044="Medical conditions associated with adverse events in pregnancy";
var content_f3_60_4044=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F60799&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F60799&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Conditions associated with increased risk for adverse health events as a result of unintended pregnancy",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        Breast cancer",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Complicated valvular heart disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Diabetes: insulin-dependent; with nephropathy/retinopathy/neuropathy or other vascular disease; or of &gt;20 years' duration",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Endometrial or ovarian cancer",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Epilepsy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hypertension (systolic &gt;160 mm Hg or diastolic &gt;100 mm Hg)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        History of bariatric surgery within the past two years",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        HIV/AIDS",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ischemic heart disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Malignant gestational trophoblastic disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Malignant liver tumors (hepatoma) and hepatocellular carcinoma of the liver",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Peripartum cardiomyopathy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Schistosomiasis with fibrosis of the liver",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Severe (decompensated) cirrhosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Sickle cell disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Solid organ transplantation within the past two years",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Stroke",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Systemic lupus erythematosus",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Thrombogenic mutations",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Tuberculosis",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Medical Eligibility Criteria for Contraceptive Use, Fourth Edition, World Health Organization, 2009. Available at: file://whqlibdoc.who.int/publications/2009/9789241563888_eng.pdf",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_60_4044=[""].join("\n");
var outline_f3_60_4044=null;
var title_f3_60_4045="ACCESS criteria sarcoid A";
var content_f3_60_4045=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F65081&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F65081&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    ACCESS study criteria for organ involvement in patients with biopsy-confirmed sarcoidosis-I",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Organ",
"       </td>",
"       <td class=\"subtitle1\">",
"        Definite",
"       </td>",
"       <td class=\"subtitle1\">",
"        Probable",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"5\">",
"        Lungs",
"       </td>",
"       <td class=\"sublist1_start\">",
"        1. Chest roentgenogram with one or more of the following:",
"       </td>",
"       <td>",
"        1. Lymphocytic alveolitis by bronchoalveolar lavage (BAL)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Bilateral hilar adenopathy",
"       </td>",
"       <td>",
"        2. Any pulmonary infiltrates",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Diffuse infiltrates",
"       </td>",
"       <td rowspan=\"3\">",
"        3. Isolated reduced diffusing capacity for carbon monoxide",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Upper lobe fibrosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        2. Restriction on pulmonary function tests",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"3\">",
"        Skin",
"       </td>",
"       <td>",
"        1. Lupus pernio",
"       </td>",
"       <td>",
"        1. Macular/papular",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        2. Annular lesion",
"       </td>",
"       <td rowspan=\"2\">",
"        2. New nodules",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        3. Erythema nodosum",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"3\">",
"        Eyes",
"       </td>",
"       <td>",
"        1. Lacrimal gland swelling",
"       </td>",
"       <td rowspan=\"3\">",
"        1. Blindness",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        2. Uveitis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        3. Optic neuritis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"6\">",
"        Neurologic",
"       </td>",
"       <td>",
"        1. Positive magnetic resonanceimaging (MRI) with uptake in meninges or brainstem",
"       </td>",
"       <td>",
"        1. Other abnormalities on magnetic resonance imaging (MRI)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        2. Cerebrospinal fluid with increased lymphocytes and/or protein",
"       </td>",
"       <td>",
"        2. Unexplained neuropathy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        3. Diabetes insipidus",
"       </td>",
"       <td rowspan=\"4\">",
"        3. Positive electromyogram",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        4. Bell's palsy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        5. Cranial nerve dysfunction",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        6. Peripheral nerve biopsy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"2\">",
"        <p>",
"         Hypercalcemia",
"        </p>",
"        <p>",
"         Hypercalciuria",
"        </p>",
"        <p>",
"         Nephrolithiasis",
"        </p>",
"       </td>",
"       <td rowspan=\"2\">",
"        1. Increased serum calcium with no other cause",
"       </td>",
"       <td>",
"        1. Increased urine calcium",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        2. Nephrolithiasis analysis showing calcium",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"4\">",
"        Cardiac",
"       </td>",
"       <td>",
"        1. Treatment responsive cardiomyopathy",
"       </td>",
"       <td class=\"sublist1_start\">",
"        1. No other cardiac problem and either:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"2\">",
"        2. Electrocardiogram showing intraventricular conduction defect or nodal block",
"       </td>",
"       <td class=\"sublist1\">",
"        Ventricular arrhythmias",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Cardiomyopathy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"2\">",
"        3. Positive gallium scan of heart",
"       </td>",
"       <td>",
"        2. Positive thallium scan",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Judson, MA, RP Baughman, AS. Teirstein, ML Terrin, and H Yeager, Jr. 1999. Defining organ involvement in sarcoidosis: the ACCESS proposed instrument. ACCESS Research Group. A Case Control Etiologic Study of Sarcoidosis. Sarcoidosis, Vasculitis, and Diffuse Lung Diseases 16:75-86. Copyright &copy; 1999 Sarcoidosis, Vasculitis, and Diffuse Lung Diseases.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_60_4045=[""].join("\n");
var outline_f3_60_4045=null;
var title_f3_60_4046="Biological effects of VIP";
var content_f3_60_4046=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F59411&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F59411&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Biological effects of vasoactive intestinal peptide",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\" class=\"container\">",
"     <colgroup span=\"2\" width=\"50%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tbody>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            1. Cardiovascular system",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1_start\">",
"            Vasodilation",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Peripheral",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Splanchnic",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Coronary",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Extracranial",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Cerebral",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Pulmonary",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Genital",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Chronotropic effect",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Inotropic effect",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            2. Digestive system",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1_start\">",
"            Esophagus",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Relaxation of lower sphincter",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Contraction in the body",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1_start\">",
"            Stomach",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Relaxation of antral smooth muscle",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Relaxation of fundic smooth muscle",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Relaxation of oluscularis mucosae",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1_start\">",
"            Small intestine",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Relaxation followed by contractions of circular muscle",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Contraction of longitudinal muscle",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Stimulation or water and ion secretion",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Stimulation or Brunner's gland secretion",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1_start\">",
"            Large intestine",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Relaxation of smooth muscle",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Water and chloride secretion",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1_start\">",
"            Gallbladder",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Relaxation of smooth muscle",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Inhibition of fluid and NaCl absorption",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1_start\">",
"            Liver",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Stimulation or biliary secretion",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1_start\">",
"            Pancreas",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Stimulation of water and HCO",
"            <sub>",
"             3",
"            </sub>",
"            -secretion",
"           </td>",
"          </tr>",
"         </tbody>",
"        </table>",
"       </td>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tbody>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            3. Endocrine function and metabolism",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1_start\">",
"            Metabolism",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Lipolysis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Glycogenolysis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1_start\">",
"            Adrenal gland",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Stimulation of adrenal steroidogenesis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1_start\">",
"            Kidney",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Stimulation of renin secretion",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1_start\">",
"            Pancreas",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Release of insulin, glucagon, somatostatin, and pancreatic polypeptide",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1_start\">",
"            Pituitary/hypothalamus",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Release of prolactin, oxytocin, and vasopressin",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1_start\">",
"            Thyroid",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Stimulation of hormone secretion",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            4. Urogenital system",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Inhibition or myoelectrical and smooth muscle activity",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Potential of electrically induced and pilocarpine-induced prostatic secretion",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            5. Respiratory system",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Bronchodilation",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Stimulation of submucosal gland secretion",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            6. Central nervous system",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Excitation of cerebral cortical and spinal cord neurons",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Hyperthermia",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Stimulation or glycogenolysis and of glucose utilization",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Hypnogenic and antidipsogenic effects",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            7. Immune system",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Inhibition of mitogen-induced transformation of T-lymphocytes",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Stimulation of Ig synthesis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Inhibition of mast cell histamine release",
"           </td>",
"          </tr>",
"         </tbody>",
"        </table>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Fahrenkurg J. Pharmacol Toxicol 1993; 72:354. Copyright &copy; 1993 Pharmacology &amp; Toxicology.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_60_4046=[""].join("\n");
var outline_f3_60_4046=null;
var title_f3_60_4047="Actions antiulcer drugs";
var content_f3_60_4047=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F57131&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F57131&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Actions of antiulcer medications",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 371px; height: 222px; background-image: url(data:image/gif;base64,R0lGODlhcwHeAPcAALKysubm5v/MzP///wAAAH9mZoCAgH9/f7+/v1lZWT8/P3Nzc3+Z/wAz//Ly8u/v7y8vL9/f34+Pj4WFhc/Pz//l5W9vbywsLJ+fn+zs7F9fX6+vrx8fH8XFxVly2Kampr/M/59/f09PTw8PDwsLCz9m/w4ODtfX17+ZmT8zMxYWFv/Y2GRkZDc3NysrK01NTZubm7q6uu+/v1ZWVhwcHB8ZGSEhIX9/5Q8MDJCQkAAZf56enkdHR08/P3p6eqysrI+i74GBgUJCQu/y/+vr6/j4+NjY2HOM8v/y8k9y/8nJyc+lpRxJ+6+MjC8mJi9Z/6+//9/l/19MTI+l/9+ysl9//49ycp+y/2+Czg4+/ay57Nfa5zk5OYWSxf/b2yxS629ZWf/f3x9M/+fn50Ji4v/4+As6+jlf+P39/VZ29f/7+8/Y//f39w8//5CawPv7+6aqtm+M//Dw8P/V1f/r6yFK8CtU+puiuxZC9f/Pz/X19fT09Pr6+v/v7+rq6kdq956u7e3t7brE6v/i4v/19f/o6IGX8E1q3Tda5sDAwMnP6f/S0nqKymSB9GR60+np6QAv7z8/cj9MfwApz7+l2CxMyywyTAAMP0dk139ypRY/5UpKSmR61CxGrJiYmFZptQAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAACH5BAAAAAAALAAAAABzAd4AAAj/AAcIHEiwoMGDCBMqXMiwocOHECNKnEixosWLGDNq3Mixo8ePIEOKHEmypMmTKFOqXMmypcuXMGPKnEmzps2bOHPq3MkTZCIDQIMKHUq0qNGjSJMqXcq0qdOnUKNKnUq1qtWrWIcmamiAQAGvYL+KDUt2rNmyaM+qTct2rdu2cN/KjUt3rt26eO/qzct3r9++gOemMMC1gIDDiBMrXsy4sePHkCNLnky5suXLmDNr3sy5s+fPiAsQZthVAAHTqE+rTs16tevWsF+rXkFghQLatnHfrr17hYUKBCocAC4ceOzjspErT858ufPm0J9Lj059uvXq2K9rhy66MGIvFcKL/xdPB4n58+jTnyc0kU+R9/Djy4evx4H9+/aLVGCMooD//wAGKOCABBZooH8ogKbgggw26OCC3ZGmmhcE7GHfAvdhKEcGP2TgYYcfesihiB0GYOKJKKao4oostmiiAwfENsMCNNZo44045qjjjjxykd2P2wUJ5JBCFknkkchFuJABhglQwR4uRinllFRWGYAD+ykWAg1Wdulligs0+eCYZJZpJoSjLalaBQ586eabVjogWw9BwGlnlAsgqaeRfO7pZ5+AcpemQkwexuadiCZ6ZZaJ4RCDopAGEOaZlFZq6aWLKUnomgtE6mmXMLZmwqeJ5hnoqX+miuqqqsqmaUKFOv/ZJqm0uoilYlbwUKudPISA6a/ABqvgqwiVFtysuyZ7opytSaDslycQ0CqrrPWEEG3UTuvqoLA2eeizyrIRRmJbguulBD0Ii1lKCCAA0QEDRICBQSuoyxmxBxlbQafm1nrCACOkVoOz/VZJQwjaZiuAQQiMoAAEFjBEwEEYzHvQAfA+NDECCtCb8Met4WtQrN8W/KkcfZDLpclTSlCDvZcx3PEAIkjwAAYH2DzAAxQ84K678eb8wAAaaIDAAxFIcIDFGBcUQc4R7Kx01ANsPDNB9cKcmcgF6Yssy4oOTWFqBIPtIg0ggyyzQBYcQIEECEjQMQIcQNDxxBQosAEGEAz/oIACB0SwNwIawNv0QBRwsLcFDyiAwQYQRG21xwqnzTVBJH9ttp1Dj4uYDAScsHmLLmttGcMQIIABB1HLe8DGEAxdNdEHtJv64QO8rUHHuBNt8QAYiNBu4bNzTK/pmF0+kL78jg5n566FoKvzKsZgQhNpU8swB1ADDwEGCEwu0MQKFI7x0xlrIMIGcg/QuwJAuw84xu6Kj3X2lnNbrLeaU1/lGHIYgOcS04Oy+S8AJ3CBmJAnmbUNBH7jG4DxIkg8gTzgcBOTIO8yJpAK3uxqQ7PfQLLGQMooTyBeO2CUMuAADNmHBwPYwNhcEzoVmogHPcCf9goyQYHw7QAisN/E/x4AgcJBgAJ0c5v6LPA393EwXhCzgAaIBriaFe9qI9Thx044gMzZsEUOIMR4wpCHxkjviwtwggxKSBmD8KwgSJTgzigwkPghUXYRABoCekbHCFCNIHscSB6p5q43FoSEbIwMF5n3RRbtgGjPMSD1JIADLe7QWoe0pLYWyb9GsmhohfDCY0AnugNKgABNSGQbMXlIVUpmkWvqnydNtIM9DKAQzDmjKaVVuV76CQWa9GXlOGkoWc7SRLYcoGIKuEtfufJM/nlmCWFpmn0dk0ULwGVsajhJXgbzm8/5ijDBuUn95auT11TRHhilpek5bwcEcKY0zRTNeZqOmsdKZ4rExv8cSYLNeuQc53XEGdCCboeYstKnifzgAAE2BgWjcl4CF2hPMtWzovbCpzWv+QA2mEANMmSOFJq3OR4Y9KSxIahAUXokhJaskYF4QxkGMQfIUIEASnBeGteIUXpStKe/0qgxqReIAQwCOzN4JwGWwNKVLkelTY1qyMw5MnQ20gGFoAwOfjC6E9AglUD1aViFpVGS2pBZ1AmBC3SaAqlGFapOdetTqdo1q37xVpJxgj8LpgQCUGGsYm2QDEJgICskKKxCnWWoqBPRzfkorpAdEkFBB0wrBAYsOWxBAjbL2c4KwQYEcAJegMnUyJrGpUN13gPKIJmRjm4HNeApYB+Dgtr/9udAAwJDCmpQg0pK6wLAFUJnh0vc4ibAAh8AgHKXy1zmToAFxh1uC4BLAmnhIAUp6IF/QlBb2Y6prMekQRigc9Ocms2rCDPtkJgKzLG0ta3SkpYNgHuBF0T3vhMQghBg0Nz++ve/AA6wgAWcgwk8d7PTvUB8CdDWr2Dvpn1C7TFXC5kCJHVzC0iBvahw29xid7fxVQF97btZHxh4AskdsIqVu9kVu/jFMIbxBwxsgc1SlwDXTUGBwFphumIultd8A3S2ujklmECTlh2LFOJ7AeEa98Q5iLGU/dviKVv5ylhWLgwm4APjvsCbSfLx8ux6VXZqaa2bm4EUykSFEPQA/wck0OxwJ8DfLNs5wFW+s573HOMXgEGRYkYhp67pAAQcNTZ7NdcP/PoxYDohziyIMp8njecEUPrSmG5uAqgj4WMGUJSLWYIJSgk2Lvy0M21+sw1eMIFMu1rTln61rPWcgFMrJrGzHIOQYyOFC4PNZa0CAwHibIE6z1rWeT62sqW86bl6J6Gz5AMdGiMDR23OBfLUzGBVzeplKzvZ3g73gGsNaK6ohg518qQeoINmsC1aSKDLbLHF/e1Y0/ve/222oJ6NhAx4Ug5lKGNj9JpmW0Nm2wRoAXLxXW+GO5y55O6xuU3Tb5gSYA7METWpTdbXH8U74Qt/+LENLPKH6zvMz/8ugx8aibLH9BrDa56Mm0Ge4pLb/OaufoHBQxPoLqpmAJ70wwOQY22zmQCYy0GYCkKO86Y7nc8KdjZpmgR0T6KhpoxR6+Yk4ITIhKAGS3+62Mdu5wsc9jH4RIMnM+CCQ8sm0eCaAXSwF3ay2/3uMI76vqcugBUUQYUZ0AMfBkAIOiASMRp37NkXAwYSWADvIjcCKxVCBBebvdwSEoAC/n5AB2wAWyL1NdjA7Bon2MDYkGe45CePkMo7N7oqYEtqiBkGNqgQr46p9qPM1lfGNAEHL0h9yVfPeoO4frmbxpjyMUaA5SufAApYID5TazK0Iqfd7m5ram6qAh8If/gHORr/RrD4wIVYgI7xc8jxWfzEDBbE/a+bfc8L9VLn4X7gcAfXAmIuABl8JQE1930OR3yI03wOAUEH4X4EoYAHAUHkxxDrBwAJ8DoJmIDSN3+ncQDUVzCLFRsQ5TwHoxo1cAGoJ4ADaBCFwwGIIwIKIAE7szvwEgEcUDgboEcbMDsxpADrUzUbUD4CEQG7YzEQFIM404IWBIMFEYETOBAMGEEDEX+qQUz1tzljoAdmphiutXUvIwAI83gmaHMEKBAjQER9xAE944KpMwBtQ0Rw04MCoTezAzlIMy8EMC8iMC8ccDR36Df1I0F5+ACsMwBp2DYEoYRP5ITv5z4XOHEEsIHP/xIDeoAGhAAdODU6aGMaBOCFXwh+BLEBIjAAEhAxoYg43HMAu8OHAsE6MhhBO8iEAoExeSMQCPCJECQ+8JM4GHOKA2GIOJiIBQGFpzV/hjGFBZMBfKAGdIB1jmFho1M6XbiJNxeGGsABD6OCuIMAqdMudISAEqABFuCCs4OATkg/M2M8tahBb2g77RJIu6hph9iEOHgAi5h5Gjg6C0AHAUMdXFVSlkUC3geNYFgQYygQR0Q3AtEzI0BHueM3N7gzHMABsjMxpniQ8QgvA5kzqGiLR5OQFNmOEJcx8MiAwOgVwghtZlMEoAYZWrc50ZJwAQiQD0eAnjgQo3gAdvOJFP9gNxAAL5AzM97oig+gAXYDLxnUNJBTRENzjhMEQTn5ME+khCGZgPKYGNM3OkUAeshBcFtHACwAkzgXhhcRiCvBi65oEPDnGlLoiLuCBosQGR9ojwTwkl55ghqBAVPEEoYYlWY5j2oiAPW4OdhhViyzAC0wl9FYfAdBlr24gAQxkmm5OY+gBpFRXm6iBYZwBJiZmZppCIJQJQtgb4YZk4hpfO5olhU4lTzHiGpJKxmAAE8lelKyBUCQBnbQAHaQBpqZm0fwB1mQBWcABFISBEIQmpyoEvLCEbyol42JliVJjOYSCEgQGUQ2JYKQBllgB4agBVUiCIbABGegnS3yAzb/QJyRZxE+80fnaUEI8EfxokdYtJ4WoZiIyJiKSJUY6JerSSrrthzY1yJAYAdZkAad+SVbcAQBqggtQgDkKZoQUT4j4DY76Ti5wz01k5MHIKE2aQEiMEUa4DAYEAEQAzgSZDfwmBBkqZyvyJze4ZzK8gAydXiKUW07ECVAwARMAARbcCeKYJ1HkKMq4gKttqD4BpYLoQARI4hR8wAjIIhAQ0RJuqSHwzoTZAEWA5F0o5APAZUVaJaoeRhVWTAuWgbU0QPutCI1eqORogVngKYpMgNdKaT3RqQKgYDQ9zd3s4B2ukHpuJRAAz89lKWlWZa+6D4qyncsSioZIFPK5BhN/zBqLAIINgqcpHKmkmoiEqACcBqnEYGAI8CenToQn/qEGSOlPmkxkfOn6ueOKMqEfLkp+GkuSoAGFvAcoDOjK2IIWVCptUKpJ0IDmpipyyanCYGAfLMBM3mhqiMBxXqs8HOh8TICe4SNG+CsqNoQiomijtmc+XknfJBVk0GmLJIGTDCgz3KmgBAA0AWs4SasCPGhiAOLsrg0Q0MB8GqKS1NHbhM0FnOcESGf8+mKXSoAX6ose0AB0+GoJqIFWQAIW2AHduCj/fIJkIAJBPCPK/YQHaCuAcauHNE7HpGcW7qc8rei2/omgaAGbTkZA4MiZ9AADcAEafApWnAEa+qyNv/7smdwBFqwAJZQB5pwBy+GsRrLcCR3bEtIn74YsNT0l8mCJdhRLieiBTd7ropSnVnQAE8QB1MAAlzbtVMQB0/QAJBQCW5wCGaABS4mtENrZT5gsXZ3tKuarST7LPcHGSt7Ii1rs1kAsXCiplg7BVHAEFEwBWH7BWTQAGirYn5jQQqApQWRsWsbYzBwAf4IeZsWsguotPfZiM+yAMZBHStjIkBwsy6rqwSaBg1QAiAgESBQAg1gBo5wsUP0PQRBAb8DuZHrYglAAi8gl2N3tP+KiHJrqCXrJnXrGHdrIkygt42AoH2bBW0ABRYBBW1gBl2guBNDu4DEQbibuwI2ATb/YAOSlnoTuKrj06qwkoHF+yVOm3ShGwCj2wC/iSijmwRDgBFDkASIO2BVoz4Mw73eK2AfIAQk8KbfB7zYWqhLMozr6yXHuxgyUAO2GgAN27yJMroMwBEMsL8BVjUWYIYPVI1/QwHdG8DNZQFxVoLke4iLCbDoWyyq0cBd4rnUwQW0MrpX4BFXwMH/VTwDia8DUcImDACTqwJB+oVLaL7Du8AmuSvrZFOV+CmA0AAZ/BEbzAgAhoN8IzsSBMBDjHwEAIAACbzBG48vnC/qqyxy8ABYKRspIJiJsgVZUAUiUQVmAAc9zEHGKkjxI8S5OwEiNr7QCLeYS6gjS7zJogdl/6CMjdEENLBxkPIHYnC/ITEEYoAIPewQfjy0H9ACBWyYyed8ryPKrxN99qma/sIHFJAH1JF/fdsAqzsSINAA1/vFU8YCJCAEvruJE2BcQlADsheF2korfvAG0xYZifcpTJAEJpEEeGDLMZYDF2DEazsBGoZ5fcm0kSIBsvocLyezDRC4JREFtAzNK/YBXwaaGmvNnDbMkRKmKXlwRecpf1ACBTEEsbwGXcu1QxAFXLsGFFECmGzOAuYDIqbC6mrNr7S5MqwiiUoA4zUd/akoW9AAOUwQUwDLA3AFDFAFYsAADBAFDFACDJAEdCwRO4zHBO1fMODJbhu57Cx1THyoXv+iB8dMGUuAAxMcKaNLyQPx0Sc9AK07ECAtEE8AAldQAiQtEFCg1NI7ACNdBZQ8BDy80suFy707xAqNza6qzXfCBW28HDWQbp/SCPZMEGvwBEPQBgMx1AJR1AMgBvp8v0lwBWswyVGQw3GQwU09ECVwCFa9XOBrA0dswjG9dzPd0CkyACk7GU4Am5FyBlU8EFo7AEnw1G4N1SRdAnQs0iXw0VHQBlsrEG0A0htM1F8Q2OhMAups2NcscZnHuYnyCAMwHVIw0ZHSAE/900/w2Sed2R0NAoEbBWIgvUUt0r09ALDctQMBBQ1g1T6QwgR92CiHyImSAdE5GVbwyLui0QP/kdYCsdYCAdyTDQJPIBBVENKBS9UDUAJTIBAAPd7Pbc5F/NK2vNWwnc2KfSJ7gB2Nunu14t0CUdkCcdlCfdZQPdkDUAW9nQQh3dtPkMP5+wRPwMzybc6bltVWTd3M8ZiI4gBqAKOMkdM7TSsCfhJr0ABAq9WBHNjKhd9ox9B3MgZscHHUATpk3d2xjBKzDGA58KvkOcCffN++DMxrcciJbSd+wAd9IHCR8djgcuIm0ePMBQMWIASxp6BCisItsMu5mwDz83yk3HwXesYjk8ZvkgFo8CO4beK7fRLODQAf4AMvAFoLpuXEKc3UTNCEbJoiK8xz+yZsMAiUsd2QvCuS/60SDJDaAGABWX7nLGBggryJH7BpYrzSl+vn76e5qOwmY0AArPwcJgDgz2LWKvHXzGUBdh5fCZblJABcchbpEzDpTwfIJIhvMLHJEth+IbvEhMLAb/IAKSMZEVziytLTBMEATR0Hbz3eqwsCUFAFJbAGTX3SVwAFSWC/CUHVietcCkYA49lcWzYBNZYAQgBcrg7rmyXrtB5uLe14DpfrAFa+hXy+p0yPDcwGs8ppNlwwFX3RAqHblv3eDfDWGTzSUbAGbZDDdd3ezD4FFn4QKf1f+WXALjbu5X7u0ywtrw5cnHVir4bLuvxw8p5vHJTASP7rTdwlVycZlGky9UwQBf9/4Mpt8Ake8DavujiPEALtbRi/WS8AXKtOXx9ftFOWA+Fb2Ax3EEH5NxDTECysho6LELpOxmUskWbeNTHsJn6gBoEJNlIrzjVP8zNf1HBd9hms82NvEORcyyU3Y1wG9ELPZB6/WSDvX6vd2ktvENoLij/Iju1JNfDYM3XEnkE870RZ777eLStfJS3nddwNNss8EDNf2W1wv+l982Nf1DqP7QjhzMIH912WAEF/Aas+X/X1AirgeChmcwYxkzwkAkAUMT90RBgAfRGTiQTAMfUj+6FKEFX/jlvK6fj+JWNgAjOEHARg7P0itbGcuk8g1QMwBWJQAg6u+Wjf3r097Qf/Mctu75Vw38svUF0iFl+oT2Im1vrKZhCHs458TD4NGUJM2JDn6EQGEfxX/4sKrPI0DRABBA4UyKaPAIQJFSIMQUACQYgRJU6kWPGPmCEDGgzg2NHjR5AlQIDsOEQMIgApVa5k2dLlS5gxZc58+eEFCRYqJ+xM0PPCTwJBbfx80dPHThg0laYEecACxwMHCAygAEGD1AEIOFh9MGAqx68DFCDwCvUAyA4wE4T1yLYjgQMFFBYwQBKkAQICCDioOFGCmhF6BeclrNdhX8SJFW/JUkWjXcgeRUKuYgbOUsyZNW/WqcJGDpo7J/RM8PNCUAIqfgrpaQFpZpAROHQFK3ZD/22OEURIKItbLNmvUdGqPfuWZFipg+lG7mhAbgW+igUGGuBl4fUmh6Vv5z4QUAMGzMVDZtCAEWf06dWzXJvgg/ocO1n0bPGTRFDVF1gncD0h6UqSDoBgAwQkmMoCDRCwYCoNMEBgwAE4cLC333oT7qO0XkoAK5DcAkuuhJYTDy8BDohOsRjQ0GAwFgnD4aHExuOoO4mAaOAKGXMc4IoGsEDPDSw8+AKPOtYzMjMYLlBhgiNfim+C+RKo74L7UvvJrggkOGAD2rSM4KwsDyBrgC9vK24ADCIYoDgExvQoQ5c2NK5Dj5IjTETmnBMAOunG4KOC665LgQXpcqRRojTA0/9RvPJ81AyROhqQVFI8Lmvy0plYIEGI9zBV6slFQx0Pzpbk/MjDsuKaq64RCTsRMTY2aLFFK1w4oVAKL/zo0IhsbCCJjET1aIgkeuQs0kkbMMMNT5uF6YMWSLDAWaWEtZYkUtk7C1UP7dQLz8j05DMxBwjJI1CFliAghu1801WsGXmFyNc2oLgWijbM6AI9R5I1j1qAW/JBtf8CdulahDvKdiVT5zwVKhARAhcyEk1MTI4H5ihsY71kICAI7sBqE4GrPFIgXnkJAuIMSSdbFIQSGiDD0s3u+CJZRwzWOSWbSEhgZ5YSTnhhlUzl9iNvCZjYLnFflSiDIspYAV2FwOD/ojuwojpAATDbhKBNdlOGaAsgsmjgiSmiEC+KKZ5o4It9OYPDgwY8wEJSMoAGOgcbPtMbAKFjwyBHolNa67jjVA2R1TxdpeiRGdQ4IA+OKzfh1pBzPQuBqDiICkaxx/5j0ifimAIE1FOfIg63zSCDWbmxwOOLO1LCosi/gU6AhBc61RmyBxBQk6Pghy/eowjGRODkjoSHrHAAGqawrY6SXpqkpiUawwE06FiE6nRx2IFGd8+Ed4DQKQLkDzv8TXZ2D+LmzA0yzKjjvNzzTylJFXzY2WQNjOAAVdna4Cjgud0QUAGDE5AFRKCBAQRwgRGAgAW4lhUIKCAs0NvQ0ToU/zEBXO8uebEYRDLwBgKsoHKzIkANQEY+zZkMZYeawQ8SowVOTMJ1sEvPHbrggTrsUH9DVIkFSNAC31HLZE8ZAATU9IARNHFMD3DiAKC4puJwIHnMs8DgIhQ8DlDgTcRxGPWqtzERfiR7BBkDGgYBvus4YQa84oibIjA8jogRfbwykA0TE4QW0M9+8asdTdzwQzLc7G1kwALNiEjEDwgBJwEz2ZgIoABMnowtl8wkFjkyluV9ckygZJ7CyPgwOilOYowLl+MIwoYVxlIKLpCXoQ4Vg6D4ETE8+BkA4ICFRErqC2TwQDGN6YFDDKkBszsEIR/5TJdMgGBK7MhYODICPP8OAJsd2Wb1srhFjjSII04M5Rg1tC3EIQ2NrKTYc171ADWcC44JsQINMHcoW3bnBDTIpWJM0EuW+PCYA+0CD6F50Jq0x1mV5AgGBrQBEaxpLBiQgEM3AFGJcu5kERgBAijwoA1sLSul5AgHzTe9OakyhOxkWl4swIaBPIAAXohli0JggrClT6cD4QJqdFkRXAIUoUM9Et+W5CmPpKkjFIiKHjmHga4wdYBruooXszLVL3kxAlYt6Sk9eEblsBR7cpkDGqYzgDDMMyENGd9O3boA1BDgpxQJAgGESlS8qkdTvbuU0N61KA5+tS0qTaNHSEQANfhhDCYIQ0031hDQuTX/fTuIq1wTQ4Ma3DWvm90MDKLlP4TupFnS+6r1xHoXEPVBDgZRK0O0I1md7sAEcV0AYiRQgwJolrO7xYwPjlgw3qKng+k8FQgL2xzChMEEgGGhTV8LW52egAAuCEpt+8LPEKjgb4QLLnp6lpPucqZhgjXtePSEkDIASq2Qha5kd0BLxdwWITWYFtC4G17OSNNv+MWM9HxDPcKeVo2F0UAFHKsX9kr2BzOAr05nYN3E8MAKhNGufWUEPf7OpD1JzDAZBQuVdZoXhNaBY4J1qgQW8JMAbdUpDXKKGBMsISE1AO/vmPcABehxOB3urJKYxONTljGlxhWwYQ/82Oem7ARB/6Auaq620xjQQDq4HEx26muwslCRqxSwKoaBHBNNcerLpeKaVLR2ZricWYNhFXFrBWDi0NW1si8OHQvmqJgg9GAhDbkywMoCAa5e1ZRj1gy0pEVonZBG0QlQgRQK8GhIPxoFqzLvkRGcZLGdYLaoufNOXcDiXVaOz1gmgAYi+hHODRrRmRnYBYC76pVcAAVHPi5HzgtHMJgA1OmTwKYJcDm3KoEA24lxoEbtZwJYIIzVVAAEOIBJCngZ1i7pmW5XTQIqqLXWAzhscwngBBcoQbIzwKmBPibZIPBgyjiI5bEXOhUEjIA2dTyTtKftEr7t996WVlqRmwNC7OCAUG49Af+DxR2A98KWB5HtS57B526kfsWh8051V++9md3xddp50ba/bR1Lj+lasidwga3aKxDp3nOXDfE2xPt6pot2JHmqvjiSlATaVfN727dWSBNwwAOVpy8GLuj0yROuGOnKYJ4+t7Z67lvzzRgRiTlv7c4r1wORSzYGJoDwyQMwgxcmxkDeHoy6pg71DEdykoTWuce5DUKfAx22BmL4yXEqnQUAHHwy6IG+0Y5fabp6zByfp9UHg+n0BcEEcz15lLcDV7JXjgQ4/3t4P6DQDgRO8wOgSdvbLIDs1D195Kaz11kwcMXk3c0JYXrlM2xUT2w+cJ2vutsPWwDU7/QEPDC51yH/8unH87tFTji768PLgk0QT8cU6ModA+cm8azkhwMtpg5uYH3sX/8Gl2DziEBUgK6nj+Ry9z1BlGAC7qh+9Qnhu9+Nz9sY1LGU1sRAoCu0KJIyZyUeKAED/P9/Hfg/AQzAErgBSmuVbwk/sdm6ois/gUi39BO+yimAyXu/7sq8kaomsmgTiRIBCpCNksEATCoODIAoEXiAreGNNSETDEjBPBIBBbgNjti/8PiwAWAAHei+PPk+BZSXHzCBsHNAnhK9ilC/9eu5GrgA0LBAzsJArdAaDiCLz4koCuASCJCADewKERgcBbCAB5CAr3kALSoLrUAAMbwjJ8KxMaFBVEIl/wYwwMWptATUKboTQohIOe7gAQlkIY/BAY1jQqJywq/xGik8AIfCAD2yJjLZGs+pkHKyJnhjnrGQgDK7IM5TCQ8ID5T6rxvMwTuxPR5MnwW4OzskCAloMKQjAKU7wkChgh5YO0BEKCecv0LMCmU7C2uSDTPBxQ2URODIwN84gARpk+HZPx0grrZ4wwNsnDkUGwYrPTsEO+6QgB7YQ8eaNRv4sVh8plnUQCxivgHYgJOJQQwKJ14ERkhExzaZjTyaQUzURE70DRzUwXAJRXkhud4rRYIwgYOTDh4IAVacJyvAgRZ4tW3MnW4UJSzagAyCADFiyJPRgAwSgXN8xF+0SP80aUgZpEEbHADrW8ZWasZDUQKiCzp9/AEp246ks8bI0wsw8BkOO0igwUDZQxg2jMfpmcdP/Dzw4xUG1EeJOL1p1LOAbK0lSAEVsICYlMmAocmatJabNKOHUcY4RECl6cHEkC0i1EcaYLzrYklrrMYWUEqm1BmnfEpRYUMb1MlvAUWJwUrE2IFdA0qBOL9prIGiZEUZCAGxJMuydJazRMtFiUqc/AqqXCU5vEq63KkgaEDEoAGWA8uWrByP6cul/Mv0CEzBzJGb/DC27DeehMvF7A4u2EqJkK+8TE0B2EvLxEwj0UzN+6vxMEZkfIvDXKnE7MnRzDQCMMmK4KfJDE7/sKxMAmgBFpiAy3TNmdDMA/iSCHgADbBE6OzCrtgaDegKBNiA6BSjEXzOrTmA5nOQk7rElMhEqZTKz9w5e9xNeZGAJ4svvFRN+VSIvZSCFLCSBPCBJVTO5TwOrqEgsrCAswC0cKQAAQ3Hk9maB6CAKNKABIHOsxDGrBgBigQJjqxNjvjIqmRGxWRPeeGBIHzMyBROEpVMAlCXAmghAtCPBPAP/nQJzfyKA4qK7YQAjxCgqJiKCxmLC4miawJGC31HIfuv9HTLEBJND4WxfrSt+JxPJ907FLAC+wwKFnVR/ozROhpEjyonkRkZTwrG4giLSLQLwizMG4RDxLRK3UzS/+7YgZRUDOA00RKd02skAClAjSo1SEDEUisaAT1ivm16gAhQABUUI+G4IqfgCBG4DQSIKC79CLXE0CINTYjYTBnJgO0QSvh8Uk4tSipAgQIAgxRgNxtoAf7QxvfjU6poyLOASAV4ThGAAAiIqAN4NgihoByjgEwSo0f1iDL1oNs0vA4diI+IAB27FnDsCAs4Vo/AVOlwsWcdUTmdVjqNvFlLUScgABK4gBdggf2EOtgUFtkMlc6szUn1vresVI8QAXmDDFQhiWVlKJJw1sTYOulAzU7NV0791ALogRrY1hatuXAVlXEdTEw8RjrpkGC1vTsJP+ThAHFiQRdEALgYHP8LIkeqgEHeUKpGFYEoRFCMHQB6RYzGlI4ZoFaUrdZpbYhstYEX8AE9fVEjMc8hpZBz3cF0JQiPkAALwKisiMIzjAAC8KhwtCItkg3m442xoKDn/JoDElSrGtm+AD7FcIFJ01eszdrVBNX7VAHWmIBvldn0yMSO1NA05dA1FQiPcEhtwk5fpBAFUYCO4tlKotvf4CgsbNZU9M2JCAqV/duUDdyyIwAwUFHVKAqwFVvNoNlNzElPbEtK1dnc4KQRGByM/AqG5E7OMR8eLY5cFJBSklqKkAB1U4wfcAKtTV3VXYglAFVRrQErQdyYVdzyhMe3gL7aWNjcdFiOsFuMutz/6nwKKlrHdhwLcRwn4XmisBDdiQBR6QiCOwVc6RVc6vW2WStcUjVV16BdIWUL4fCQm63HnCXWcdIxecPIBqIiBYhVKZzICrEAq/gaXCVQjmBeieBHf7SC1d1f/gUfFAiBfs3WbUXcsP1Lxs2akzJMNMVNNeVdS2UO+4WIo/MndZleC65eDJ5MKlAaArjP2M1P5JRJmkWOMP2I8G2n8VXbB4bgxJiB3OuLGMCB/p1hGnaz1g3VFMhWAhiKojiK5Jw2D0DYOuEW3W1gdV1hyIhggoBWPMtgJ75gKDZRj8mOwtVhHgbh2eWxA9ZR8wmLE2aa9WRTxLDX55WCGj5jNC5K/xlAgSZ4tBQYVW39CdLoj534YaIiW6ThkI8wWwZGWyQV44FYAMesiB94YkOOYkTG4Gvl4Pv04LgyjQswVdI4ip0oYKBh3OA4E7b44rFKYUCmCKqVDsJLY1IuZaxdYxRIZQCGtDd+Y9hFjaH4CUleNFqu5cSliQPOGjopYj/+5L4Qtu6w2kMe5kQuZmKWwFlb5BRdZg5mZmfuYPzg1lomjU7ovwD8P0mQBBwUQP8rgccFTXQ9Ul+uCNLtjhnQX1NOZ3VeZ1a84Uh75wLIhBuYZ3q+gUiIhHrOZ0oASYpp2HGmiB/wyoarRmMu6GM2aIQ+aLBM0clUT0/+55SJYXaeaP+Krmj5fLTa212I3qnZSmiPVuiPDmmQ5uCGNtK03eiUkTCLXmmWbml0weiO02gPzYDNE926EmmcHumc3mmUZWhaM+k/dkCaXipizKOiDh6itQvRlWiXbmqnpmiYLjyGFcndHOpPugoCVQCsThMNkJAkvt8K1mmx5mmyHutY8unIc2hxnmmGkqkKcetyogAYNB/mVemnvmu8RuOohiNhPenFtOoK4ajAjqJy8tMv1NuIyDuzLmvGXmyzRmvHUmu/pkvA1upa5cKr8Opy4gALMEPEhggjzOuJRmJrmRqL3mvw6eugLr/KxkLaIFTPBsYvZNd5Y17FbmzcllPSFhYVyu3/FoFsb5Ps1fa9yoY+RZS/OkLejrBtvRPtdO6IBV2q5tMSZh2AeO2I+hOP7M4R065o1KYa1U7S4pbXVR2Bp4jVCvpsgrhtx/ZtlmweWrTuEvxY8v7SyChYu+jt9kYjzwvnyQZKwE4Y5oVM56Zo+PZGb/oIrhGBE/SkCIhOL5pOLxQOpnqA6SRBCsjbAejuhABVeP5wEA9xER/xFGjuQAlvttY80R27/XbvOW0ez+kc4w60C5IAWj0LoN3CJhqcDZAqjhqcr7FuXPScMdFv5WhmJH9mJU9yJl9yJ+9vnF1r9gxwhBHd0C5wdW4eLQ3yhsq/++NiXa0jD7TR6oFfA4rx/+i8P47g8AJHcfYcgwyIczmfczqvczsfg8RucT1/ceRWyIycNwTn4nJankc9gBFYtgcZGc31CCPfcygXXylH6ZS5ciw35QNXyIkjCWvCKOFo1wOQACh6oi8ZIMP20+KFPjZ3bjeXdHmBPEd3cUu79AohgAzqQgWvdUNtVVm9znCs9VFHEz+timY7x45odFgv6chl9VY38UpH490WlVQX7VVXdhpx9WN/9Zp69lAxdmwPbqCm9mVvdnEfd9WddnAPvmtP925fd8AV7nM/FEond3mf97w093dPDGtnd31Xd37/aZ7kggUIeIEfeIIveIM/eIRPeIVf+IPnAmand4iP+K3UnmoCUOYmv/gnz3iM33iN7/h9//h+D/mzNlKJL3mTP/mMtkqRX3mQb3mWb3fbK/ERn3mar3mbv3mcz3md33me73mf/3mgD3qhH3o3drtEMACkT3qlX3qmb3qnf3qoj3qpn3qqr3qrv3qsz3qt33qu73qv/3qwX/pE0HayL3uzP3u0T3u1X3u2b3u3f3u4j3u5n3u6r3u7v3u8z3u933u+73u//3vAD3zBt5aAAAA7);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    H2 receptor antagonists (H2RAs) inhibit acid secretion by blocking histamine H2 receptors on the parietal cell. The proton pump inhibitors (PPIs, eg, omeprazole, lansoprazole, pantoprazole, esomeprazole, and rabeprazole) effectively block acid secretion by irreversibly binding to and inhibiting the hydrogen- potassium ATPase pump that resides on the luminal surface of the parietal cell membrane. The mechanism involved in antacid healing of peptic ulcers may include neutralizing gastric acid, but probably also includes a number of other factors.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_60_4047=[""].join("\n");
var outline_f3_60_4047=null;
